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1. Abstract 
 
The FK506-Binding Proteins 51 and 52 (FKBP51/52) belong to the immunophilin 
superfamily. Both proteins are highly homologous. They are composed of three 
domains and adopted similar conformations. They have cochaperone activity by 
participating in the Hsp90-steroid receptor complex to regulate the glucocorticoid 
receptor (GR) signal transduction. FKBP51 has been shown to be a negative 
regulator whereas FKBP52 is a positive regulator of the glucocorticoid receptor. 
FKBP51 is involved in the etiology of stress-related psychiatric disorders and has 
potential as a novel therapeutic target for psychiatric disorders. Few synthetic ligands 
for FKBP51 and FKBP52 were described and all of them display unfavorable 
pharmacokinetic profiles which make them unsuitable to study the biological roles of 
FKBP51 and FKBP52. In this project, the aim was to limit the ligand flexibility by 
ligand preorganization to mimic the FKBPs ligands active conformation and to focus 
on the improvement of their ligand efficiencies.  
The bicyclic [3.3.1] aza-amide and bicyclic [4.3.1] aza-amide core structures were 
designed as rigid replacements for the pipecolyl-monocyclic scaffold. Their potential 
binding modes were first analyzed in silico. A synthetic route was then establised to 
prepare a series of bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic [4.3.1] aza-
amide derivatives 5. Their activities were tested in a competition binding fluorescence 
polarization assay, by isothermal titration calorimetry and in a GR hormone 
radioactive binding assay. Ligand 5h was indentified as the most efficient FKBP 
ligand known today. It is the first lead-like ligand (MW= 367Da, LE= 0.29, clogP= 
0.95) for the clinically relevant FKBP51 and offers three rigidly defined attachment 
points (R1, R2 and C8) for further lead optimization. The comparison of the three 
series compounds indicated that the bicyclic [4.3.1] aza-amide scaffold has a better 
degree of preorganization than the bicyclic [3.3.1] aza-amide scaffold which in turn is 
preferred over the monocyclic scaffold. The cocrystal structures of 4g, 5g and 5f with 
FKBP51 FK1 domain showed their binding modes are similar to those observed for 
compound 2 in complex with FKBP51 FK1. 
Based on the cocrystal structures of 5g and 5f, the C8 substituted bicyclic [4.3.1] aza-
amide scaffold was designed to increase the contact surface between ligand and 
protein to further enhance the binding affinity. A new stereoselective synthetic route 
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was established and optimised in which a stereoselective carbon-carbon bond 
formation by intramolecular N-acyliminium cyclization was the key step. The cocrystal 
structure of 71 with FKBP51 FK1 confirmed the desired conformation obtained from 
the stereoselective synthesis. A further racemic dihydroxylation of the C8 vinyl group 
substantially improved the affinity for all FKBPs yielding ligands with low nanomolar 
potencies that rivalled those of the natural product FK506. The higher binding affinity 
was proposed to be obtained from a putative hydrogen bond between the C11-OH of 
73a and Tyr57 which was to be confirmed in the future by the corresponding cocrystal 
structure.  
These results provided valuable information for the further optimization of FKBP51 
ligands. 
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2. Introduction 
 
2.1 The FK506 binding protein (FKBPs) family 
 
The FK506 binding proteins (FKBPs) belong to the immunophilin family with high 
binding affinity to the immunosuppressive drugs FK506 and Rapamycin. It is a highly 
conserved class of proteins found in all organisms with peptidyl prolyl isomerase 
(PPIase) activity1-3. The PPIase activity catalyzes cis–trans isomerization reactions of 
peptide bonds involving the amino acid proline (Figure 1) which is regarded to be 
necessary for the proper folding of several proteins.4 
 
N
NHR2O
O
N
NHR2
O
O
R1
R2HN
cis trans
R2HN
R1
 
Figure 1: Peptidyl prolyl cis/trans-isomerization by PPIases. 
 
In the nucleus, FKBPs regulate transcription5, 6, histone chaperon activity7, 8 and 
chromatin modification9, 10, cancer progress11, 12 and chemoresistance13, 14. In the 
cytoplasm, FKBPs play important roles in protein stability15-17, protein trafficking18, 19, 
receptor signaling20, 21, kinase activity, intracellular Ca2+ homeostasis via interaction 
with calcium channels like the ryanodine receptor, regulation of inositol 1,4,5-
triphosphate receptor21, 22 and cation channel like TRPC123.  The human FKBP family 
consists of FKBP12, FKBP12.6, FKBP 13, FKBP15, FKBP22, FKBP24, FKBP25, 
FKBP36, FKBP38, FKBP51, FKBP52, FKBP60, FKBP65 and FKBP133 with their 
homologs usually also be found in other mammalian FKBP families24-27 among which 
the FKBP12, FKBP12.6, FKBP38, FKBP51 and FKBP52 are the most studied and 
explored paralogs.24, 25  
 
2.2 FKBP51 and 52 Structures 
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The amino acid sequences, domain organization and three-dimensional crystal 
structures of the full-length human FKBP51 and the overlapping fragments of human 
FKBP52 have been reported28, 29. They are homologous proteins with 60% identity 
and 75% similarity in their amino acid sequences. Both proteins are composed of 
three domains and adopt similar conformations (Figure 2). 
The N-terminal FK1 domain has the PPIase and FK506 binding activity and it is the 
primary regulatory domain for steroid hormone receptors20, 30. Both the Hsp90 
binding and the PPIase pocket are neccssary for the modulation of the SHRs31, the 
PPIase activity per se is not necessary. The 40s and the 80s loop (residues 71-76 
and 118-122 for FKBP51, respectively) represent the largest structural divergence in 
the FK1 domain between FKBP51 and 52. In the 40s loop, the Asn74, Glu75 and Pro76 
in FKBP51 is replaced by Lys74, Asp75 and Lys76 in FKBP52. The proline rich loop (80 
loop) which sits on top of the binding pocket with Leu119 in FKBP51 and Pro119 in 
FKBP52 was found to be a major cause for the different functions of FKBP51 and 
FKBP52 on the steroid hormone receptors. The mutations of A116V and L119P in 
FKBP51 was found to switch the activity to full FKBP52-like characteristics towards 
AR activation.31  
The PPIase-like FK2 domain is structually similar to the FK1 domain but exhibits no 
PPIase activity or FK506 binding activity. Like the FK1 domain, FK2 also has the 
typical FKBP fold - an antiparallel six stranded β sheet around a central α helix. The 
function of the FK2 domain is still not clear. A mutant of FKBP51 containing a three 
amino acids deletion (D195, H196 and D197) deletion in the FK2 domain still binds to 
Hsp90 but the integration into progesterone receptor complexes is abnormal which 
might be due to the decreased interaction with the receptor complex.29  
The C-terminal TPR domain is made up of three tetratricopeptide repeat (TPR) 
domain of a consensus 34-amino acid motif and is responsible for binding to Hsp90 
through interaction with the EEVD motif in the C terminus of Hsp90.28, 29, 32 The 
residues at the TPR/Hsp90 binding interface are highly conserved in both FKBP51 
and FKBP52 with the exception of Q333, F335, A365 in FKBP52 and 
R331,Y333,L363 in FKBP51. These variations may account for the different binding 
activity of them to Hsp90. 
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                   FKBP51                                                      FKBP52 
 
Figure 2 The crystal structure of FKBP51 (PDB number 1KT0)  and a composite of two partial 
structures for human FKBP52 (PDB numbers 1Q1C and 1P5Q) are shown in ribbon format colored 
based on secondary structure. The C-terminal TPR domains are shown in blue, the FK2 domains 
are in organe, the FK1 domains are in red. The figure, including the overlay of the two partial 
FKBP52 structures, was created using pymol. 
 
2.3 Cellular and Physiological Functions of FKBP51 and FKBP52 
 
Although FKBP51 and FKBP52 share high sequence and structural similarity, their 
cellular and physiological functions are different. 
 
2.3.1 The role of FKBP51 and FKBP52 in steroid receptor signaling 
 
FKBP51 and FKBP52 were first identified in complex with the steroid hormone 
receptors33, 34 and are best known as heat shock protein 90 (Hsp90) associated co-
chaperone to regulate steroid hormone receptors (SHRs)30. They function 
antagonistically to each other. In most cell types, FKBP51 decreases the signal 
transduction of the SHRs35 whereas FKBP52 increases it for androgen receptor 
(AR)36, glucocorticoid receptor (GR)20 and progesterone receptor (PR)37. As an 
exception FKBP51 was found to increase rather than decrease the signalling of the 
AR in prostate cancer cell lines38, 39. Most SHRs, especially the glucocorticoid 
receptor (GR), primarily stay in the cytoplasm in the ligand free state and migrate to 
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the nucleus upon ligand binding after a Hsp90-assisted maturation process40, 41 
(Figure 3).  
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Figure 3: Model of FKBP51 and 52 on steroid hormone maturation, ligand binding and nuclear 
translocation. 
 
The latest model of FKBP regulation of SHRs maturation, hormone binding and 
nuclear translocation was postulated as follows42, 43: The FKBP binds to the C-
terminus of Hsp90 via the TPR domain to enter the Hsp90-dimer-SHR complex, 
which is stabilized by the p23 cochaperone41. It brings the FKBP FK1 domain into 
contact with the receptor ligand binding domain to directly influence hormone binding 
affinity. As a result of the differences in the FK1 domain especially the proline rich 
loop of FKBP51 and FKBP52, hormone binding is repressed in the presence of 
FKBP51 and potentiated in the presence of FKBP52. Upon steroid binding, the SHR 
heterocomplex exchanges FKBP51 for FKBP52, which is able to interact with dynein. 
The whole SHR–chaperone complex translocates through the nuclear pore complex 
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followed by receptor transformation, binding of the steroid-activated receptor to 
hormone response elements and gene transcription regulation. The Hsp90–FKBP52 
complex further assists the cytoplasmic retrotransport of a number of Hsp90-
associated factors.43 In intact cells, FKBP51 was shown to slow down the nuclear 
translocation of the GR, possibly by blocking FKBP52 mediated recruitment of the 
dynactin motor complex. Through the active involvement of FKBP51 and FKBP52 in 
steroid receptor signaling, they play important roles in a variety of diseases which 
depend on these hormone signaling pathways. 
 
2.3.2 Biological implications of FKBP51 and FKBP52 in diseases 
 
2.3.2.1 Stress related diseases 
 
The hypothalamus-pituitary-adrenal (HPA) axis is a stress hormone system triggering 
the physiological and behavioral response to chronic and acute stress in humans. 
Upon stress the hypothalamus secretes corticotropin releasing hormone (CRH) which 
triggers the synthesis and release of adrenocorticotropic hormone (ACTH) in the 
pituitary gland and results in secretion of cortisol in the adrenal gland into the blood 
to act on various tissues. The HPA axis is controlled by a negative feedback exerted 
by cortisol via the GR to inhibit the further release of CRH and ACTH thereby 
maintaining homeostasis of the HPA axis (Figure 4). The imbalance in the HPA axis 
was correlated with the risk for and course of diseases such as major depression, 
bipolar disorder, post-traumatic stress disorder (PTSD), schizophrenia and anxiety 
disorders.44 One of the reasons for the inappropriate reaction of the HPA axis to 
stress was claimed to be the malfunction of GR45. FKBP51 and FKBP52 were shown 
to have opposing functions on GR20, 46. In clinical studies, the risk allele carriers of 
the single nucleotide polymorphisms rs1360780 in the FKBP51 -encoding gene 
showed higher FKBP51 protein levels. The same SNPs were also associated with a 
more rapid response to antidepressants and more lifetime depressive episodes47-50. 
FKBP51 polymorphisms have been reported to be correlated to bipolar disorders50, 
suicidal events,51-54 the recovery from psychosocial stress in healthy individuals55, 
peritraumatic dissociation56 and PTSD57, 58. In several independent animal model 
studies, FKBP51 has been shown to be an negative modulator of GR activity and 
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important in stress coping behavior and adaptation to stress59-62. The induced fkbp5 
mRNA levels and the FKBP51 expression pattern in the brain after a stress or 
glucocorticoid challenge was shown to be region specific and correlates to the fkbp5 
baseline level.63 All these findings strongly indicated the important role of FKBP51 in 
the etiology of stress-related psychiatric disorders and the potential as a novel 
therapeutic target for psychiatric disorders. 
 
Stress
 
Figure 4: The Hypothalamic–Pituitary–Cortisol System64 
 
2.3.2.2 Cell proliferation and cancer  
 
FKBP51 is a protein with a progressively emerging role in cancer biology. The active 
role of FKBP51 in cell proliferation and cancer was shown by the increased level of 
FKBP51 in physiological conditions of cell growth and differentiation with preferential 
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expression in mitotically active cells65-68 and in gliomas69, retinal tumor cells70, 
melanoma71, 72, prostate cancer73, 74 and prostatic hyperplasia 75. In prostate cancer 
cells, FKBP51 was indentified as a positive regulator of AR and androgen- 
dependent cell growth, which is distinctly different from the effect observed on GR 
and PR, where FKBP51 is a negative modulator39, 76-79. FKBP51 was described to 
enhance NF-κB mediated transcription to protect from apoptosis upon a number of 
stimuli and to enhance cell viability or proliferation in leukemia71 and melanocyte 
malignancy80. Via the action on GR, FKBP51 suppressed proliferation in colorectal 
adenocarcinoma81 and the dexamethasone-induced expression of FKBP51 by the 
GR in myeloma cells has been interpreted as an adaptive process before cell 
death82. The decreased FKBP51 expression in several cancer cell lines and in 
pancreatic cancer tissue was correlated with increased AKT phosphorylation and a 
reduced cell sensitivity to chemotherapeutic agents13, 14. FKBP51 was proposed to 
negatively regulate the activity of the cell growth regulator AKT and serve as a 
scaffolding protein to recruit the phosphatase PHLPP13. Taken all together, the 
involvement of FKBP51 in a wide variety of cancers indicated FKBP51 as an 
important molecular player with divergent functions and represented a promising 
cancer therapy target.39, 69, 71, 72, 83  
By contrast, less is known about the role of FKBP52 in cancer. The recently observed 
increased expression of FKBP52 in prostate needle biopsies from human patients84, 
prostate cancer cells85 and breast cancer cells86 together with the androgen, 
progesterone and glucocorticoid insensitivity phenotypes observed in FKBP52 
knockout mice36, 37, 87-89 indicated FKBP52 as a potential therapeutic target in a 
variety of diseases dependent on these hormone signaling pathways. 
 
2.3.2.3 Immune system 
 
FKBP51 also plays a role in immune-related diseases and inflammation mainly 
through regulation of GR activity and modulation of NF-κB-dependent gene 
expression by FKBP5169, 90-93. It was shown that FKBP51 modulates the stability of 
IκB, the phosphorylation of NF-κB and enhances DNA binding of NF-κB. Enhanced 
FKBP51 expression in bone marrow cells was observed in rheumatoid arthritis90 and 
in the treatment of chronic obstructive pulmonary disease94. The inhibiting of 
endogenous MHC class II-restricted antigen presentation by FK506 was also shown 
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to be mediated by FKBP5195. Additionally, like other smaller FKBPs, FKBP51 can 
bind to FK506 to mediate inhibition of the calcineurin which activates nuclear factor of 
activated T cells96, 97. 
 
2.3.2.4 Reproductive development and reproductive success 
 
The important role of FKBP51 and FKBP52 in mammalian reproductive development 
and reproductive success was shown by the studies of FKBP51 knockout and 
FKBP52 knockout mouse lines.  
Male FKBP52 knockout mice display phenotypes consistent with partial androgen 
insensitivity where the secondary sex organs are mainly affected with dysgenic 
prostate, smaller seminal vesicles, ambiguous external genitalia and retention of 
nipples into adulthood while the primary sex organs like testes remain unaffected.36, 
89 Female FKBP52 knockout mice seem to be morphologically normal but sterile.37 A 
failure of embrynomic implantation and decidualization was found to be the reason 
for the infertility which indicated the crucial role for FKBP52 in female reproduction 
and uterine signaling88. 
FKBP51 knockout mice display no obvious morphologically phenotypes and 
reproduce normally compared to FKBP52 knockout mice. The double knockout of 
both FKBP51 and FKBP52 genes is embryonic lethal in mice98 indicating that 
FKBP51 and FKBP52 have some crucial but redundant roles in embryonic 
development.  
 
2.3.2.5 Neurodegenerative diseases 
 
With their high expression in the central and peripheral nervous system, FKBP12, 
FKBP38, FKBP51, FKBP52 and FKBP65 also play important role in 
neurodegenerative disorders with neurotropic, neuroprotective and neurotransmitter 
releasing effects15, 99-101. In Parkinson’s Diesease (PD), FKBP52 was found to be 
associated with RET51, which is a tyrosine kinase receptor important in the 
development and maintenance of the nervous system in a phospohorylation 
dependent manner. This was independent of Hsp90 or other chaperones102. In 
studies of PD and Alzheimer’s Disease (AD), FKBP51 and FKBP52 showed 
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contrasting effect on tau stability. FKBP51 preserves tau levels but reduces its 
phosphorylation and enhances the tau mediated MT polymerization15 whereas 
increased levels of FKBP52 is correlated with decreased tau stability101, 103. The 
PPIase activity of FKBP51 and FKBP52 are regarded critical for the regulation of 
tau104, 105. FKBP52 was also shown to interact with Atox1106, 107 to modulate Aß 
pathogenesis by modulating Aß generation and toxiciy via copper homeostasis in 
AD108, 109. A transgenic mouse model of amyotrophic lateral sclerosis indicated the 
correlation of decreased expression of FKBP52 with degeneration of anterior lateral 
horn neurons and deregulation of axonal transport110. 
 
2.4 Chemical biology of FKBPs ligands 
 
2.4.1 Immunosuppressive FKBPs ligands 
 
Best known as immunosuppressive ligands used in the clinic as transplantation 
medicine, FK506 and rapamycin (Sirolimus) bind to FKBPs with very high affinity. 
Isolated from Streptomyces tsukubaensis, FK506 consists of a FKBP binding domain 
and an effector domain with which the FKBP-FK506 complex binds and allosterically 
inhibits the secondary target calcineurin to induce the immunosuppressive effect111. 
FKBP12, FKBP12.6 and FKBP51 are thought to be the primary FKBPs to mediate 
the immunosuppressive action of FK50697, 112. 
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Figure 5: Clinically used immunosuppressive FKBPs ligands derived from FK506 and rapamycin.113 
The modified substructures were shaded in yellow. 
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Isolated from Streptomyces hygroscopicus, rapamycin binds to FKBPs and exhibits 
the immunosuppressive activity via a different ternary partner, the serine-threonine 
protein kinase mammalian target of rapamycin (mTOR). Many immunosuppressive 
FK506 and rapamycin analogs (Figure 5) were designed and used in various phases 
of clinical trials or in the clinic against various disorders like breast cancer, melanoma 
and advanced renal cell carcinoma, metastatic soft-tissue sarcomas etc. with 
improvement in terms of side effects, solubility and efficacy113. 
 
2.4.2 Non-immunosuppressive FKBPs ligands 
 
Besides the immunosuppressive effects, FK506 and Rapamycin were also shown to 
have neuroprotective and neurotropic effects114, 115. The non-immnosuppressive 
FKBPs ligands were developed to reduce the suppression of immune responses of 
FK506 and Rapamycin but preserve or improve the neuroprotective and neurite 
outgrowth promotive activities in a variety of neuronal cell systems. These ligands 
were active in animal models of cerebral ischemia116, 117, traumatic brain injury118, 
diabetic neuropathy119, Parkinson’s disease120-122, and other types of physical 
neuronal injury123-126. 
Semi- or biosynthetic analogs of FK506 or Rapamycin are one type of the non-
immunosuppressive FKBPs ligands. Their bindings to calcineurin/ mTOR were 
abolished by modification of the effector domain (e.g., FK1706, meridamycin, 
normeridamycin, ILS920, Way-124466, Wye-592, L685-818) (Figure 6). 
The second type of non-immunosuppressive FKBP ligands consists of small 
synthetic FKBPs ligands. They were designed to mimic the dicarbonyl pipecolyl 
moiety of the FK506 and rapamycin but lack the effector domain (Figure 7). VX-
10,367 is the most potent synthetic FKBP12 ligands known to date127 while its 
analogue biricodar (VX-710) was reported to retain high potency for FKBP12. It was 
investigated in several clinical trials as chemosensitizing agents but it displayed only 
modest affinity for FKBP51 and FKBP52128. GPI1046 and its analogs (GPI1485, 
JNJ460/GM284129) were reported to have neurotrophic and neuroprotective activities 
and high FKBP12 binding affinity although contrary results were also reported116, 130-
133. GPI1046 was inactive for FKBP51 and FKBP52134. GPI1485 was claimed as the 
active form of its prodrug GPI1046 produced after in vivo ester hydrolysis135.  
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Figure 6: Representive biosynthetic or semi-synthetic analogs of FK506 or rapamycin 
as non-immunosuppressive FKBPs ligands 113 
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GPI1485 failed to show activity in two phase II clinical trials136 and was inactive in a 
PPIase assay of FKBP12137. Various FK506 analogs (VX-853, V-13,661 and V-
13,670) were claimed not to bind FKBP12 but to other unidentified protein targets to 
produce at least some of the effects of FK506126, 138. VX-853 (Timcodar) was shown 
to be active in two animals mode of peripheral nerve diseases and advanced to a 
phase II clinical study for diabetic neuropathy113. It showed no affinity for for FKBP51 
and FKBP52134, the selectivity profile of these ligands for other FKBP family 
members are unknown. The cycloheximide analog DM-CHX was developed as a 
selective FKBP ligand for FKBP38 vs. other FKBP homologs and it was active in an 
animal model of focal cerebral ischemia117. Hudack et al. designed a 
tetrahydroisoquinoline moiety A via acyl iminium chemistry followed by systematic 
structure activity relationship study to give A1 and A2 with low nanomolar affinity for 
FKBP12139. 
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Figure 7: Synthetic neuroimmunophilin ligands. The core of FK506 or rapamycin or 
equivalent groups are shown in yellow140. 
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2.4.3 FKBP51 and FKBP52 ligands 
 
Compared to the active research on the biology of FKBP51 and FKBP52, few efforts 
for the discovery of novel synthetic FKBP51 and FKBP52 ligands were described. The 
first described synthetic ligand for FKBP51 and FKBP52 with low micromolar affinity 
was SLF141, a simplified analogue of FK506 and rapamycin that was originally 
developed for FKBP12 with low nanomolar affinity142. Ranganath Gopalakrishnan et 
al. elaborated the first detailed first structure–activity relationship study for FKBP51 
and FKBP52 ligands based on SLF134. Compared to FK506, SLF has the piperidine 
core derived from the diketoamide pipecolinic core of FK506 and rapamycin but it 
lacks the effector domain. Based on the co-crystal structure of SLF and FKBP51, a 
series of synthetic FK506 analogues for FKBP51 and 52 based on the pipecolate 
scaffold C were prepared. In particular, a cyclohexyl ring system which more closely 
resembles the pyranose ring in the high-affinity ligands rapamycin and FK506 was 
implemented instead of the tert-pentyl group to target the proline rich loop.  
The best compounds of this series are C1 and C2 (Figure 8) with binding affinities of 
1 µM to 4 µM. Furthermore, a focused sulfonamide library for FKBP51 and 52 were 
prepared using a solid phase strategy143. With the same pipecolate scaffold C, 
sulfonamids were attached at the R2 position as bioisosteric replacement of the 
metabolic labile diketo amide moiety. Compound C3 was claimed to be the best 
known ligand for the large FKBPs to date, albeit without selectivity while C4 has 
exceptionally high affinity for FKBP12, rivaling those of the natural products FK506 
and rapamycin. However, C4 displayed but only low micromolar affinity for FKBP51 
and FKBP52. 
Unfortunately all of the described FKBP51 and 52 ligands are very large, show only 
modest binding affinity and suffer from low drug-like Properties. 
As SLF and FK506 were the only two public known FKBP51 and FKBP52 ligands141 
at the start of this thesis, they were used as prototypes for our structure based 
rational ligand design.  
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Figure 8: Representive FKBP51 and FKBP52 ligands. 
 
2.5 Interactions of 2 (SLF) and polycyclic ligand 3a with FKBP51 
 
FK506 (1) (Figure 9a) binds to the peptidyl prolyl isomerase (PPIase) domain of 
FKBP51/52 and inhibits their PPIase activity. SAR studies with synthetic FKBP 
ligands indicated the dicarbonyl pipecolyl-scaffold (shadowed in Figure 9) of FK506 
as the most important group for their binding to FKBPs. The α-keto amide has been 
suggested as an analogue of the twisted amide in the transition state of the peptidyl-
prolyl isomerisation catalyzed by FKBPs144, 145. 
SLF (2) (Figure 9b) is a simplified synthetic analogue of FK506 with micromolar 
affinity for FKBP51/52. Its cocrystal structure with the FK506-binding domain of 
FKBP51 and a first SAR study were recently reported134. Upon binding of compound 
2, FKBP51 adopts a very similar conformation as found in the FK506 complex. Most 
active site residues are virtually superimposable in the two co-crystal structures 
(Figure 9c). A comparison with the cocrystal structure of FK506146 showed that most 
of the key interactions are conserved. The conserved interactions include 
hydrophobic contacts between the piperidine ring and the indole of Trp90, hydrogen 
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bonds between the C8-amide carbonyl and Tyr113-OH and between the C1-amide 
carbonyl and Ile87-NH, a dipolar interaction between C1 and Tyr113-OH (142°, 3.2Å) 
and aromatic hydrogen contacts of Tyr57, Phe67 and Phe130 with the C9-carbonyl. Part 
of the lower binding affinity of 2 may be due to its higher flexibility compared to 
FK506. Compound 2 and all other known FKBP51/52 ligands, including the natural 
products FK506 and rapamycin display unfavorable pharmacokinetic profiles and 
suffer from a very low ligand efficiency (<0.18). This is below the widely accepted 
lower limit of 0.3147 (Figure 9a and 9b). 
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Figure 9: (a) Immunosuppressive drug 
FK506 (1). (b) A synthetic analog thereof 
SLF (2). The pipecolate and α-keto amide 
core structure as the key FKBP 
recognition motif is shaded gray with 
binding affinities for FKBP51, FKBP52 
and FKBP12. The ligand efficiency (LE) is 
defined as the ratio of Gibbs free energy 
(∆G) to the number of non-hydrogen 
atoms (N) of the compound: LE = (∆G)/N, 
where ∆G = -RTlnKi with RT equal to 0.6 
kcal/mol. The unit of LE is kcal/mol/non-
hydrogen atom148. (c) Surface 
representation of FKBP51 in complex with 
2 (4DRK) (magenta). FK506 bound to 
FKBP51 (3O5R) is superimposed in cyan. 
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Figure 10: (a) The polycyclic ligand 3a and its binding affinities for FKBP51, FKBP52 and FKBP12. (b) 
Cocrystal structure of 3a (marine blue) with the FK506-binding domain of FKBP51. Key residues of 
FKBP51 are show in orange, hydrogen bonds are dashed red. Dipolar-dipolar interactions are dashed 
in green, van-der-Waals contacts are dashed yellow.  
 
Studies with the smaller homolog FKBP12 showed that binding affinity and ligand 
efficiency might be improved by macrocyclization149 or by rigid polycyclic scaffolds139. 
Flexible ligands are thought to suffer an entropic penalty upon binding due to the 
freezing of rotatable bonds150. In turn, reducing ligand flexibility, e.g., by 
macrocyclization, is an appealing concept to improve potency. It is also well known 
that flexible ligands often adopt higher energy conformations upon binding to fine-
tune ligand-protein interactions151-154 Thus, in principle, additional binding energy 
could be gained by preorganizing or stabilizing these high-energy active 
conformations. Thus representative examples of the polycyclic scaffold 3a-3e were 
synthesized (Table 1). Unfortunately, these did not enhance binding affinity and 
ligand efficiency for FKBP51/52. 
To get an insight into the molecular binding mode, the polycyclic ligand 3a was 
cocrystallized with the FK506-binding domain of FKBP51 (Figure 10). Compound 3a 
bound to the FKBP51 FK1 domain in a similar way as the core of FK506 or the 
synthetic analog 2 with most of the key interactions conserved. The pipecolyl ring of 
the ligand sits atop the indole of Trp90 of FKBP51 which forms the floor of the 
hydrophobic binding pocket. Two hydrogen bonds between the C16-amide carbonyl 
and Tyr113-OH and between the C1-amide carbonyl and Ile87-NH are observed. These 
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two hydrogen bonds are a hallmark of FKBP ligands. Tyr113-OH also approaches the 
C1 carbonyl almost perpendicular (88.3°) at 3.4Å. This putative dipolar interaction has 
been observed previously in FKBP-ligand structures but might be less strong in case 
of 3a155. The C17-carbonyl engages the three ε-hydrogens of the aromatic residues 
Tyr57, Phe67 and Phe130 which form the apparent carbonyl binding pocket of FKBPs. 
The C8 of the bicyclic bridge system forms van-der-Waals contacts with the tip of 
Phe77.  Ring B and ring C stack on top of each other via π-π interactions. The 
preorganization by the rigid ring B might lock ring C into a conformation favourable 
for binding. The stacking of these two rings could represent a productive ligand 
hydrophobic collapse156. Favourable van-der-Waals interactions between Tyr57 and 
C15-OMe, between Asp68 and C19-OMe, and between Tyr113, Ser118 and C20-OMe 
also contribute to the binding of the ligand. This is supported by the inactive ring C 
analogs 3b-3e where the aromatic ring C is replaced by an aliphatic moiety or 
sulfonamides aromatic ring (Table 1). 
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>100 >100 2.1±0.3 
(0.23) 
 
Table 1: Binding affinities and ligand efficiencies of polycyclic ligands 3a-3e for FKBP51, 52 and 12. 
 
Cyclohexyl rings that mimic the pyranose of FK506 or rapamycin were recently 
shown to be preferred substructures compared to the trimethoxyphenyl moieties in a 
monocyclic scaffold134. In contrast, in the polycyclic context a dramatic decrease of 
the binding affinity was observed when ring C was changed to the cyclohexyl α-keto 
amide substructure in 3b. The lower affinity of 3b might be due to less favourable 
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intramolecular interactions leading to the loss of the preorganized conformation. 
Likewise, derivative 3c bearing the tert-penyl group present in 2 was also inactive. 
Although sulfonamides were suitable surrogates for the α-keto amide substructure in 
monocyclic FKBP51/52 ligands143 , polycyclic aza-sulfonamide compounds 3d and 
3e were both inactive. This might be because these sulfonamide aromatic rings were 
locked at different angles compared to the constrained sulfonamides due to π-π 
interactions with ring B. 
 
2.6 Reported compounds with similar scaffolds as 4 and 5  
 
The proposed [3.3.1] aza-amide scaffold and [4.3.1] aza-amide scaffold were not 
found in nature. The closest natural products are exemplifed by the [4.2.1] alkaloids 
such as anatoxin A157 and [3.2.1] aza-amide scaffolds in the tropane alkaloids158 
(Figure 11). The closest synthetic analogues of the [3.3.1] aza-amide scaffold were 
reported as part of the polycyclic scaffold 3139. 
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Figure 11: The chemcial structure of (a) Anatoxin A, (b) Tropane 
 
In the synthesis of anatoxin A159, 160, tropane alkaloids161 and the polycyclic scaffold 
3139, the intramolecular N-acyliminium cyclization was employed as a key step. 
 
2.7 Intramolecular N-acyliminium cyclization 
 
The N-acyliminium or N-acyliminium ion chemistry has been extensively employed 
for the synthesis of N-heterocyclic ring systems related to alkaloids. It has been 
systematically studied especially by Speckamp et al. based on the succinimide 
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system.162 Under acidic condition, the hemiaminal D1 is converted to the N-
acyliminium ion intermediate D2 (Scheme 1). Compared to the iminium ion which has 
been widely employed in the Mannich reaction, the Bischler-Napieralski reaction and 
the Pictet-Spengler reaction, the carbonyl group adjacent to the nitrogen atom greatly 
increased the electrophilic reactivity of the N-acyliminium ion which broadens the 
range of nucleophiles that can be used in carbon-carbon bond formation reactions. 
Because of its high activity, the N-acyliminium ion intermediate is seldom if ever 
isolated162, 163 and usually is generated in situ. Intermediate D2 was found to be 
reactive towards a wide variety of π-nucleophiles including alkenes, allenes, alkynes 
and aromatic and heteroaromatic systems162.  
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Scheme 1: Mechanism of N-acyliminium chemistry. 
 
The intramolecular N-acyliminium cyclization is widely employed especially in the 
synthesis of bicyclic and polycyclic N-heterocyclic ring systems. Some examples 
even showed high stereocontrol during the C-nucleophilic additions to N-acyliminium 
species164, 165 which makes the intramolecular N-acyliminium cyclization even more 
attractive for the synthesis of alkaloidal ring systems. 
Generally, the N-acyliminium ion can be generated from three sources. α-
Oxygenated amides is the most common source of N-acyliminium ions while the use 
of other α-substituted amides such as bisamides, α-chloroalkyl amides and α-
thioalkyl amides were also reported162. The α-oxygenated amides can be prepare by 
addition of an amide to an aldehyde or ketone under acid condition (reaction 1 in 
Scheme 2)164, electrochemical oxidation of amides or carbamates (reaction 2 in 
Scheme 2)166, reduction of cyclic imides in the presence of an alcohol (reaction 3 in 
Scheme 2)167, and addition of Grignard reagents to cyclic imides (reaction 4 in 
Scheme 2)168. Acylation of imines with an acid chloride or acid anhydride to afford 
acyliminum species was also reported (reaction 5 in Scheme 2)169. Although the 
protonation of N-acylimines is possible in principle, very few examples have been 
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described (reaction 6 in Scheme 2)170. The limitation is mainly due to the 
tautomerization of the N-acylimines to enamides when α-hydrogen atoms are 
present. 
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Scheme 2: Summary of the N-acyliminium ion generation. 
 
The intramolecular N-acyliminium cyclization has been used to construct pyrrolidines, 
piperdines and related rings171-174, pyrrolizidines175, indolizidines176, 177, spirocyclic 
systems178, ring systems containing a seven-membered or eight-membered ring179, 
polycyclic and bridged systems180. Some of its applications in preparaion of bicyclic 
or polycyclic N- heterocyclic ring systems of natural products are shown in Scheme 3. 
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Scheme 3: Some examples of intramolecular N-acyliminium cyclization in preparation of bicyclic and 
polycyclic N- heterocyclic ring system of natural products. 
 
A silicon-directed N-acyliminiun ion cyclization was employed to prepare the fused 
bicyclic structures of Isoretronecanol177 and Epilupinine (reaction 1 and 2 in Scheme 
3 )176.  For the spirocyclic systems of Perhydrohistrionicotoxin, the furan ring was 
found to be a good -nucleophile for the intramolecular N-acyliminiun ion cyclization 
(reaction 3 in Scheme 3)176. The bridge bicyclic system in Quinocarcin was prepared 
through acylated amide reduction followed by cyclization (reaction 4 in Scheme 3)181. 
The lewis acid induced cyclization of enolic π-nucleophiles could easily afford the 
tropane-like system (reaction 5 in Scheme 3)182. An 8-Azabicyclo[4.2.1] system like in 
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Anatoxin-a was shown to be obtained by lewis acid-induced cyclization of an 
unfunctionalised alkene π-nucleophiles159 (reaction 6 in Scheme 3).  
The intramolecular N-acyliminium cyclization was also crucial in the synthesis of 
other natural products like Gephyrotoxin183, Laudanosine180, Yohimbine184, 
Ajmalicine185, Vindorosine186, Gelsemine187, Sarains188 and so on. 
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3.  Aim of this project    
 
FKBP51 and FKBP52 have important implications in diseases like cancer and 
depression. However, all known FKBP51 and FKBP52 ligands display unfavorable 
pharmacokinetic profiles which make them unsuitable to study the biological roles of 
FKBP51 and FKBP52. 
In this project, the aim was to limit the ligand flexibility by ligand preorganization to 
mimic the FKBPs ligands active conformation and to focus on improvement of their 
ligand affinities and efficiencies. Two new classes of conformationally defined 
pipecolyl analogs based on aza-amide bicycles as rigid replacements for the 
pipecolyl-monocyclic scaffold were designed. First, efficient synthetic procedures for 
the bicyclic [3.3.1] aza-amide and [4.3.1] aza-amide core structures had to be 
developed. Second, the bicyclic [3.3.1] and [4.3.1] aza-amide scaffold had to be 
derivatized to identifiy the best substituents and to probe the energetic contribution of 
the individual subgroups. Third, a detailed biological and biophysical characterization 
of selected analogs was intented to elucidate the molecular underpinnings of binding 
of the constrained FKBP ligands in detail. 
The final goal was to provide efficient and well understood scaffold for the further 
optimization of FKBP51 ligands. 
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4. Results and discussion 
 
4.1 Design of conformationally defined FKBP ligands 
 
The multiple interactions of 3a with the protein made the direct assessment of the 
contribution of the C1-C6 cyclization difficult. We therefore decided to synthesize 
bicyclic [3.3.1] aza-amides derivatives 4 (Figure 12). This rigidified aza-amid nucleus 
is a simplified mimic of the 3a core with the idea of limiting the flexibility of these 
monocyclic ligands which may decrease the entropic costs upon binding meanwhile 
increasing the flexibility of the R1 and R2 substituents to allow them to increase the 
interactions with the protein. The unrestricted substituents could be better suited to 
mimic the active conformation of monocyclic pipecolate-based FKBP ligands like 2. In 
such a constrained bicycle, the C1-carbonyl oxygen is preoriented for interaction with 
Ile87. A hydrogen bond with the backbone amide of this residue is a hallmark of most 
FKBP ligands known so far. In addition, the important hydrophobic interaction 
between the piperidine ring and the indole of Trp90 together with the hydrogen bond 
between the C8-amide carbonyl and Tyr113-OH would be highly conserved. Further 
optimization of R1 could more closely resemble those present in the monocyclic 
ligands like 1 to help to improve the binding affinity. The bicyclic [4.3.1] aza-amide 
derivatives 5 (Figure 12) with a similar structure as 4 and a two-atom linker between 
C1- C6 was also proposed. It could adopt to a similar conformation as 4 and with the 
possiblity of further modification at C8 and C9 position. 
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Figure 12: Proposed bicyclic [3.3.1] aza-amide derivatives 4, bicyclic [4.3.1] aza-amide derivatives 5 
and the corresponding monocyclic derivatives 6 derived from 1 (FK506), prototypic synthetic FKBP 
ligand 2 (SLF) and polycyclic ligand 3a. 
 
4.2 Computer modelling 
 
Computer modelling of the bicyclic [3.3.1] aza-amide nucleus 7 and the bicyclic 
[4.3.1] aza-amide nucleus 8 into the binding pocket of FKBP51 indicated no obvious 
sterical hindrance between the protein and the bicyclic aza-amide nucleus 7 and 8 
(Figure 13). The C1-C6, N7, O1 and O10 of the bicyclic [3.3.1] aza-amide nucleus 7 
and C1-C6, N7, O1 and O11 of the bicyclic [4.3.1] aza-amide nucleus 8 were overlaid 
with the corresponding atoms of 2 (SLF) in the cocrystal structure of 2 and FKBP51 
FK1 domain. The binding mode of the bicyclic [3.3.1] aza-amide nucleus 7 and the 
bicyclic [4.3.1] aza-amide nucleus 8 was nearly superimposable with the common 
elements of the pipecolate and α-keto amide region (Figure 1 and 4). Small 
deviations were observed which may be due to the bicyclic ring strains in 7 and 8. 
The geometry of the important hydrogen bond acceptor C1=O was quantified by the 
O1-C1-C2-N7 dihedral angle which varied from 153° to 193° among known 
cocrystallized FKBP51 ligands (Table 2) while the O1-C1-C2-N7 dihedral angle in 7 is 
locked to 157° and 175° for 8. 
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Figure 13: (a).The structure of the bicyclic [3.3.1] aza-amide nucleus 7 (b) The bicyclic [4.3.1] aza-
amide nucleus 8 used for computer modeling. (c) Superimposition of 7 (orange) with 2(magenta) 
modelled into the FKBP51 FK1 domain. (d) Superimposition of 8 (yellow) with 2(magenta) modelled 
into the FKBP51 FK1 domain. (e) A space filling mode of 7 positioned into the pocket of FKBP51 FK1 
domain. f) A space filling mode of 8 positioned into the pocket of FKBP51 FK1 domain. 
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Based on this parameter, the geometry of the bicyclic [4.3.1] aza-amide nucleus 8 
along the C1-C2 bond is predicted to be preorganized nearly identical as the 
experimentally observed conformation in the unconstrained FKBP ligands, while the 
predicted dihedral angle in the bicyclic [3.3.1] aza-amide nucleus 7 deviates more. 
The similar geometry shared by the bicyclic [3.3.1] aza-amide nucleus 7 and the 
bicyclic [4.3.1] aza-amide nucleus 8 with the most unconstrained FKBP ligands might 
enhance the affinity of the bicyclic [3.3.1] aza-amide and bicyclic [4.3.1] aza-amide 
derivatives for the FK1 domain of FKBP51 and 52. We therefore decided to prepare 
the corresponding bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic [4.3.1] aza-
amide derivatives 5 to address the contribution of the bicyclization. 
 
 Compound 
(PDB number) 
3a FK506 (1) 
(3O5R) 
C2a 
(4DRN) 
C2b 
(4DRP) 
C3 
(4DRQ) 
SLF(2) 
(4DRK) 
7 8 
O1-C1-C2-N7 dihedral angle 153° 179° 193° 191° 185° 185° 157° 175° 
 
Table 2: The O1-C1-C2-N7 dihedral angle for all known cocrystallized FKBP51 ligands and the 
computer modelling bicyclic [3.3.1] aza-amide nucleus 7 and the bicyclic [4.3.1] aza-amide nucleus 8. 
 
4.3 Synthesis 
 
4.3.1 Synthesis of the bicyclic [3.3.1] aza-amide derivatives 4 and the 
bicyclic [4.3.1] aza-amide derivatives 5 
 
4.3.1.1 Retrosynthetic analysis and strategy of the bicyclic [3.3.1] aza-amide 
derivatives 4 
 
The retrosynthesis of the bicyclic [3.3.1] aza-amide derivatives 4 is outlined in 
Scheme 4. The R1 substructure in 4 was envisioned to be incorporated through 
alkylation from 9 followed by sequential deprotection and introduction of the α-ketone 
amide moiety or sulfonamide moiety as R2. The bicyclic nucleus 9 was expected to 
be most expediently generated by cyclization of a cis-2, 6-disubstituted piperidine 
precursor 10. The piperidine ring in 10 was thought to be obtained from 11 with 
reduction of a 2, 6-disubstituted pyridine and the amine group could be obtained from 
reduction of a cyano group. 11 could be easily prepared from 12 via aromatic 
nucleophilic substitution. 
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Scheme 4: Retrosynthesis of the bicyclic [3.3.1] aza-amide derivatives 4 
 
4.3.1.2 Synthesis of the bicyclic [3.3.1] aza-amide nucleus 17 
 
The bicyclic [3.3.1] aza-amide nucleus 17 was prepared in a 6-step synthetic route as 
shown in Scheme 5. Aromatic nucleophilic substitution of commercially available 
ethyl 6-bromopicolinate 12 with copper(I) cyanide in presence of pyridine via a 
Rosenmund-von Braun reaction afforded the corresponding cyanylated compound 
11189. Selective hydrogenation of the cyano group with Raney-Ni with concomitant in 
situ protection of the produced primary amine group with the tert-butyloxycarbonyl 
(Boc) group was accomplished in a one-pot reaction to give the product 13. 
Compound 13 was further reduced by platinum oxide in acetic acid at 50 bar H2 from 
which the cis enantiomers 14 were seperated and used for the next step.190 
Incorporation of the carboxybenzyl (Cbz) group to protect the secondary amine group 
in 14 gave the product 15. The Boc protection group was efficiently removed by 1:1 
TFA in DCM to give the primary amine product 16. Without isolation and purification, 
the crude product 16 was further subjected to ring closure in refluxing pyridine to 
yield the [3.3.1] core 17 in gram scale.  
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Scheme 5: Synthesis of bicyclic [3.3.1] aza-amide nucleus 17: (a) CuCN, pyridine, reflux, 60%. (b) 
Raney-Ni, Boc2O, H2 1 bar, RT, overnight, 68%. (c) PtO2, AcOH, H2 50 bar, RT, 2 days, 49%. (d) Cbz-
Cl, N,N-diisopropylethylamine RT, 6h, 96%. (e) 50% TFA in DCM, RT, 1h. (f) pyridine, reflux, 2h, 76% 
(2 steps). 
 
Two products were observed by TLC and LCMS for the reduction of 13. 
Theoretically, reducing the compound 13 could give four stereoisomers: two cis 
enantiomers 14a and 14b together with two trans enantiomers 14c and 14d. Only the 
cis enantiomers 14a and 14b (Scheme 6) could cyclize to afford compound 17. The 
compound 17 and products thereof will be enantiomeric mixture, but only the final 
product from 14a was expected to bind to the FKBPs due to the steric hindrance. 14a 
and 14b were seperated as racemic mixture and used for further reaction without 
stereochemical resolution. Compound 17 was characterized by HPLC, NMR and 
Mass spectroscopy, no diastereomers were observed.  
 
13
N
O
O
NH
O
O 14b
NH
O
O
NH
O
O
14a
NH
O
O
NH
O
O
+
14d
NH
O
O
NH
O
O
14c
NH
O
O
NH
O
O +
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Because of the high similarity between the bicyclic [3.3.1] aza-amide derivatives 4 
and the bicyclic [4.3.1] aza-amide derivatives 5, the following syntheses of 17 to 
afford 4 will be discussed later together with the synthesis of  the bicyclic [4.3.1] aza-
amide derivatives 5. 
 
4.3.1.3 Retrosynthetic analysis and strategy of the bicyclic [4.3.1] aza-amide 
derivatives 5 
 
The retrosynthesis of the bicyclic [4.3.1] aza-amide derivatives 5 is outlined in 
Scheme 7. The analysis was based on the synthetic route of bicyclic [3.3.1] aza-
amide derivatives described above. The R1 substructure in 5 was envisioned to be 
incorporated through alkylation from 18 followed by sequential deprotection and 
introduction of the α-ketone amide moiety or the sulfonamide moiety as R2. The 
bicyclic nucleus 18 was expected to be most expediently generated by cyclization of 
a cis-2, 6-disubstituted piperidine precursor 19. The piperidine ring in 19 was thought 
to be obtained from 20 by reduction of a 2,6-disubstituted pyridine and the amine 
group could be obtained from reduction of a cyanomethyl group. 20 could be easily 
prepared from 21. 
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Scheme 7: Retrosynthesis of the bicyclic [4.3.1] aza-amide derivatives 5 
 
4.3.1.4 Synthesis of the bicyclic [4.3.1] aza-amide nucleus 27 
 
The novel bicyclic [4.3.1] aza-amide nucleus 27 was prepared in a 7-step synthetic 
route as shown in Scheme 8. Aromatic nucleophilic substitution of commercially 
available 6-bromopicolinic acid 21 with acetonitrile in presence of n-butyl lithium 
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afforded the corresponding cyanomethylated product 22191. The carboxylic acid 
group in 22 was further subjected to methylation under mild condition with 
trimethylsilyldiazomethane in MeOH at room temperature to give the product 20192. 
Selective hydrogenation of the cyanomethyl group with Raney-Ni with concomitant in 
situ protection of the produced primary amine group with the tert-butyloxycarbonyl 
(Boc) group was accomplished in a one-pot reaction to give the product 23. 
Compound 23 was further reduced by platinum oxide in acetic acid at 50 bar H2 to 
afford a mixture of diastereomers which were used for the next step.190 Incorporation 
of the carboxybenzyl (Cbz) group to protect the secondary amine group in 24 gave 
the product 25. The Boc protection group was efficiently removed by 1:1 TFA in DCM 
to give the primary amine product 26. Without isolation and purification, the crude 
product 29 was further subjected to ring closure to yield 27 in refluxing pyridine.  
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Scheme 8: Synthesis of the bicyclic [4.3.1] aza-amide nucleus 27: (a) Acetonitrile, BuLi, -78°C, 3h, 
87%. (b)Trimethylsilyldiazomethane, MeOH, RT, overnight, 46%. (c) Raney-Ni, Boc2O, H2 1 bar, RT, 
overnight, 76%. (d) PtO2, AcOH, H2 50 bar, RT, 2 days, 98%. (e) Cbz-Cl, N,N-diisopropylethylamine 
RT, 6h, 86%. (f) 50% TFA in DCM, RT, 1h. (g) Pyridine, reflux, 2h, 34% (2 steps). 
  
Attempts to use 12 as starting material failed as 28 was found to be the main product 
under the condition of 1.1eq BuLi and 1.5eq acetonitrile at -78°C. (Scheme 9) 
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Scheme 9:  Side reaction of cyanomethylation based on 12 (a) 1.5eq Acetonitrile, 1.1eq BuLi, -78°C, 
3h, 75%.  
 
Similar to the intermediate 14 described above, two products were observed for 24 
by TLC and LCMS. Theoretically, reducing compound 23 would also give four 
stereoisomers: two cis-enantiomers and two trans-enantiomers. Only the cis-
enantiomers 24a and 24b (Scheme 10) could cyclize to afford compound 27. The 
compound 27 and product thereof will be two enantiomeric mixture, but only the final 
product from 24b was expected to bind to the FKBPs due to the correct positioning of 
the C1-carbonyl group. The diastereomeric mixture of compounds 24a, 24b, 24c and 
24d were used for further reaction without diastereomeric separation.  
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Scheme 10: The four stereoisomeric products 24a, 24b, 24c, 24d from the reduction of 23 
 
Most of the synthetic steps carried out in Scheme 5 had good yield except the last 
two steps. The cyclization reaction in refluxing pyridine for two days to give the 
product 27 was accompanied by hydrolysis of ester in 26 and decomposition of 26. 
The total yield for the final two steps was as low as 34%. One reason is that only two 
diastereomers of the four diastereomeric mixtures in 26 could cyclize to afford 
enantiomeric mixture of compound 27. Furthermore, it might be due to the increased 
ring size that it becomes more difficult to construct the lactam ring through 
cyclization. Reactivity in cyclization reaction is influenced by the activation energy in 
the transition state. The activation energy is thought to reflect the strain energy of the 
ring to be formed and is markedly dependent on ring size. The higher strain energy 
makes the cyclization of 27 to form the 7-membered ring more difficult193. Compound 
27 was characterized by HPLC, NMR and Mass spectroscopy, no diastereomers 
were observed.  
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4.3.1.5 Synthesis of the bicyclic [3.3.1] aza-amide derivatives 4 and 
bicyclic[4.3.1] aza-amide derivatives 5                           
 
Because of the high similarity between the bicyclic [3.3.1] aza-amide derivatives 4 
and the bicyclic [4.3.1] aza-amide derivatives 5, their following syntheses were 
carried out in the same way. The successful synthesis of bicyclic [4.3.1] aza-amide 
compound 17/27 makes further incorporation of different R1 and R2 substitutions into 
the scaffold 17/27 possible (Scheme 11).  
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Scheme 11: Synthesis of bicyclic [3.3.1] aza-amide derivatives 4 and bicyclic [4.3.1] aza-amide 
derivatives 5: (a) 28a-28c (R1-Br), NaH, THF, RT, 3 days (25% -95%). (b) Pd/C H2 1 bar, RT, 1h (71% 
-100%). (c) 33a or 33b (R2-OH) EDC-HCl, HOBT, TEA, RT, 6h (23% -76%). (d) 34a-34d (R3-Cl), 
DIPEA, DCM, RT, overnight (13% -53%). 
 
The R1 and R2 substitutents were selected based on previous preliminary structure-
activity relationships for FKBP51143. R1 was intended to mimic the 3-[3,’4’-
dimethoxyphenyl)propyl branch of the ester “top” group in the monocyclic ligand 2 or 
possibly the ring C of 3a. The R2 groups were chosen to resemble the α-keto amide 
and the pyranose moieties in FK506. Sulfonamides as R3 were shown to be suitable 
surrogates for the α-keto amide substructure in monocyclic FKBP51/52 ligands143. 
The series of bicyclic [3.3.1] aza-amide ketoamide derivatives 4a-4c and bicyclic 
[4.3.1] aza-amide ketoamide derivatives 5a-5d were synthesized from 17/27 through 
a 3-step synthetic route as shown in scheme 8. 17/27 in dry THF was deprotonated 
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followed by addition of 28 to give the substituted products 29/30. The Cbz-protected 
amine group was deprotected by catalytic hydrogenation using Pd/C in MeOH to give 
the free amine product 31/32194. The secondary amine group in 31/32 was coupled 
with α-keto acid 33 to give the final product 4a-4c and 5a-5d.139  
The series of bicyclic [3.3.1] aza-sulfonamide derivatives 4e-4g and bicyclic [4.3.1] 
aza-sulfonamide derivatives 5e-5g and 5i were prepared by coupling the secondary 
amine group in 31/32 with commercial sulfonyl chloride 34a-d.139  
To further clarify the contribution of the R1 group to the overall ligand efficiency, the 
bicyclic ligands 4h and 5h without R1 were prepared by hydrogenation cleavage of 
the Cbz group in 17 and 27 followed by coupling of the secondary amines of 35 and 
36 with 2-oxo-2,3-dihydro-benzothiazole-6-sulfonyl chloride 34c. (Scheme 12). 
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Scheme 12: Synthesis of bicyclic [3.3.1] aza-amide derivative 4h and bicyclic [4.3.1] aza-amide 
derivative 5h: (a) Pd/C H2 1 bar, RT, 1h (82% for 35,100% for 36) (b) 34c, DIPEA, DCM, RT, 
overnight (43% for 4h, 12% for 5h) 
 
All of these two series of ligands were obtained as an enantiomers mixture, but only 
one of the enantiomers was expected to bind to the FKBPs due to the steric 
hindrance. Ligands were characterized by HPLC, NMR and Mass spectroscopy, no 
diastereomers were observed.  
   
4.3.1.6 Synthesis of the monocyclic derivatives 6 
 
To assess the role of the cyclization, the corresponding mononcyclic derivatives 6 as 
reference compounds bearing the same substituents as in 4 and 5 were prepared 
(Scheme 13). Nucleophilic substitution of commercially available Boc-pipecolic acid 
37 with 28a followed by cleavage of the Boc group afford 39. This was then 
converted to corresponding α-keto amide 6a and sulfonamides 6e-6g. (scheme 10) 
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Scheme 13: Synthesis of monocyclic ligands 6a and 6e-6g: (a) K2CO3, acetone, reflux, overnight 
(100%)  (b) 20%TFA in DCM, RT, 2h (100%) (c) 33a (R2-OH), TEA, HATU, DCM, RT, overnight (42% 
for 6a) (d) 34a-34c (R3-Cl), DIPEA, DCM, RT, overnight ( 20%-48% for 6e to 6g) 
 
4.4 Competition binding fluorescence polarization assay 
 
4.4.1 Binding affinity of the bicyclic aza-amide series.  
 
A competition binding fluorescence polarization assay141 was used to evaluate the 
binding of potential ligands to the FKBP12 and to the FK1 domain of FKBP51 and  
FKBP52. SLF 2 linked to a flurophore was used as a tracer. The affinity of any new 
synthesized ligand was assessed by its ability of competition with fluo-2 for the 
FKBPs.  
Among the α-keto amide series (Table 3), the tert-pentyl series compounds 4b, 5b 
and 6b were all inactive for FKBP51/52. The higher affinities of 4a compared to 4b 
and 5a compared to 5b for FKBP51/52/12 indicated that the trimethoxyphenyl moiety 
is a better R2 substructure than tert-pentyl for the bicyclic scaffolds. The activity of 5c 
for FKBP51/52/12 suggested the cyclohexyl analog which more closely mimics the 
pyranose group of the high affinity natural product ligands like FK506 is also effective 
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in the bicyclic context. The higher affinity of 5a compared to 5d for FKBP51/52/12 
suggests that a three-atom spacer compared to a two-atom spacer is preferred for 
optimal positioning of the dimethoxyphenyl group in R1. This is consistent with the 
SAR observed for monocyclic FKBP51/52 ligands.134  
 
Compound FKBP52 FKBP51 FKBP12 
 n 
R1 R2 
Ki (µM)  
(LE) 
Ki (µM) 
 (LE) 
Ki(µM) 
 (LE) 
4a 1 OMe
OMeO  
O
O
OMe
OMe
OMe  
79.4±20 
(0.15) 
51.1±7.6 
(0.15) 
0.2±0.01 
(0.24) 
5a 2 OMe
OMeO  
O
O
OMe
OMe
OMe  
45.2±13.5 
(0.15) 
23.7±3.1 
(0.16) 
0.3±0.007 
(0.23) 
6a - OMe
OMeO  
O
O
OMe
OMe
OMe  
>100 >100 0.3±0.03 
(0.22) 
4b 1 OMe
OMeO  
O
O  
>100 >100 3.5±0.1 
(0.24) 
5b 2 OMe
OMeO  
O
O  
>100 >100 1.5±0.1 
(0.24) 
6b - OMe
OMeO  
O
O  
>100 >100 0.9±0.1 
(0.27) 
4c 1 
 O
O
OMe
OMe
OMe  
>100 >100 6.3±0.02 
 (0.26) 
5c* 2 OMe
OMeO  HO
O
O
 
27.2±0.2 
(0.17) 
 
19.7±0.5 
(0.18) 
 
0.6±0.1 
(0.23) 
6c* - OMe
OMeO  HO
O
O
 
>100 >100 2.78 
(0.22) 
5d 2 OMe
OMe 
O
O
OMe
OMe
OMe  
>100 >100 1.5±0.04 
(0.21) 
 
Table 3: Binding affinities of monocyclic or bicyclic ketoamide ligands for FKBP51, FKBP52 and 
FKBP12 determined by fluorescence polarization assay141. LE is indicated in parentheses. *Mixture of 
diasteromers. 
 
With simplified R1 in 4c, the affinity for FKBP51/52/12 was abolished regardless of R2 
indicating the importance of binding contributions by suitable R1 groups. The 
comparison of 4a, 5a and 6a for FKBP51/52 indicates that the bicyclic [4.3.1] aza-
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amide scaffold has a better degree of preorganization than the bicyclic [3.3.1] aza-
amide scaffold which in turn is preferred over the monocyclic scaffold. The same 
trend was observed for FKBP51/52/12 in the cyclohexyl analog series (5c > 6c). In 
terms of ligand efficiency,where the free energy is divided by the number of non-
hydrogen atoms147, the bicyclic [4.3.1] aza-amide scaffold and bicyclic [3.3.1] aza-
amide scaffold both represented a clear improvement over the monocyclic scaffold. 
 
4.4.2 Binding affinity of the bicyclic aza-sulfonamide series.  
 
A library of sulfonamide ligands was first described for FKBP12195. Recently, 
sulfonamides were identified as suitable surrogates for the α-keto amide substructure 
in monocyclic FKBP51 ligands143. To test whether this SAR would be extended to the 
constrained bicyclic scaffolds, selected phenyl sulfonamides were introduced at the 
N7 position of the bicycles. All the bicyclic [3.3.1] aza-sulfonamides and bicyclic 
[4.3.1] aza-sulfonamides have low mircomolar binding affinities for FKBP51/52. 5g 
even displayed submicromolar affinity for FKBP51 while all bicyclic sulfonamides 
have submicromolar or even low nanomolar level binding affinities for FKBP12. All 
sulfonamides had better binding affinities than the corresponding a-keto-amide series 
compounds for FKBP51/52/12. For the sulfonamide series, the bicyclic [4.3.1] scaffod 
provides better binding affinity than the bicyclic [3.3.1] scaffod than the monocyclic 
scaffod. The same trend was also observed for the α-keto amide series before (Table 
4). 
For the first three sulfonyl aza-sulfonamide series (Table 4), the preferred 2-(3’,4’-
dimethoxyphenyl)oxy ethyl substituent identified above was kept constant as R1 
group. With the m,m-dichlorophenyl substructure as R2, for FKBP51/52/12 both the 
[3.3.1] aza-sulfonamide 4e and the bicyclic [4.3.1] aza-sulfonamide 5e have better 
binding affinity than monocyclic sulfonamide 6e while 5e is slightly worse than 4e. 
With the benzothiazole substructure as R2, for FKBP51/52 both the [3.3.1] aza-
sulfonamide 4f and the bicyclic [4.3.1] aza-sulfonamide 5f have better binding affinity 
than monocyclic sulfonamide 6f. For FKBP12, 5f is better than 6f than 4f. 
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Compound FKBP52 FKBP51 FKBP12 
 n 
R1 R2 
Ki [µM] 
(LE) 
Ki [µM] 
(LE) 
Ki [µM] 
(LE) 
4e 1 OMe
OMeO  S
O
O
Cl
Cl 
12.2±3.7 
 (0.20) 
8.8±1.1 
 (0.21) 
0.14±0.01 
(0.28) 
5e 2 OMe
OMeO  S
O
O
Cl
Cl 
1.6±0.3 
(0.23) 
1.2±0.2 
(0.23) 
 0.01±0.002 
(0.32) 
5i 2 OMe
OMeO  S
O
O
Cl
Cl
OH
 
3.5±0.4 
(0.21) 
 
1±0.1 
(0.23) 
 
0.4±0.04 
(0.24) 
 
6e - OMe
OMeO  S
O
O
Cl
Cl 
>100 >100  0.4±0.006 
(0.27) 
4f 1 OMe
OMeO  S
O
O
N
S
 
>100 64.8± 12.3 
(0.17) 
0.9±0.2 
(0.24) 
5f 2 OMe
OMeO  S
O
O
N
S
 
3.6±0.5 
(0.21) 
2.1±0.2 
(0.22) 
0.03±0.007 
(0.29) 
6f - OMe
OMeO  S
O
O
N
S
 
>100 >100 0.1±0.00003 
(0.28) 
4g 1 OMe
OMeO  S
O
O
NH
S O
 
>100 13.9±0.9 
(0.19) 
0.07±0.0004 
(0.28) 
5g 2 OMe
OMeO  S
O
O
NH
S O
 
1.2±0.2 
(0.22) 
0.3±0.02 
(0.24) 
0.001±0.0003 
(0.34) 
6g - OMe
OMeO  S
O
O
NH
S O
 
12.4±1.3 
(0.19) 
7.6±0.5 
(0.20) 
0.002±0.0001 
(0.35) 
4h 1 H 
S
O
O
NH
S O
 
46.4±3.8 
(0.26) 
27±1.7 
(0.27) 
0.1±0.0005 
(0.42) 
5h 2 H 
S
O
O
NH
S O
 
22.6±1 
(0.27) 
9.8±0.5 
(0.29) 
0.06±0.002 
(0.41) 
6h - ethyl 
S
O
O
NH
S O
 
>100 >100 0.2±0.004 
(0.38) 
 
Table 4: Binding affinities of monocyclic or bicyclic sulfonamide ligands for FKBP51, FKBP52 and 
FKBP12 determined by fluorescence polarization assay141. LE is indicated in parentheses. 
   
With the benzothiazolone substructure as R2, for FKBP51/52/12 the bicyclic [4.3.1] 
aza-sulfonamide 5g has better binding affinity than monocyclic sulfonamide 6g, but 
the [3.3.1] aza-sulfonamide 4g is worse than 6g. The p-hydroxyl m,m-dichlorophenyl 
substructure as R2, the bicyclic [4.3.1] aza-sulfonamide 5i showed higher binding 
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affinity compared to the similar analog 5e for FKBP51/52 but not for FKBP12. When 
R1
A substituent was minimized or deleted, (the series of 4h, 5h and 6h), as expected 
this reduced the affinity to FKBP51/52/12 but only to a rather small extent, at least in 
the context of the high-affinity benzothiazolone substituent as R2. As observed 
before, the cyclization improved affinity (5h > 4h > 6h) and the same trend was 
observed for the smaller homolog FKBP12. For these sulfonamide series, the bicyclic 
[4.3.1] aza-amide scaffold and the bicyclic [3.3.1] aza-amide scaffold also showed a 
clear improvement over the monocyclic scaffold with the constantly highest ligand 
efficiency value of the bicyclic [4.3.1] aza-amide scaffold. Importantly, however, 
removal of the R1A substituent increased ligand efficiency in all cases. Ligand 5h is 
much more efficient than the natural products FK506 or rapamycin and represents 
the most efficient FKBP ligand known today. It is the first lead-like ligand (MW= 
367Da, LE= 0.29, clogP= 0.95) for the clinically relevant FKBP51 and offers three 
rigidly defined attachment points (R1, R2 and C8) for further lead optimization. 
The assay results of the α-keto amide series and the sulfonamide series strongly 
suggests that the higher affinities of the [4.3.1] aza-amide series are indeed an 
inherent property of the seven-membered bicycle. Importantly, for all four sulfonyl 
[4.3.1] aza-amides 5 prepared low micromolar affinities were obtained which is 
almost a factor of ten better than the corresponding sulfonamide analogs of 2, i.e., in 
an optimized monocyclic scaffold143.  
 
4.5 Cocrystal structure of 4g, 5f and 5g with FKBP51 FK1 
 
 
To better understand the enhanced binding of the [4.3.1] aza-amide bicycles, the 
ligands 4g, 5f and 5g were cocrystallized with the FK506-binding domain of FKBP51 
with resolution of 1.08Å, 1.1Å and 1.15Å respectively (Figure 14). The overall binding 
modes of 4g, 5f and 5g were similar to those observed for compound 2134 or for a 
sulfonamide-based analog143 in complex with FKBP51. Importantly, the positioning of 
the C1-carbonyl oxygen of 5f and 5g and the geometry of the hydrogen bond to Ile87-
NH was more similar to those observed for FK506 or to 2 than those of the [3.3.1] 
bicycles 4g or 3a compared to the latter two. 
The dihedral angle formed by O1-C1-C2-N7 of 5f and 5g were between 173° and 
175°. This is very similar to unconstrained FKBP ligands when bound to FKBP51 
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(167°-179°, Table 5). In contrast, the O1-C1-C2-N7 dihedral angle of the [3.3.1] bicycle 
4g was substantially smaller (148°). This translated into an altered orientation of the 
C1-carboyl group towards the Ile87-NH donor (quantified by the C1-O1-Ile87N-Val86C 
dihedral angle and the O1-C1-Tyr113O angle). The C1-O1-Ile87N-Val86C dihedral angle 
was substantially smaller for the [3.3.1] bicycles (122° for 4g, 97° for 3a) compared to 
the [4.3.1] bicycles (147°-167°, Table 5), which resembled much closer the 
unconstrained FKBP ligands (144°-196°, Table 5). Likewise, the O1-C1-Tyr113O angle, 
which defines the C1-Tyr113O dioplar contact, is much more similar between the 
[4.3.1] bicycles (100°-102°) those and the unconstrained FKBP ligands( 99°-114°) 
than those observed for  the [3.3.1] bicycles (90° for 4g, 86° for 3a). 
Similar to 3a the C8-methylenes of the bicyclic linker in 4g, 5f and 5g form van-der-
Waals contacts with Phe77 while the C9-methylene of 5f and 5g do not seem to 
engage in any contacts with the protein nor intramolecularly with other parts of the 
ligand. The benzothiazole substituent and benzothiazolone substituent as R2 sit in a 
pocket below the 80s loop (Ser118-Ile122) which is known to be functionally relevant for 
the modulation of the steroid hormone receptors by the large FKBPs 31. Here, two 
orientations for the benzothiazole/benzothiazolone substituents seem to be possible, 
each rotated vs. each other by 180°. In one conformation of the thiazolones, the 
sulfur is within hydrogen bond distance to Ser118. The C15-H of 5f engages the 
backbone carbonyl of Leu119 below van-der-Waals distance (2.9Å).  
 
  Compound 
(PDB number) 
C1-Tyr-O 
dipolar 
distance 
(Å) 
angle  
O1-C1-Tyr113-
O 
O1-Ile87N 
bond 
distance (Å) 
dihedral angle  
O1-C1-C2-N7 
dihedral 
angle  
Val86C-
Ile87N- O1-C1 
3a 3.4 86° 2.8 153° 96° 
FK506 (1) 
(3O5R) 
3.2 101° 2.9 179° 144° 
C2a (4DRN)134 3.5 114° 2.9 193° 197° 
C2b
134 
(4DRP) 
3.5 111° 
 
2.8 191° 164° 
C3
143 
(4DRQ) 
3.1 99° 3.0 185° 158° 
SLF(2)134 
(4DRK) 
3.2 107° 2.9 185° 144° 
5f in conformation1 3.0 102° 2.8 173° 142° 
5f in conformation2 3.0 102° 2.9 172° 144° 
5g in conformation1 3.0 100° 2.8 175° 152° 
5g in conformation2 3.0 102° 2.8 175° 158° 
4g in conformation1 3.1 90° 2.8 147° 128° 
4g in conformation2 3.1 90° 2.8 148° 122° 
 
Table 5 Quantification of structual parameters for known cocrystallized FKBP51 ligands and the 
cocrystallized FKBP51 ligands 4g, 5f and 5g.  
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Figure 14: The bicyclic sulfonyl [3.3.1] aza-amide derivative 4g, the bicyclic sulfonyl [4.3.1] aza-
amide derivative 5f and 5g and their cocrystal structures with the FK506-binding domain of FKBP51, 
resolved to a resolution of 1.08Å, 1.1Å and 1.15Å respectively146. Color code is as in Figure 2, 
putative hydrogen bonds are dashed in orange, aromatic hydrogen bonds are dashed in cyan. Lys121 
is removed for clarity. 
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In the homologous cocrystal structure of 5g, Leu119 moves outward and the O14-
thiazolone engages  the carbonyl of L119 in a dipolar interaction. Almost identical 
contacts are observed for the thiazolone in the corresponding [3.3.1] analog 4g. For 
both conformations of 4g, 5f and 5g, the ortho-hydrogens of the aryl sulfonamide 
form aromatic hydrogen bonds with Tyr113 and Asp68, respectively, similar to those 
previously observed for monocyclic pipecolate sulfonamide ligands143. Importantly, 
only minimal interactions of the benzothiazole or the benzothiazolone ring are 
present for 5f, 5g and 4g. Indirectly the C9 stabilized the observed conformation. The 
2-(3’,4’-dimethoxyphenyl)oxy ethyl substituent R1 overlays almost perfectly with the 
3-(3’,4’-dimethoxyphenyl)propyl moiety in the complex of 2, sitting in a cradle formed 
by Gly84-Ile87 and Tyr113. 
 
 
Compound 
 
Scaffold N7-Tyr113-O 
distance (Å) 
Oa- Tyr113-O 
distance (Å) 
pyramidalization(a) 
FK506  3.6 2.6 176° 
C2a  (comp 3f-1196) 3.9 2.7 180° 
C2b (comp 3f-2196) 3.7 2.6 -178° 
SLF (2) (comp 2a196) 3.6 2.6 -179° 
C3 (comp 20197) 
N
O
O
R26
R1
 3.8 3.4 146° 
3a 3.5 2.6 -178° 
4g (conformation1) 3.3 3.6 139° 
4g (conformation2) 
N
N
O
R24
R1
 
3.2 3.6 140° 
5f (conformation1) 3.1 2.8 136° 
5f (conformation2) 3.0 2.7 132° 
5g (conformation1) 3.3 3.2 136° 
5g (conformation2) 
N
N
O
R2
5
R1
 3.3 3.2 139° 
 
Table 6: Quantification of the N7 and S=Oa interactions with Tyr113 of FKBP51 for the known 
cocrystallized FKBP51 ligands and for bicycles of this work. (a) The pyramidal is quantified by the angle 
of S-N7 vs the C2-N7-C6 plane. 
 
A strong tendency for pyramidalization of N7 of the sulfonamides was also observed 
which indicated a substantial degree of sp3 hybridization (Table 6). For all bicylcic 
sulfonamides a distance below 3.3 Å was observed between Tyr113-OH and N7 
accompanied by an increased distance between Tyr113-OH…OA=S. The Tyr113-
OH…OA=S contact in 5f, 5g and 4g is substantially longer than the corresponding 
bond distance in α-keto amide ligands like 5a and 2 (Table 6). In the cocrystal 
structure of 5f, Tyr113-OH clearly approaches the OA=S and N7 within a distance of a 
4. Results and discussion 
 
45 
 
bifurcated hydrogen bond. Both sulfonamide oxygens in 5f, 5g and 4g are involved in 
several close edge-on aromatic CH…O contacts. The strong tendency for 
pyramidalization and the shifting from a hydrogen bond to a bifurcated hydrogen 
bond (to OA=S and N7 ) together with the higher binding affinity of the bicyclic aza-
sulfonamides than the corresponding α-keto amides indicated that the bicyclic aza-
sulfonamide might better represent the active conformation for FKBP51. 
 
4.6 GR hormone radioactive binding assay 
 
The main physiological role of FKBP51 is believed to be the inhibition of 
glucocorticoid receptor signalling, especially in stressful situations113. The FKBP51-
GR interplay has been difficult to assess pharmacologically, however, largely due to 
lack of appropriate chemical probes. With the optimized FKBP51 ligands in hand we 
therefore set out to investigate the functional consequences of FKBP51 inhibition in a 
GR hormone radioactive binding assay, a defined reconstituted biochemical model of 
GR activity that obviates many of the pitfalls of the assays used earlier113, 198. The 
functional effects of the ligands were assessed by their ability to block the inhibitory 
effect of FKBP51 on GR activity. Gratifyingly, we observed a clear dose-dependent 
recovery of GR binding by 4g, 5g and 6g (Figure 15), which showed functional 
activity on an important downstream FKBP51 target and mirrored their affinities to 
FKBP51 in the fluorescence polarization assay results (Table 4). 
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 Figure 15: Relieve of FKBP51-
mediated suppression of the 
glucocorticoid receptor hormone 
binding affinity by 4g, 5g and 6g. 
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4.7 Thermodynamic analysis 
 
The [4.3.1] bicyclization contributed ∆∆G>2kcal/mol to the binding energy compared 
to the monocycles. This is more than could have been achieved by van-der-Waals 
contacts of the bridging C8-methylene 199. Towards elucidating the origin of the 
additional binding energy in more detail, the thermodynamic parameters for complex 
formation of the most advanced compounds 4g, 5g and 6g with FK506-binding 
domain of FKBP51 were determined by isothermal titration calorimetry (ITC) (Figure 
16). The binding affinities (Kd) of 4g, 5g and 6g were obtained by ITC were 10.5µM, 
0.36µM and 3.3µM respectively which is in excellent agreement with the fluorescence 
polarization assay results (Table 4). 
The binding of 6g and 4g was driven both enthaplically and entropically. Surprisingly, 
however, we observed a strong increase in binding enthalpy ∆H for the [4.3.1] bicycle 
5g compared to 6g and 4g (-13.5kcal/mol vs -3.0 and -4.5kcal/mol, respectively) 
which was largely compensated by a substantial entropic offset. Similar, on first sight 
counter-intuitive negative changes of binding entropy upon ligand rigidification have 
recently been observed by several groups200-203. In one case the counterproductive 
entropic change was shown to be caused by a stronger ordering of the protein by the 
more rigid ligands203. The large increase in binding enthalpy of 5g vs 6g is probably 
due to (i) the better hydrogen bond acceptor properties of the C1-amide compared to 
the C1-ester, (ii) stabilization of the conformation of O1-C1-C2-N7, (iii) additional van-
der-Waals contacts by the C8-methylene. (iv) stabilization of the N7 pyramidalization. 
The direct comparison of 5g and 4g reveals the strong orientation dependence of the 
hydrogen bond and dipolar contact network around the C1=O carbonyl which could 
account for a substantial amout of the additional binding entropy of  5g. Importantly, 
amide vs ester replacements had previously been shown to be inactive in the 
monocyclic scaffolds134, 143 . 
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(a)                   6g 
 
4g 
 
5g 
 
Compound ∆H 
(KCal/mol) 
∆S 
(KCal/mole/K) 
T∆S 
(KCal/mol) 
∆G  
(KCal/mol) 
Kd  
(µM) 
6g -4,47800 0,00983 2,88166 -7,35966 3,25733 
4g -2,98600 0,01260 3,69369 -6,67969 10,49318 
5g -13,57000 -0,01680 -4,92492 -8,64508 0,35842 
(b)      
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Figure 16: (a). Thermodynamic 
parameters for binding of 4g, 5g 
and 6g to FK506 binding domain 
of FKBP51. (b) Thermodynamic 
signatures of 4g, 5g and 6g 
upon binding to the FK506-
binding domain of FKBP51. 
 
 
 
4.8 Synthesis of the C8-derivatized bicyclic [4.3.1] aza-amides 57 
 
From the above results, the bicyclic [4.3.1] aza-amide scaffold was identified as a 
priviledged substructure for FK506-binding proteins (FKBPs). The cocrystal 
structures of the bicyclic [4.3.1] aza-amide derivatives 5f and 5g in complex with 
FKBP51 FK1 revealed the possibility to further introduce additional substituents into 
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the bicyclic [4.3.1] aza-amide nucleus at C8 which would increase the contact surface 
with the FKBP51/52 and may help to increase the binding affinity. Therefore we 
designed and synthesized a new series of C8-derivative bicyclic [4.3.1] aza-amide 
derivatives 41 (Figure 17). 
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Figure 17: (a) Proposed C8-derivatized bicyclic [4.3.1] aza-amide derivatives 41 based on the bicyclic 
[4.3.1] aza-amide derivatives 5 and the C8-substituted bicyclic [4.3.1] aza-amide nucleus 42 used for  
the computer modelling study. (b) The superimposition of the energy-minimized C8-derivative bicyclic 
[4.3.1] aza-amide nucleus 42 (yellow) with compound 2 (blue) bound to the FKBP51 FK1 domain 134. 
(c) Space filling model of the energy-minimized C8-derivative bicyclic [4.3.1] aza-amide nucleus 42 
positioned into the FKBP51 FK1 domain as in b. 
 
The C8-derivatized bicyclic [4.3.1] aza-amide nucleus 42 was modelled into the 
binding pocket of FKBP51 (Figure 17b, 17c). The C1-C6, N7, O1 and O11 of the 42 
were overlaid with the corresponding atoms of 2 (SLF) in the cocrystal structure of 2 
and FKBP51 FK1 domain. A conserved binding mode of C8-derivative bicyclic [4.3.1] 
aza-amide nucleus 42 was enforced with the common elements of the pipecolate and 
α-keto amide region (Figure 9) being nearly superimposable in the two structures. It 
indicated no obvious sterically hindrance between the protein and the bicyclic aza-
amide nucleus 42. 
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4.8.1 Retrosynthetic analysis and strategy 
 
To control the stereochemistry at C2, C6 and C8 a new synthetic strategy was devised 
as outlined in Scheme 14. The bicyclic nucleus 43 was envisioned to be prepared 
from 44 through carbon-carbon bond formation between C6 and C8 by N-acyliminium 
cyclization. The stereochemistry of C6 would be dictated by the stereochemistry at C2 
whereas the stereochemistry at C8 was envisioned to be substrate-controlled by 
steric interference with C4 of the piperidine ring. An electron-donating group at the 
vinyl group of C8 was thought to facilitate the intramolecular cyclization as well as to 
subsequently provide a functional group for further diversification. The amide moiety 
in 44 could be incorporated by coupling between 45 and 46. 
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Scheme 14: Retrosynthsis of the C8-substituted bicyclic [4.3.1] aza-amide nucleus 43. 
 
4.8.2 Synthesis of the bicyclic [4.3.1] aza-amide nucleus 57 
 
The commercially available 44 was alkylated with 45 to afford compound 28a, which 
was reacted with commercially available 47 to yield compound 48. The 
allyltrimethylsilyl group was introduced by a metathesis reaction with Grubbs catalyst 
I in DCM as a cis/trans isomeric mixture 50 (1:1 based on NMR) followed by 
deprotection of the Boc-protection group with silica to give the N10-building block 51. 
The secondary amine group in 51 was coupled with commercial (S)-6-oxopiperidine-
2-carboxylic acid 52 in presence of HOAt, EDC-HCl and DIPEA in DCM at room 
temperature to give 53 followed by Boc-protection of the N7-position in 53 to give the 
compound 54. 54 was regioselectively reduced with DIBAL-H followed by cyclization 
within 30% TFA in DCM and cleavage of Boc protection group to afford 57 in a one-
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pot reaction with 76% yield and excellent diastereoselectivity (dr>99:1 determined by 
NMR) (Scheme 15). 
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Scheme 15: Synthesis of 57 (a) K2CO3 in acetone, reflux, overnight, 46% (b) NaH in DMF, 0°C, 2h, 
69% (c) Grubbs catalyst I in DCM, reflux, 67% (d) SiO2, 150°C, vacuo, 85% (e) HOAt, EDC, DIPEA in 
DCM, RT, 24h, 90% (f) BuLi, (Boc)2O in THF, -78°C, overnight, 72% (g) 3eq  DIBAL-H, THF, -78°C (h) 
30% TFA in DCM at 0°C (76% for two steps) 
 
The C2 position is particularly prone to racemization. To support the absence of 
racemization, simplified model reactions were carried out (Scheme 16). The Boc-
protection group in 48 was cleaved with 50% TFA in DCM at room temperature 
followed by coupling with commercial (S)-6-oxopiperidine-2-carboxylic acid 52 to 
afford 59. The N7-position in 59 was protected with Cbz group to give the compound 
60 which had excellent enantiomeric excess (ee >99:1) based on chiral HPLC 
analysis. 
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Scheme 16: a).Synthesis of a model compound 60 to check the racemization at C2 position.(a) 50% 
TFA in DCM, RT, 2h (b) HBTU, DIPEA in DCM, RT, 24h, 95% (c) BuLi, Cbz-Cl in THF, -78°C, 5h, 
60%. b) Chiral HPLC spectroscopic data of 60. 
 
4.8.3 Systematic study of the cyclization reaction. 
 
A mechanism study showed that when 55 was treated with 10% TFA in DCM  at -
78°C and stirred at -20°C for 2h, 55 was converted to 61 as the only product 
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observed in LCMS. With further addition of TFA to 50% at 0°C, 61 was converted to 
57 as the only product which supported that the cyclization was through 
intramolecular N-acyliminium cyclization but not intramolecular iminium cyclization 
(Scheme 17). 
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Scheme 17: Mechanism study for the cyclization step based on 55. (a) 10% TFA in DCM, -78°C, 2h 
(b) 50% TFA  in DCM, 0°C , 2h, (76% for two steps) 
 
Before the establishment of the crucial intramolecular N-acyliminium cyclization, 
different cyclization conditions were tested. As the N-acyliminium cyclization was 
planned to be carried out under acid condition, the N7-position in 53 was first 
protected with Cbz-protection group instead of the acid sensitive Boc-protection 
group to afford 62. Different reduction conditions were then carried out to selectively 
reduce 62 (Scheme 18). 
Under condition b 204, 205 only trace amounts of 63 were produced but the cleavage of 
Cbz group to afford 53 (based on NMR and Mass spectroscopy) as the main product. 
Condition c could afford the production of 63 but with low conversion rate while 
excessive amounts of NaBH4 in MeOH afford 63 with 64 as a side product. The side 
reaction could be reduced to a smaller extent by using excessive amounts of NaBH4 
under mild acidic condition (pH= 6) in MeOH (condition d)206. No reaction was 
observed when THF or DMF was used as solvent instead of MeOH. Condition e was 
found to be the best to convert 62 to 63 without any side reaction. Unfortunatly, 63 is 
very labile and attempts to purify 58 by chromatography were unsuccessful and the 
production of 63 was deduced from LCMS results. 
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Condition Product 
b 1.2eq LiEt3BH,THF,-78°C 53 
c 1.2eq NaBH4,MeOH,0°C 63+64 
d excessive NaBH4,MeOH,0°C under acidic condition by adding 10%TFA 63+64 
e 3eq DIBAL-H, THF, -78°C 63 
 
Scheme 18: Different reduction conditions and possible products from the reduction of 62. a) BuLi, 
Cbz-Cl in THF, -78°C, overnight, 60% 
 
To better understand this reduction reaction, a model reaction was carried out to 
check the reduction condition and stability of the hemiaminal product. When 65 was 
treated with NaBH4 in MeOH at 0°C, 66 and 67 were produced. Both of them were 
purified with chromatography and characterized with NMR (Scheme 19). The low 
yields might be due to other side reactions such as Cbz group cleavage of 65, but 
further efforts to elucidate the side reactions were not put forth. 
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Scheme 19: A simplified model study of the selective reduction step based on 65. (a) 2.2 eq NaBH4 in 
MeOH, RT, 2h, (26% for 64, 21% for 65) 
 
The lability of 63 might be due to the coexistence of the electron-rich substructure 
and hemiaminal in one molecule. Thus, 63 was used for the next step without 
purification. 
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Scheme 20: Three conditions for the synthesis of 62 based on 57. 
Condition 1: (a) excessive NaBH4, MeOH,0°C, (b) 20% TFA in DCM at 0°C, (c) 60% TFA in DCM at 
0°C, (34% for three steps) 
Condition 2: (a) excessive NaBH4, MeOH,0°C (d) 10% TFA in DCM at 0°C, (51% for two steps) 
Condition 3: (a) 3eq DIBAL-H, THF,-78°C (d) 20% TFA in DCM at 0°C, (83% for two steps) 
(e) 33% HBr in acetic acid at 0°C, 69% 
 
When NaBH4 was used as a reducing reagent, 20% TFA was added to the reaction 
mixture of 63 at 0°C to afford the methoxylated compound 68 in situ followed by 
cyclization in the presence of 60% TFA in DCM at 0°C to afford 70 with 34% yield in 
all three steps and excellent diastereoselectivity (dr>99:1 determined by HPLC) 
(Scheme 20 condition 1). Later it was found that the methoxylation step was not a 
prerequisite and that 63 could be converted to 70 directly by cyclization with 10% 
TFA in DCM at 0°C with 51% yield for all two steps and excellent diastereoselectivity 
(dr>99:1 determined by NMR) (Scheme 20 condition 2). Different acidic conditions 
like SnCl4207, 208, TiCl4 or formic acid161, 208 instead of TFA were tried for the 
cyclization process. Rapidly decomposition of 63 was observed in the presence of 
the lewis acid SnCl4 or TiCl4 at -78°C while slow conversion and many side reactions 
were observed when formic acid was used at -20°C . When DIBAL-H was used as a 
reducing reagent, the reaction mixture of 63 was evaporated in vacuo followed by 
cyclization within 20% TFA in DCM at 0°C with 83% yield for two steps and excellent 
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diastereoselectivity (dr>99:1 determined by NMR) (Scheme 20 condition 3). The Cbz 
group in 70 was then cleaved by 33% HBr in acetic acid at 0°C to afford 57 with 69% 
yield. 
 
4.8.4 Functionalization of bicyclic [4.3.1] aza-amides nucelus 57 
   
At this point a m,m-dichlorophenylsulfonyl group as a preferred substructure for 
FKBPs was installed at the N7 of 57 in presence of DIPEA to afford 71 with moderate 
yield and conversion ratio which might be due to the steric hindrance of the 
secondary amine. The terminal vinyl group at C8 in 71 was further submitted to 
dihydroxylation. The attempts to stereoselective dihydroxylate the vinyl group in 71 
was conducted with AD-Mix-Alpha or AD-Mix-Beta at room temperature. 
Unfortunately, the dihydroxylation with 7 eq AD-Mix-Alpha affored 72 as a 6:1 
diasteremeric mixture of C11 epimers with only 60% conversion, while with 2 eq AD-
Mix-Beta, 73 was obtained with 100% conversion but still as a 2:1 diasteremeric 
mixture of C11 epimers (Scheme 21). Diastereomers were observed by NMR for both 
72 and 73 which could not be separated by HPLC.  
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Scheme 21: Synthesis of 71, 72 and 73 (a) 34a, DIPEA, DCM, RT, overnight, 48%, (b) 7eq AD-Mix-
Alpha, water, t-BuOH, RT,57%, (c) 2eq AD-Mix-Beta, water, t-BuOH, RT,94%. 
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Scheme 22: a) Synthesis of 65 
(a) 6eq tert-Butyldimethylsilyl 
trifluoromethanesulfonate, 2,6-
lutidine, DCM, 0°C. b) HPLC 
spectroscopic data of the 
crude 74. 
 
 
In a small test reaction, the double silylation of 73 resulted in two separable peaks 
with the same mass identified by LCMS. These two peaks have a ratio of 2:1 by 
HPLC analysis (Scheme 22). Further purification of these two peaks was to be 
carried out in the future.  
Although the attempt to stereoselective dihydroxylate the vinyl group in 71 was 
unsuccessful, the terminal vinyl group at C8 allows for a versatile and straightforward 
derivatization to further improve the interaction with FKBPs. An overview for future 
SAR study is outlined in Scheme 23. 
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Scheme 23: Possible derivatization of the terminal vinyl group at C8 for compound 71 
 
4.9 Competition binding fluorescence polarization assay 
 
The affinities of the C8-derivatized ligands 71 and 73 for FKBPs were measured by a 
fluorescence polarization assay using purified human FKBP12 or the purified FK506-
binding domain of FKBP51 and FKBP52 expressed in E.coli (Table 7)141. As SLF (2) 
has a comparable higher binding affinity than other simplified synthetic ligands, it was 
linked to a flurophore to be used as a fluorescence-labelled ligand. The affinity of 71 
and 73 were assessed by its ability of competition with the fluo-2 for the FK1 domain 
of FKBP. 
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Compound 71 retained slightly improved binding affinity and similar ligand efficiency 
compared to the corresponding C8-unmodified control 5e demonstrating that 
substituents can be accommodated in the C8-position. The approximately 5 times 
better binding affinity of 73 compared to 5e might result from the increased contact 
surface between ligand and protein. The introduction of additional hydroxyl groups at 
C11 and C12 substantially improved the ligand affinity and efficiency for all FKBPs 
yielding ligands with low nanomolar potencies. 73 is 175 times (for FKBP51) and 75 
times (for FKBP52) better than 63 and rivalls the affinity of the natural product FK506.  
 
FKBP51 FKBP52 FKBP12 Compound 
Ki(µM) LE Ki(µM) LE Ki(µM) LE 
71 1.4 ±0.2 0.22 2.1±0.4 0.21 0.03±0.003 0.28 
73 0.008 ± 0.02a 
 
0.29 0.03 ± 0.08 
 
0.27 <0.001b  
 
 
5e  8.8±1.0 0.21 12.3±3.7 0.2 0.14±0.01 0.28 
FK506 0.09±0.02a 0.17 0.23±0.07  0.16 0.0006±0.0001  0.22 
 
Table 7: Binding affinities 71, 73 and 5e for FKBP51, FKBP52 and FKBP12. (a) With sg586 as tracer. 
(b) This the detection limit of tracer fluo-2. 
 
4.10 Cocrystal structure of 71 and FKBP51 
 
The X-ray crystal structure of the FKBP51 FK1 domain complexed with ligand 71 was 
solved to 1.08 Å resolution. In this complex, FKBP51 adopts the same folding 
topology as observed in FKBP51 complexed with 5f and 5g. The ligand adopts a 
similar binding mode compared to that of 5f or 5g with the common pipecolate ring 
being nearly superimposable (Figure 18). The pipecolyl ring of the ligand sits atop the 
indole of Trp90, which forms the floor of the FKBP binding pocket. Similar to FK506 
the C1-carbonyl of the pipecolate forms a hydrogen bond with the backbone amide of 
Ile87 with a distance of 2.8Å, almost the same as the [4.3.1] bicycles 5f and 5g (2.8-
2.9 Å). The C1-O1-Ile87N-Val86C dihedral angle was 167° (Table 8). This is very 
similar to 5f and 5g (142°-158°, Table 5) and resembled the unconstrained FKBP 
ligands (144°-196°, Table 5). The dihedral angle formed by O1-C1-C2-N7 of 71 was 
175° which is the same as in 5g, only marginally different from 5f, and very similar to 
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unconstrained FKBP ligands when bound to FKBP51 (167°-179°, Table 5). Likewise, 
the O1-C1-Tyr113O angle and C1- Tyr113O dipolar distance which define the C1-Tyr113O 
dioplar contact, are 101° and 3.1Å respectively. Both values are similar to the [4.3.1] 
bicycles 5f and 5g (100°-102°, 3.0 Å). 
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Figure 18: The C8-substituted bicyclic [4.3.1] aza-amide derivative 71 and cocrystal structures with 
the FK506-binding domain of FKBP51, resolved at a resolution of 1.08 Å. 71 bound to the FK1 domain 
of FKBP51. Key residues of FKBP51 are show in orange, the two hydrogen bonds between O1 and 
HN-Ile87 and between O13a and HO-Tyr113 are shown dashed red. The dipolar interaction between the 
C1-carbonyl and HO-Tyr113 is dashed in green. Aromatic hydrogen bonds between C15-H and OH-
Tyr113, C19-H and OH-Asp68 are dashed in cyan. van-der-Waals interactions between Cl18 and C-Lys118 
are dashed yellow. The halogen bond between Cl16 and O-Ser118 is dashed magneta. 
 
One oxygen of the sulfonamide (S=Oa) forms a rather weak hydrogen bond with the 
hydroxyl group of Tyr113 with a distance of 3.2Å which is longer than the 
corresponding bond distance in α-keto amides like FK506, 5a and 2. FKBP51 and 71 
engage in a number of aromatic CH···O-acceptor interactions, e.g., the oxygen of the 
sulfonamide (S=Ob) and the ε-hydrogens of Tyr
57, Phe67 and Phe130. As expected, 
the dichloro aryl ring sits below the 80s loop and packs on Ile122. The two ortho-
hydrogens of the sulfonylphenyl ring form close contacts (2.9 Å) with the p-oxygen of 
Tyr113 and with carboxylate of Asp68 (2.8 Å), respectively. These two contacts are 
much shorter than normal aromatic hydrogen bonds. One of the aromatic chlorines 
might form a van-der-Waals contact with Lys121 (3.3 Å). The other chlorine 
approaches Ser118 to form a halogen bond (2.5 Å) with the C16-Cl-Ser118-O angle of 
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166°. The Ser118 Such short distance is rather uncommon for halogen bonds. Like 4g, 
5f and 5g (Table 6), 71 also has a similar N7 pyramidalization (Table 8) and a short 
distance of 3.4 Å between N7 and Tyr113-OH. The C11 approaches Tyr57 with a 
distance of 3.7 Å and the C12- C11- Tyr113-O angle of 125°. The C8-vinyl substitution 
points out of the pocket which clearly confirmed the desired conformation obtained 
from our stereoselective synthesis and also indicated the possibility of introducing 
more potential ligand-protein interaction with further allyl functionalization. 
 
Compound 
(PDB 
number) 
C1-
Tyr113-O 
dipolar 
distance 
(Å) 
angle  
O1-C1-
Tyr113-
O 
O1-
Ile87N 
distance 
(Å) 
dihedral 
angle  
O1-C1-
C2-N7 
dihedral 
angle  
Val86C-
Ile87N- 
O1-C1 
O8/S=Oa 
Tyr113-O 
distance 
(Å) 
N7-
Tyr113-O 
distance 
(Å) 
Pyramid
alization
(a) 
Fk506 (1)  
(3O5R) 
3.2 101° 2.9 179° 144° 2.6 3.6 176° 
71 3.1 101° 2.8 175° 167° 3.2 3.4 134° 
 
Table 8: Quantification of structual parameters for cocrystallized 71 with FKBP51 FK1 and compared 
with the cocrystal structure of FK506. (a) The pyramidalization is quantified by the angle of S-N7 vs the 
C2-N7-C6 plane. 
 
4.11 Hypothetical binding mode of 73a and 73b  
 
The low nanomolar potency of 73 based on the dihydroxylation of 71 showed the 
importance of these two hydroxy groups. Due to the difficulties of stereoselective 
dihyroxylation and purification, their cocrystal strucutures with FKBP51 FK1 domain 
were not available. Based on the cocrystal strucuture of 71 with FKBP51 FK1 
domain, the hypothetical binding mode of 73a and 73b were proposed by computer 
modelling which was carried out by Dr. Uwe Koch from Lead Discovery Center 
GmbH (Figure 19). 73a and 73b bind to the FKBP51 FK1 domain with the conserved 
binding mode as 71. The only difference between 73a and 73b is at the C11 position 
with a R-conformation for 73a and a S-conformation for 73b. In 73a, the C11-OH 
approaches Tyr57 and Asp68 with a distance of 4.2Å and 3.8Å respectively which 
would be too far to form hydrogen bonds. In 73b, the C11-OH approaches Asp68 with 
a distance of 3.8Å which is still above the threshold of hydrogen bond while it might 
engage in a hydrogen bond with Tyr57 with a proposed distance of 2.9 Å. This could 
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explain the higher binding affinity of the 71. The angle formed by C11- O11-Tyr57- O of 
73b was 133° and the dihedral angle C8- C11- O-Tyr57 was 62°. While the angle 
formed by O11- Tyr57- O- Tyr57-C4 angle was 147° and the dihedral angle O11- Tyr57- 
O- Tyr57- C4- Tyr57-C3 was 117° (Table 9). This hypothesis has to be confirmed in the 
future by experimental cocrystal structures. 
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Figure 19: a, b) The structure of 73a and 73b used for computer modelling study. c). Computer 
modelling of 73a (blue) bound into the FKBP51 FK1 domain with the distances measured between C11 
hydroxy group and Tyr57 and Asp68. d) Computer modelling of 73b (blue) bound into the FKBP51 FK1 
domain with the distances measured between C11 hydroxy group and Tyr57 and Asp68. The distance 
measurement between C11 hydroxy group and Tyr57 and Asp68 are dashed yellow. 
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Compound 
 
C11- O11-
Tyr57- O 
angle 
dihedral angle  
C8- C11- O-Tyr57 
O11- Tyr57- O- Tyr57-
C4 angle 
dihedral angle  
O11- Tyr57- O- Tyr57- C4- 
Tyr57-C3  
73b 133° 62° 147° 117° 
 
Table 9: Quantification of structual parameters for the proposed hydrogen bond between Tyr57–OH 
and C11-OH. 
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5. Conclusion 
 
In order to improve the ligand affinities and efficiencies of the the FKBPs ligands, new 
scaffolds were proposed to preorganize the ligands to limit the flexibility and mimic 
the active conformation. The bicyclic [3.3.1] aza-amide and bicyclic [4.3.1] aza-amide 
core structures were designed as rigid replacements for the pipecolyl-monocyclic 
scaffold and their potential binding modes were analyzed in silico. With the synthetic 
route established in this study, a series of bicyclic [3.3.1] aza-amide derivatives 4 and 
bicyclic [4.3.1] aza-amide derivatives 5 were prepared. Their binding affinities for 
FKBP51, 52 and 12 were measured with a competition binding fluorescence 
polarization assay. Among the α-keto amide series, the trimethoxyphenyl moiety is 
shown to be a better R2 substructure than tert-pentyl for the bicyclic scaffold, while 
the cyclohexyl analog which more closely mimic the pyranose group in the high 
affinity natural product ligands is also effective in the bicyclic context. A three-atom 
spacer compared to a two-atom spacer is preferred for optimal positioning of the 
dimethoxyphenyl group in R1. For the sulfonyl aza-amides series, the 
benzothiazolone substituent was found to be the best R2 to afford 5g with nanomolar 
affinities for FKBP51/52/12. When R1 substituent was minimized or lacking, the 
affinities of the bicyclic compounds to FKBP51/52/12 were only reduced to a rather 
small extent with the benzothiazolone substituent as R2. Ligand 5h is much more 
efficient that the natural products FK506 or rapamycin and represents the most 
efficient FKBP ligand known today. It is the first lead-like ligand (MW= 367Da, LE= 
0.29, clogP= 0.95) for the clinically relevant FKBP51 and offers three rigidly defined 
attachment points (R1, R2 and C8) for further lead optimization. Both compound series 
indicate that the bicyclic [4.3.1] aza-amide scaffold has a better degree of 
preorganization than the bicyclic [3.3.1] aza-amide scaffold which in turn is preferred 
over the monocyclic scaffold. The higher affinities of the [4.3.1] aza-amide series are 
an inherent property of the seven-membered bicycle. Such a trend was also 
observed in a GR hormone radioactive binding assay and isothermal titration 
calorimetry (ITC) measurements of 4g, 5g and 6g. The higher binding affinity of 5g 
compared to 4g and 6g was dissected to be a strong increase in binding enthalpy 
with a substantial entropic offset compensation. The cocrystal structures of 4d, 5c 
and 5d with the FKBP51 FK1 domain showed that their binding modes are similar to 
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those observed for compound 2 in complex with FKBP51 FK1. This confirmed the 
rational design of the ligands and also provided valuable information for future SAR 
studies. 
Based on the cocrystal structure of 5c and 5d, a C8 substitution was proposed to be 
introduced into the bicyclic [4.3.1] aza-amide scaffold which was identified as a 
priviledged scaffold for FK506-binding proteins (FKBPs). The C8 substitution was 
predicted to increase the contact surface between ligand and protein to further 
enhance the binding affinity for FKBP51 and 52. The idea was supported by 
computer modelling which showed the steric possibility for further incorporating 
substituents at the C8 position. A new stereoselective synthetic route was established 
and optimised in which a stereoselective carbon-carbon bond formation by N-
acyliminium cyclization was the key step with 76% yield and excellent 
diastereoselectivity (dr>99:1 determined by NMR). In the cocrystal structure of 63 
with FKBP51 FK1, the retained binding mode of 63 compared to the corresponding 
C8-unmodified control 5e demonstrates that substituents can be accommodated in 
the C8-position. It confirmed the desired conformation obtained from the 
stereoselective synthesis and also indicated the possibility of introducing more 
potential ligand-protein interaction by further functionalization of the vinyl group. The 
racemic dihydroxylation of the C8 vinyl group substantially improved the affinity for all 
FKBPs yielding ligands with low nanomolar potencies that rivalled those of the 
natural product FK506. The higher binding affinity was proposed to be obtained from 
a putative hydrogen bond between the C11-OH of 64b and Tyr57. This will be 
confirmed in the future by a corresponding cocrystal strucuture. A more detailed and 
systematic SAR study of the terminal vinyl group at C8 will be carried out. 
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6. Materials and Methods 
 
6.1 Biological analytical methods 
 
6.1.1 Molecular modelling  
 
The co-crystal structure of SLF, FKBP51 or Compound 3a with the FK1 domain of 
FKBP51 were obtained from Dr. Andreas Bracher in Prof. Ulich Hartl `s group at Max 
Planck Institute of Biochemistry. Two of these structures were later published (4DRK 
and 3O5R) 134, 209.  
All computer simulations were performed on Dell computer AMD athlon™64x2 dual 
core processor 3800+ 2.00GHz, 960MB RAM. Microsoft windows XP professional 
version 2002 service pack 2. 
 
6.1.2 Molecular modelling of FKBP51 with bicyclic derivatives 7, 8, 42 
 
The bicyclic [3.3.1] aza-amide nucleus 7, the bicyclic [4.3.1] aza-amide nucleus 8 and 
the C8-derivative bicyclic [4.3.1] aza-amide derivatives 42 were constructed with 
Chemdraw 3D ultra 10.1. The structures were first drawn and cleaned up followed by 
energy calculation and minimization by MM2 computations with the minimum RMS 
gradient value at 0.1. Then, the C1-C6, N7, O1 and O10 of the bicyclic [3.3.1] aza-
amide nucleus or the C1-C6, N7, O1 and O11 of the bicyclic [4.3.1] aza-amide nucleus 
was aligned and overlaid with corresponding atoms of 2 in the cocrystal structure of 2 
and FKBP51. The resulting structures were saved as pdb files and visualized in 
PyMol.   
 
6.1.3 Competition Binding Fluorescence Polarization Assay 
 
The competition binding fluorescence polarization assay was performed as 
described141 under the guidance of Dr. Christian Kozany and Bastiaan Hoogeland.  
Fluorescence polarization (FP) assays are widely used in high throughput screening 
in drug discovery. The flurophore-labeled ligand with size less than 5000 Da210 is 
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excited by polarized light and emit depolarized light due to the rapid molecular motion 
of the flurophore during its fluorescence lifetime. This is usually in the nanosecond 
range and defined as the period between absorption of an excitation photon and the 
emission of a photon through fluorescence (Figure 14). If the flurophore-labeled 
ligand binds to a receptor of significantly greater size, the rotation of flurophore 
compared to the fluorescence lifetime is severely slowed down which causes less 
depolarization of the original plane of polarization. The extent of binding can be 
quantified by measuring the extent of depolarization. 
 
 
Figure 14: (a) and (b) Scheme of FP assay mechanism. (c) Scheme of a competition binding FP 
assays. 
   
In competition binding FP assays, an inhibitor competes with flurophore-labeled 
ligand in binding for a receptor which results in the increase of free flurophore-labeled 
ligand in solution. Thereby relatively less polarized light is emitted. Titration of the 
flurophore-labeled ligand and receptor complex with the inhibitor gives the relative 
binding affinity (IC50) of the inhibitor. The competition binding FP assay allows the 
determination of binding affinity of inhibitors from low nanomolar to high micromole 
range quickly and reproducibly. 
 
+ + 
Competitor Fluo-ligand+receptor Fluo-ligand Competitor+receptor 
High polarization Low polarization 
Polarized 
exitation 
light 
Emitted light  
is depolarized 
Polarized 
exitation 
light 
Emitted light  
remains polarized 
Rapid rotation 
slow rotation 
Fluo-ligand 
Fluo-ligand+receptor 
a: 
b: 
c: 
6. Materials and Methods 
 
67 
 
6.1.4 Isothermal Titration Calorimetry experiments 
 
The Isothermal Titration Calorimetry experiments were performed by Anne-Katrin 
Fabian. 
 
Bacterially expressed, affinity purified human HisFKBP51FK1 (aa 1-140)141 was 
dialysed against ITC buffer (20mM HEPES pH=8, 150mM NaCl, 5% DMSO). The 
activity was confirmed by active site titration in an FP Assay as described before141. 
The pH of protein was determined and ligand solutions were degassed and matched 
within 0.02 pH units. 
ITC experiments were performed with a MicroCal iTC200 titration microcalorimeter 
(GE Healthcare). All experiments were conducted at 20°C. Compound 3d (1mM) was 
measured by injection into the measurement cell containing the protein (89µM). Due 
to the limiting solubility compounds 2d and 4d were measured in a reverse setup 
injecting the protein (0.5mM and 0.16mM, respectively) into a solution of the ligand 
(40µM for 2d, 15µM for 4d). Heats of dilution were measured in blank titrations and 
subtracted from the binding heat values. ORIGIN software (version 7.0 Microcal) was 
used for data collection and analysis. 
 
6.1.5 GR hormone binding assay. 
 
The GR hormone binding assay was performed by Alexander Kirschner. 
 
6.1.6 Crystallography 
 
The crystallography was performed by Dr. Andreas Bracher as described209.  
 
6.1.7 Reference compounds 5, 6b , 6c and 6h 
 
The polycyclic compounds 5 and monocyclic compounds 6b , 6c and 6h were 
prepared by Christoph Kress and Ranganath Gopalakrishnan. 
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7. Experimental Section 
 
7.1 General chemical methods  
 
All reactions were preformed in flame-dried glassware fitted with rubber septa under 
argon unless otherwise noted. Air- and moisture-sensitive liquids were transferred via 
syringe. Organic solvents were dried over MgSO4 and concentrated by rotary 
evaporation.  
 
7.1.1 Nuclear Magnetic Resonance (NMR) 
 
The NMR measurements were performed by Claudia Dubler and Dr. David S. 
Stephenson. 
 
The 1H, 13C-NMR-spectra, 2D HSQC, HMBC, COSY and NOESY were recorded on 
a Bruker AC 300, Bruker XL 400 or Bruker AMX 600 at room temperature at the 
NMR-facility, Department of Chemistry and Pharmacy, Ludwig-Maximilians-
Universitaet Muenchen. Chemical shifts were reported in δ values (ppm); the 
hydrogenated residues of deuterated solvent were used as internal standard (CDCl3: 
δ = 7.26 ppm in 1H NMR and δ = 77 ppm in 13C NMR). Signals were described as s, 
d, t, and m for singlet, doublet, triplet and multiplet respectively. All coupling 
constants (J) were given in Hz. 
 
7.1.2 Mass Spectrometry 
 
The Mass spectra (m/z) were obtained on a Thermo Finnigan LCQ DECA XP Plus 
mass spectrometer (ESI) at the Max Planck Institute of Psychiatry while the high 
resolution mass spectrometry was carried out by Elisabeth Weyher at MPI for 
Biochemistry (Microchemistry Core facility) on Varian Mat711 mass spectrometer 
(ESI) or on a JMS GCmate II JEOL mass spectrometer (EI) by Dr. Lars Allmendinger 
at the Department of Chemistry and Pharmacy, Ludwig-Maximilians-University 
Munich.  
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7.1.3 Flash Chromatography 
 
Flash chromatography was performed using thick-walled glass columns and silica gel 
60 (0.04 – 0.063 mm) from Roth. The relative proportion of solvents in mixed 
chromatography solvents refers to the volume: volume ratio. 
Interchim Puriflash 430 with an UV detector was used as automated flash 
chromatography.  
 
7.1.4 Thin Layer Chromatography 
 
Thin layer chromatography (TLC) was performed on alumina plates coated with silica 
gel (Merck silica gel 60 F254, layer thickness 0.25mm) using the indicated solvent 
ratio (volume: volume). UV- active compounds were detected by UV- light 
determination (λ = 254 nm and λ = 366 nm), non-UV-active compounds were 
detected with different TLC staining solutions: 
 
Hanessian’s Staining Solution:   
                                  5 g CeSO4, 
                                                        25 g NH4MO7O24 · 4 H2O, 
                                    450 mL H2O,  
                                       50 mL, H2SO4 
 
Ninhydrin Staining Solution:          
                                           0.5 g Ninhydrin, 
                                        100 mL EtOH,  
                                     5mL AcOH  
 
Potassium Permanganate Staining Solution: 
 
                                                                           1.5 g KMnO4,  
                                                                           10 g K2CO3,  
                                                                           1.25 mL 10% NaOH  
7. Experimental Section 
 
70 
 
                                                                            200 mL H2O  
 
The TLC plates were dipped in one of the reagents listed above and then heated to 
stain the spots.  
 
7.1.5 High performance liquid chromatography (HPLC) 
 
Analytical HPLC: Beckman System Gold 125S Solvent Module, System Gold 
Diode Array Detector Module 168 
 
Column: Jupiter 4 µm Proteo 90 A, 250 x 4.6 mm, Phenomenex, 
Torrance, USA, 
Wavelength:            224nm, 280nm, Diode Array 
 
Mobile phase: 
 
Solvent A: 95% H2O  
 5% AcCN 
 0.1% TFA 
 
Solvent B: 95% AcCN 
 5% H2O 
 0.1% TFA 
 
Flow rate:                 1ml/min 
 
Standard Gradient: 0-100% B in 20min, 1 ml/min 
 
7.1.6 Preparatory Thin Layer Chromatography 
 
The pre-coated preparative TLC plate SIL G-200 UV254 was purchased from 
MACHEREY-NAGEL GmbH (layer: 2.0mm silica gel with fluorescent indicator UV254).  
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7.1.7 Preparative HPLC  
 
The compounds were dissolved in 40% buffer B, and the purification was carried out 
with an injection loop volume of 2 mL. 
 
Preparative HPLC: Beckman System Gold Programmable Solvent Module 126 NMP 
Beckman Programmable Detector Module 166 
Column: Phenomenex Jupiter 10µ Proteo 90 Å, 250 x 21.2 mm 10 micron 
Wavelength:             224 nm 
 
Mobile phase: 
Solvent A: 95% H2O  
 5% MeOH 
 0.1% TFA 
 
Solvent B: 95% MeOH 
 5% H2O 
 0.1% TFA 
Flow rate:                 25ml/min 
 
7.1.8 Chiral HPLC  
 
Pump: Waters 515 HPLC Pump 
Detector: LDC Analytical Spectromonitor 5000 Photodiode Array Detector 
Column: DAICEL Chemical Industries LTD. Chiralcel OD-H 
 
Solvent A: Hexane 
Solvent B: i-propanol 
wavelength: 220nm 
Standard Gradient: 1:1 60 min, 0.5 ml/min 
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7.1.9 Chemicals 
Chemical names follow IUPAC nomenclature. Starting materials were purchased 
from Aldrich, Lancaster, Fluka, Merck, Roth and were used without purification. 
 
Substance name 
CAS-
Number 
Company 
(z)-1-Ethoxy-2-(tributylstannyl)ethene e2342g1 
Activate scientific 
GmbH 
1-Hydroxybenzotriazol 123333-53-9 Aldrich 
6-Bromopicolinic acid 21190-87-4 
Activate scientific 
GmbH 
anhydrous Acetonitril 75-05-8 Roth 
Benzyl chloroformate 501-53-1 Aldrich 
Di-tert-butyl-dicarbonat, 98% 24424-99-5 Fluka 
EDC-HCl 25952-53-8 Aldrich 
Ethyl-6-bromo-2-Pyridinecarboxylate 21190-88-5 Chempur 
Hydrogen chloride 7647-01-0 Roth 
30% Hydrogen peroxide 7722-84-1 Roth 
Lithium chloride 7447-41-8 Merck 
Magnesium sulfate 7487-88-9 Roth 
  N,N'-Diisopropylethylamine 7087-68-5 Aldrich 
N-Bromosuccinimid, 99% 128-08-5 Aldrich 
n-BuLi (2M in Cyclohexane) 109-72-8 Aldrich 
Palladium on carbon 7440-05-3 Aldrich 
Platinum dioxide 1314-15-4 Merck 
Potassium carbonate 584-08-7 Roth 
Pyridine 110-86-1 Roth 
Raney nickel catalyst 7440-02-0 Merck 
Sodium azide 26628-22-8 Merck 
Sodium bicarbonate 144-55-8 Merck 
Sodium chloride 7647-14-5 Merck 
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Sodium hydride 60 % dispersion in mineral 
oil   
7646-69-7 Aldrich 
Sodium hydroxide 1310-73-2 Merck 
Sulfuric acid 7664-93-9 Roth 
Thionyl chloride 7719-09-7 Merck 
Triethylamine 121-44-8 Merck 
Trifluoroacetic acid 76-05-1 Fluka 
(Trimethylsilyl)diazomethane 2.0M in Et2O 18107-18-1 Aldrich 
9-BBN 0.5M in THF 280-64-8 Aldrich 
1,2-Dibromoethane 106-93-4 Fluka 
1,4-Dioxane 123-91-1 Roth 
3,4-Dimethoxyphenol 2033-89-8 Fluka 
Chloroform 67-66-3 Roth 
Dichloromethane 75-09-2 Roth 
Dichloromethane dry 75-09-2 Roth 
Tetrahydrofuran 109-99-9 Roth 
Acetone 67-64-1 Roth 
Methanol 67-56-1 Roth 
Methanol HPLC 67-56-1 Roth 
Acetonitrile HPLC 75-05-8 Roth 
Toluene 108-88-3 Roth 
Diethylether 60-29-7 Roth 
DMF 68-12-2 Roth 
TFA 76-05-1 Roth 
Formic acid 64-18-6 Roth 
DIPEA 7087-68-5 Fluka 
Triethylamine 121-44-8 Merck 
MgSO4 7487-88-9 Roth 
KMnO4 7722-64-7 Merck 
NaCl 7647-14-5 VWR 
LiOH 1310-65-2 Sigma 
n-BuLi 2M in cyclohexane 109-72-8 Aldrich 
NaN3 26628-22-8 Aldrich 
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KOH 1310-58-3 Roth 
K2CO3 584-08-7 Roth 
DMAP 1122-58-3 Fluka 
NaHMDS 1M in THF 1070-89-9 Aldrich 
NaHCO3 144-55-8 Roth 
NH4Cl 12125-02-9 Merck 
HATU 148893-10-1 Nova Biochem 
CDCl3 865-49-6 Roth 
 
7.1.10 Solvents 
 
Solvents were purchased from commercial suppliers Roth and Aldrich with 
ROTISOLV®, ROTIPURAN®, ROTIDRY® and HPLC grade and were used without 
purification. 
 
Solvent Quality Company 
Acetic acid ROTISOLV ≥99,9% Roth 
Acetone ROTISOLV ≥99,8% Roth 
Acetonitril ROTISOLV ≥99,9% Roth 
Anhydrous Methanol ROTISOLV ≥99,9% Roth 
Chloroform 99 % for Synthesis Roth 
Cyclohexane ROTIPURAN ≥99,5% Roth 
Dichloromethane ROTIDRY ≥ 99,8% Roth 
Diethyl ether ROTISOLV ≥99,8% Roth 
Dimethylformamide ROTISOLV ≥99,9% Roth 
Ethyl acetate ROTISOLV ≥99% Roth 
Methanol ROTISOLV ≥99,9% Roth 
n-Hexane ROTISOLV ≥99% Roth 
Pentane ROTIPURAN ≥ 99% Roth 
Tetrahydrofuran anhydrous, ≥99.9% Aldrich 
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7.2 Chemical Synthesis  
 
7.2.1 Synthesis of 6-(cyanomethyl)picolinic acid 22 
 
To 100 ml anhydrous THF under argon at -78°C was added butyl lithium (6.02 g, 
94mmol) followed by addition of acetonitrile (4.06g, 99mmol) and stirring for 30min. 
Then 6-bromopicolinic acid 21 (2.5g, 12.38mmol) in 100 ml anhydrous THF cooled 
on ice was added dropwise. After 2 h at -78°C and 30 min at room temperature, the 
reaction mixture was concentrated in vacuo, dissolved in DCM (100 ml) and 
extracted with saturated NaHCO3 solution (3 x 100 ml). The aqueous layers were 
acidified with 10% HCl, and extracted with DCM (6 x 100 ml). The collected organic 
layers were dried over MgSO4 and concentrated in vacuo. This crude product was 
used for next reaction without further purification. 
TLC [ 20% MeOH, 0.2% TFA in CHCl3]: Rf = 0.04  
Yield: 1.76g, 10.9mmol (87.7%) 
1HNMR (300 MHz, CDCl3): δ= 8.1(d, 1H, J=7.75 Hz), 8.05(t, 1H, J=7.77, 7.77Hz), 
7.75(d, 1H, J=7.8 Hz), 4.08(s, 2H) 
13C NMR (75 MHz, CDCl3): δ= 163.69, 150.06, 146.67, 140.26, 126.86, 123.68, 
116.05, 26.47 
HRMS :163.0504[M + H] +, 185.0321[M + Na] +, calculated 163.0508 [M + H] + 
 
7.2.2 Synthesis of methyl 6-(cyanomethyl) picolinate 20  
 
13.35 ml 2M TMSCHN2 in Et2O (3.05g, 26.7mmol) was added dropwise to crude 6-
(cyanomethyl) picolinic acid 22 (1.31g, 8.1mmol) in 27 ml anhydrous MeOH at 0°C. 
After stirring at room temperature for 5h, the reaction was quenched with saturated 
NaHCO3 solution (100 ml) and extracted with DCM (6 x 100 ml). The organic layers 
were dried over MgSO4 and concentrated in vacuo. The pure product was obtained 
by flash chromatography with hexane: EtOAc 1:1. 
TLC  [Hexane: EtOAc 1:1]: Rf = 0.54 
Yield: 750mg, 4.3mmol (52.7%) 
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1HNMR (300 MHz, CDCl3): δ= 8.01-8.06 (m, 1H), 7.87(t, 1H, J=7.79,7.79 Hz), 7.64(d, 
1H), 4.02(s, 2H), 3.94(s, 3H) 
13C NMR (300 MHz, CDCl3): δ= 164.95, 151.05, 148.11, 138.61, 125.49, 124.41, 
116.60, 53.04, 26.59 
HRMS: 177.0649 [M + H] +, 199.0472 [M + Na] +, calculated 177.0664[M + H] + 
 
7.2.3 Synthesis of ethyl 6-cyanopicolinate 11  
 
CuCN (31,1g, 348mmol) was added to a solution of ethyl 6-bromopicolinate 12 (16g, 
69.5mmol) in 608 ml pyridine. The mixture was heated under reflux for 16 h, filtered 
through celite and concentrated in vacuo. Saturated NaHCO3 solution (100 ml) was 
added and extracted with DCM (6 x 100 ml). The organic layers were dried over 
MgSO4 and concentrated in vacuo. The mixture was purified by flash 
chromatography with hexane: EtOAc 1:1. 
TLC [Hexane: EtOAc 1:1]: Rf = 0.65 
Yield: 7.3g, 41.4mmol (60%) 
1HNMR (600 MHz, CDCl3): δ= 8.32(dd, 1H, J=1.15, 7.97Hz), 8.04(t, 1H, J=7.86, 
7.86Hz), 7.88 (dd, 1H, J=1.13, 7.76Hz), 4.52(q, 2H, J=7.13, 7.13, 7.12Hz), 1.40(t, 3H, 
J=7.13, 7.13Hz) 
13C NMR (300 MHz, CDCl3): δ= 163.76, 150.06, 138.70, 134,23, 131.40, 128.12, 
116.62, 62.89, 14.44  
HRMS: 177.0669[M + H], calculated 177.0664[M + H] + 
 
7.2.4 Synthesis of ethyl 6-((tert-butoxycarbonylamino)methyl)picolinate 
13  
 
To a solution of ethyl 6-cyanopicolinate 11 (7.87g, 44.7mmol) in 350 ml MeOH was 
added Boc2O (19.5g, 89mmol) and catalytic amounts of Raney nickel. The reaction 
mixture was degased with argon and stirred under 1 atm H2 at room temperature for 
24 h, filtered through celite and concentrated in vacuo. The mixture was purified by 
flash chromatography with EtOAc: DCM 1:5. 
TLC [EtOAc: DCM 1:5]: Rf = 0.34 
7. Experimental Section 
 
77 
 
Yield: 8.74g, 31.2mmol (68%) 
1HNMR (300 MHz, CDCl3): δ= 7.98(d, 1H, J=7.73Hz), 7.79(t, 1H, J=7.76, 7.76Hz), 
7.48 (d, 1H, J=7.78Hz), 5.51(s, 1H), 4.48-4.58(m,2H), 4.40-4.48(m,2H), 1.44(s, 9H), 
1.34-1.42(m,3H) 
13C NMR (75 MHz, CDCl3): δ= 165.01, 158.55, 155.95, 147.68, 137.62, 125.05, 
123.65, 79.65, 61.88, 45.85, 28.35, 14.26 
HRMS: 281.1505[M + H] +, calculated 281.1501[M + H] + 
 
7.2.5 Synthesis of methyl 6-(2-(tert-butoxycarbonylamino) ethyl) 
picolinate 23 
 
To a solution of methyl 6-(cyanomethyl) picolinate 20 (0.75g, 4.3mmol) in 54 ml 
MeOH was added Boc2O (1.858g, 8.5mmol) and catalytic amounts of Raney nickel. 
The reaction mixture was degased with argon and stirred under 1 atm H2 at room 
temperature for 24 h, filtered through celite and concentrated in vacuo. The mixture 
was purified by flash chromatography with EtOAc: DCM 1:2. 
TLC [EtOAc: DCM 1:2]: Rf = 0.54 
Yield: 860mg, 3.1mmol (76%) 
1HNMR (300 MHz, CDCl3) δ= 7.90(dd, 1H, J=1.01,7.75Hz), 7.69(t, 1H, J=7.75, 
7.75Hz), 7.31(d, 1H, J=7.73Hz), 3.92 (s, 3H), 3.48 (d, 2H, J=5.89Hz), 3.01(t, 2H, 
J=6.64, 6.64Hz), 1.34(s, 9H) 
13C NMR (300 MHz, CDCl3) δ= 165.71, 159.92, 155.87, 147.51, 137.29, 126.70, 
122.92, 78.97, 52.71, 39.90, 37.79, 28.31 
HRMS : m/z: found 281.1457[M + H] +, 303.1287  [M + Na] +, calculated 281.1501[M 
+ H] + 
 
7.2.6 Synthesis of ethyl 6-((tert-butoxycarbonylamino) methyl)piperidine-
2-carboxylate 14  
 
To a solution of ethyl 6-((tert-butoxycarbonylamino)methyl)picolinate 13 (8.74g, 
31.2mmol) in 150 ml AcOH was added catalytic amounts of PtO2 and degassed with 
argon in a hydrogenation reactor (Roth). The reaction was stirred at room 
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temperature under H2 (40bar) for 3 days. 13 was not fully converted. The reaction 
mixture was filtered through celite, concentrated in vacuo and purified by flash 
chromatography with EtOAc. The retrieval of 13 was used with the same procedure 
until 100% converted. 
TLC [EtOAc]: Rf = 0.38 
Yield: 4.35g, 15.2mmol (49%) 
1HNMR (600 MHz, CDCl3) δ= 5.07(s, 1H), 4.14-4.2(m, 2H),3.33(dd, 1H,  J=2.83, 
11.52 Hz), 3.23-3.35(m, 1H), 2.90-3.05(m, 1H), 2.66-2.70(m, 1H), 1.97-2.05(m, 3H), 
1.86-1.92(m, 1H), 1.59-1.65(m, 1H), 1.4-1.48(m, 10H), 1.32-1.4(m, 1H), 1.03-1.12(m, 
1H). 
13C NMR (300 MHz, CDCl3) δ= 175.00, 156.25, 79.3, (60.92, 60.97), (58.7, 58.75), 
55.68, 46, (29.06,29.1), (28.96,29.01), (28.37,28.41), 23.92, (14.13,14.17) 
MS (ESI) m/z: found 287.2 [M + H] +, calculated 287.20[M + H] + 
 
7.2.7 Synthesis of methyl 6-(2-(tert-butoxycarbonylamino) ethyl) 
piperidine-2-carboxylate 24 diastereomeric mixture 
 
To a solution of methyl 6-(2-(tert-butoxycarbonylamino) ethyl) picolinate 23 (644mg, 
2.3mmol) in 33 ml AcOH was added catalytic amounts of PtO2 and degassed with 
argon in a hydrogenation reactor (Roth). The reaction was stirred at room 
temperature under H2 (50bar) for 2 days, filtered through celite, concentrated in 
vacuo and purified by flash chromatography with EtOAc. 
TLC [EtOAc]: Rf = 0.31 
Yield: 646mg, 2.3mmol (98 %) 
1HNMR (300 MHz, CDCl3) δ= 4.81-4.95 (m, 1H), 3.66 (s, 3H), 3.25-3.42(m, 1H),3.05-
3.25 (m, 2H), 2.85-3.00 (m, 1H), 2.48-2.60 (m, 1H), 1.95-2.05(m, 1H), 1.85-1.95(m, 
1H), 1.45-1.65(m, 3H), 1.38 (s, 9H),1.15-1.38(m, 2H),0.95-1.1(m, 1H) 
13C NMR (300 MHz, CDCl3) δ= 173.46, 156.03, 78.98, 59.08, 54.12, 51.86, 37.48, 
37.01, 31.73, 29.15, 28.34, 24.28 
HRMS : m/z: found 287.1876 [M + H] +, calculated 287.1971[M + H] + 
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7.2.8 Synthesis of 1-benzyl 2-ethyl 6-((tert-butoxycarbonylamino) methyl) 
piperidine-1,2-dicarboxylate 15 
 
To a solution of ethyl 6-((tert-butoxycarbonylamino)methyl)piperidine-2-carboxylate 
14 (4.35g, 15.2mmol) in 50 ml DCM at 0°C was added dropwisely benzyl 
chloroformate (3.89g, 22.8mmol) followed by addition of  N,N-diisopropylethylamine 
(7.85g, 60.8mmol). Atfer stirring at room temperature for 5 h, a saturated NH4Cl 
solution (20 ml) was added. The mixture was extracted with DCM (4 x 20 ml). The 
organic layers were dried over MgSO4, concentrated in vacuo and purified by flash 
chromatography with hexane: EtOAc 3:1 
TLC [ Hexane :EtOAc 3:1]: Rf = 0.26 
Yield: 6.14g, 14.6mmol (96%) 
1HNMR (300 MHz, CDCl3) δ= 7.25-7.4(m, 5H), 5.2-5.4(m, 1H), 5.0-5.1(m, 1H), 4.7-5-
0(m, 1H), 4.36-4.52(m, 1H), 4.06-4.3(m, 1H), 3.3-3.5(m, 1H), 2.9-3.14(m, 1H), 2.18-
2.35(m, 1H), 1.5-1.8(m, 6H), 1.3-1.5(m, 10H), 1.1-1.3(m, 3H) 
13C NMR (300 MHz, CDCl3) δ=173.4, 157.1, 156.4, 136.79, 128.68, 128.17, 127.96, 
79.14, 67.8, 61.80, 53.4, 50.54, 42.58, 28.69, 26.26, 16.53, 14.33 
MS (ESI) m/z: found 421.22[M + H] +, calculated 421.23[M + H] + 
HRMS : m/z: found 421.2333 [M + H] +, calculated 421.2339 [M + H] + 
 
7.2.9 Synthesis of 1-benzyl 2-methyl 6-(2-(tert-butoxycarbonylamino) 
ethyl) piperidine-1, 2-dicarboxylate 25  
 
To a solution of methyl 6-(2-(tert-butoxycarbonylamino)ethyl)piperidine-2-carboxylate 
24 (646mg, 2.3mmol) in 7 ml DCM at 0°C was added dropwisely benzyl 
chloroformate (578mg, 3.4mmol) followed by addition of N,N-diisopropylethylamine 
(1167mg, 9mmol). After stirring at room temperature for 6 h, a saturated NH4Cl 
solution (20 ml) was added and extracted with DCM (4 x 20 ml). The organic layers 
were dried over MgSO4, concentrated in vacuo and purified by flash chromatography 
with hexane: EtOAc 2:1 
TLC [Hexane :EtOAc 2:1]: Rf = 0.46 
Yield: 812mg,1.9mmol (86%) 
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1HNMR (300 MHz, CDCl3) δ= 7.28-7.42(m, 5H), 5.02-5.26(m, 2H), 4.78-
5.01(m,0.5H), 4.66-4.70(m,0.5H), 4.20-4.44(m,1H), 3.55-3.73(m,3H), 2.85-
3.45(m,2H), 2.19-2.34(m,1H), 1.45-1.75(m,7H), 1.42(s,9H) 
13C NMR (75 MHz, CDCl3) δ=172.89, 156.45, 156.05, 136.40, 128.50, 128.45, 
128.10, 127.51, 126.92, 78.85, 67.55, 52.45, 52.08, 48.40, 37.50, 33.27, 28.70, 
28.44, 25.84, 15.88 
HRMS : m/z: found 421.2437 [M + H] +, calculated 421.2339 [M + H] + 
 
7.2.10 Synthesis of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-
carboxylate 17  
 
Step 1: 1-Benzyl 2-ethyl 6-((tert-butoxycarbonylamino)methyl)piperidine-1,2-
dicarboxylate 15 (6.11g, 15mmol) in 50% TFA in DCM was stirred at room 
temperature for 1 h and then concentrated in vacuo. DCM was added and 
evaporated for 3 times to remove the TFA. The produced 16 was used for the next 
step without further purification. 
Step 2: The crude product from step 1 in 300 ml pyridine was heated under reflux for 
2 h. The mixture was concentrated in vacuo and purified by flash chromatography 
with EtOAc. 
TLC [EtOAc]: Rf = 0.23 
Yield: 3.14g, 11.4mmol (76%) 
1HNMR (600 MHz, CDCl3) δ= 7.28-7.42(m, 5H),  5.05-5.2(m, 2H), 4.63-4.77(m, 1H), 
4.43-4.57(m, 1H), 3.63-3.77(m, 1H), 3.15-3.24(m, 1H), 1.89-1.99(m, 1H), 1.66-
1.89(m, 5H)  
13C NMR (150 MHz, CDCl3) δ=171.41, 154.19, 136.31, 128.77, 128.42, 128.15,  
67.79, (54.18, 53.47), (45.94, 45.59), (44.98, 44.13), (30.59, 30.20), (27.84, 27.43), 
18.12  
HRMS : m/z: found 275.1390 [M + H] +, calculated 275.1396 [M + H] + 
 
7.2.11 Synthesis of  benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-
carboxylate 27  
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Step 1: 1-Benzyl 2-methyl 6-(2-(tert-butoxycarbonylamino)ethyl)piperidine-1,2-
dicarboxylate 25 (3.6g, 8.6mmol) in 360 ml 50% TFA in DCM was stirring at room 
temperature for 1 hour and then concentrated in vacuo. DCM was added and 
evaporated for three times to remove the TFA. The produced 26 was used for the 
next step without further purification. 
TLC [10 %MeOH in CHCl3]: Rf = 0.31 
 
Step 2: The crude product from step 1 was dissolved in 150 ml pyridine and heated 
under reflux for overnight. The reaction mixture was concentrated in vacuo followed 
by purification by flash chromatography with EtOAc. 
TLC [EtOAc]: Rf = 0.26 
Yield: 840mg, 2.9mmol (33 %) 
1H-NMR (300 MHz, CDCl3): δ= = 7.28-7.38(m, 5H), 6.52-6.74 (m, 1H), 5.12-5.24(m, 
2H), 4.96-5.18 (m, 1H), 4.6-4.74(m, 1H), 3.14-3.22(m,1H), 2.88-2.96(m, 1H), 2.24-
2.36 (m, 1H), 2.12-2.24(m, 1H), 1.88-1.96(m, 1H), 1.56-1.76(m, 4H), 1.48-1.56(m, 
1H). 
13C-NMR (150 MHz, CDCl3): δ= = 175.24, (156.0, 155.92), (136.37, 136.30), (128.58, 
128.52), 128.23, 128.12, 127.00, 127.80, 67.63, (55.51, 55.28), (46.89, 46.44), 
(39.28, 39.26), (33.02, 32.88), (29.24, 28.91), (28.10, 27.92), (15.32, 15.26) 
MS (ESI) m/z: found 289.15 [M + H] +, calculated 289.12 
HRMS : m/z: found 289.1546 [M + H] +, calculated 289.1552 [M + H] + 
 
7.2.12 Synthesis of  4-(2-bromoethoxy)-1, 2-dimethoxybenzene 28a 
 
28a was prepared as described. 196 
 
7.2.13 Synthesis of benzyl 3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-
diazabicyclo[3.3.1]nonane-9-carboxylate 29a  
 
To a solution of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17 
(100mg, 0.4mmol) in 2 ml dry THF under argon at 0°C was added NaH (26mg, 
0.9mmol). After stirring for 15 min, 28a (238mg, 0.9mmol) was added and stirred at 
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room temperature for 5 days. The reaction mixture was concentrated in vacuo, 
acidified with 10% HCl solution (5 ml) and extracted with DCM (4 x 10 ml). The 
organic phases were dried over MgSO4, concentrated in vacuo and purified by flash 
chromatography with hexane :EtOAc 2:1 
TLC [Hexane :EtOAc 1:2]: Rf = 0.31 
Yield: 104mg, 0.2mmol (63%) 
1HNMR (300 MHz, CDCl3) δ= 7.3-7.42(m, 5H),  6.74-6.8(m, 1H), 4.45-4.50(m, 1H), 
4.34-4.42(m, 1H), 5.07-5.2(m, 2H), 4.42-4.82(m, 2H), 4.05-4.25(m, 2H), 3.9-4.05(m, 
1H), 3.77-3.9(m, 7H), 3.38-3.62(m, 2H), 1.92-2.04 (m, 1H), 1.78-1.92 (m, 1H), 1.6-
1.78 (m, 4H) 
13C NMR (75 MHz, CDCl3) δ=168.6, 154.2, 153.21, 150.14, 144.01, 136.3, 128.77, 
128.41, 128.18, 112.21, 104.20, 100.73, 67.71, 66.95, 56.68, 56.11, 54.5, 53.10, 
46.79,  45.4,  30.4,  28.2, 18.50 
HRMS : m/z: found 455.2176[M + H] +,calculated 455.2182 [M + H] + 
 
7.2.14 Synthesis of benzyl 3-ethyl-2-oxo-3,9-diazabicyclo [3.3.1]nonane-9-
carboxylate 29b  
 
To a solution of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17 
(500mg, 1.8mmol) in 15 ml dry THF under argon at 0°C was added NaH (109mg, 
2.7mmol). After stirring for 15 min, ethyl iodide (421mg, 2.7mmol) was added and 
stirred at room temperature. The reaction was checked by TLC until 17 was fully 
converted. The mixture was purified by flash chromatography with 4% MeOH in 
CHCl3 
TLC [ 5% MeOH in CHCl3]: Rf = 0.56 
Yield: 538mg, 1.8mmol (95%) 
1HNMR (300 MHz, CDCl3) δ= 7.25-7.45(m, 5H),  5.03-5.23(m, 2H), 4.65-4.77(m, 1H), 
4.45-4.65(m, 1H), 3.55-3.78(m, 2H), 3.05-3.33(m, 2H),1.95-2.07(m, 1H), 1.55-
1.90(m, 5H), 1.13-1.23(t, 3H,J=7.18, 7.18Hz) 
HRMS : m/z: found 303.1703[M + H] +,calculated 303.1709 [M + H] + 
 
7. Experimental Section 
 
83 
 
7.2.15 Synthesis of 3-ethyl-3,9-diazabicyclo[3.3.1]nonan-2-one 31b  
 
To a solution of benzyl 3-ethyl-2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 
29b (100mg, 0.3mmol) in 1 ml anhydrous MeOH was added catalytic amounts of 
Palladium on carbon followed by degassing with H2. After stirring under 1 atm H2 at 
room temperature for 2 h, the reaction mixture was filtered through celite and 
concentrated in vacuo. A 20% HCl solution (5 ml) was added and extracted with 
DCM (4 x 10 ml). The aqueous layer was basified with saturated NaHCO3 solution 
and extracted with DCM (4 x 10 ml). The organic layer was concentrated and used 
for the next step without further purification. 
TLC [5% MeOH in CHCl3]: Rf = 0.37 
Yield: 45mg, 0.3mmol (81%) 
1HNMR (300 MHz, CDCl3) δ= 3.6-3.73 (m, 2H), 3.53-3.57 (m, 1H), 3.35-3.43 (m, 1H), 
3.22-3.35 (m, 1H), 3.13-3.21 (m, 1H), 1.55-2.03 (m, 6H), 1.15-1.23 (t, 3H, J=7.19, 
7.19Hz) 
13C NMR (75 MHz, CDCl3) δ=170.96, 54.63, 51.52, 46.06, 41.34, 32.17, 29.27, 
18.51, 12.28  
HRMS : m/z: found 169.1333[M + H] +,calculated 169.1314 [M + H] + 
 
7.2.16 Synthesis of 1-(3-ethyl-2-oxo-3,9-diazabicyclo[3.3.1]nonan-9-yl)-2-
(3,4,5-trimethoxyphenyl)ethane-1,2-dione 4c  
 
2-Oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a (42mg, 0.2mmol) in 1 ml DMF was 
treated with oxalyl chloride (47mg, 0.5mmol) and stirred at 0°C for 3 h. The reaction 
mixture was first concentrated in vacuo and then dissolved in 1 ml DCM followed by 
addition of 3-ethyl-3,9-diazabicyclo[3.3.1]nonan-2-one 31b (30mg, 0.2mmol), DIPEA 
(28mg, 0.2mmol) and stirred at room temperature for 1 h. The reaction was 
quenched with saturated NH4Cl solution (5 ml) and extracted with DCM (4 x 10 ml). 
The organic layers were dried over MgSO4 and concentrated in vacuo. The mixture 
was purified by flash chromatography with hexane: EtOAc 2:1. 
TLC [Hexane: EtOAc]: Rf = 0.09 
HPLC [0-100% Solvent B, 30 min]: Rt = 18.5 min, purity (280 nm) = 99% 
Yield: 20mg, 0.05mmol (28%)  
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1HNMR (300 MHz, CDCl3) δ= 7.23(s, 1H), 7.19(s, 1H), 5.17-5.22(m, 0.5H), 5.05-
5.12(m, 0.5H), 4.13-4.18(m, 0.5H), 3.98-4.06(m, 0.5H), 3.94-3.97(m, 3H), 3.88-
3.93(m, 6H), 3.62-3.89(m, 1.5H), 3.21-3.42 (m, 2H), 3.13-3.17(m, 0.5H), 2.15-2.25 
(m, 1H), 1.72-2.05(m, 5H), 1.16-1.24(m, 3H)  
13C NMR (75 MHz, CDCl3) δ= (189.91, 189.62), (166.69, 166.19), (164.21, 163.62), 
(153.70, 153.65), (144.78, 144.72), (128.17, 128.05), (107.40, 107.29), (61.31, 
61.28), 56.65, 56.60, 56.31, (51.35, 50.55), (49.75, 48.35), (41.57, 41.47), (31.60, 
30.68), (29.09, 28.45), (18.31, 18.21), 12.19 
HRMS : m/z: found 391.1863[M + H] +,calculated 391.1869 [M + H] + 
 
7.2.17 Synthesis of benzyl 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-2-oxo-3, 
10-diazabicyclo [4.3.1] decane-10-carboxylate 30a  
 
To a solution of benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 27 
(70mg, 0.2mmol) in 2 ml dry THF under argon at 0°C was added NaH (9mg, 
0.4mmol) and stirred for 15 min followed by addition of 4-(2-bromoethoxy)-1,2-
dimethoxybenzene 28a (158mg, 0.6mmol). The reaction was stirred at room 
temperature for 3 days and concentrated in vacuo. A 10% HCl solution (5 ml) was 
added and extracted with DCM (4 x 10 ml). The organic phases were dried over 
MgSO4, concentrated in vacuo and purified by flash chromatography with hexane: 
EtOAc 1:3. 
TLC [ Hexane: EtOAc 1:3]: Rf = 0.49 
Yield: 73mg, 0.2mmol (64%) 
1H-NMR (600 MHz, CDCl3): δ= 7.24-7.36 (m, 5H), 6.56 (t, 1H), 6.49 (m, 1H), 6.46-
6.48 (m, 1H), 5.12-5.2(m, 1H), 5.0-5.1 (m, 2H), 4.55-4.65(m, 1H), 4.0-4.15(m, 2H), 
3.85-3.95 (m,1H), 3.81-3.84 (m, 6H), 3.55.3.65(m, 1H), 3.49-3.54 (m, 1H), 3.21-
3.27(m, 1H), 2.3-2.4 (m, 1H), 2.15.2.25(m, 1H), 1.94-2.01 (m, 1H), 1.4-1.7(m, 5H) 
13C-NMR (150 MHz, CDCl3): δ= = 172.23, 155.96, 153.14, 149.87, 143.63, 136.32, 
128.55, 128.47, 128.06, 127.90, 127.76, 111.88, 103.79, 100.38, 67.54, 67.22, 
56.41, 56.17, 55.85, 51.22, 47.79, 45.85, 32.24, 28.81, 28.79, 15.29 
HRMS(EI) : m/z: found 468.2261 [M] +, calculated 468.2260 [M] + 
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7.2.18 Synthesis of benzyl 3-(3,4-dimethoxyphenethyl)-2-oxo- 3,10-
diazabicyclo [4.3.1]decane-10-carboxylate 30b 
 
To a solution of benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 27 
(100mg, 0.3mmol) in 2 ml dry THF under argon at 0°C was added NaH (25mg, 
0.9mmol) and stirred for 15 min followed by addition of commercially available 3,4-
dimethoxyphenethyl bromide 28b (213mg, 0.9mmol). The mixture was stirred at room 
temperature for 2 days and concentrated in vacuo. A 10% HCl solution (5 ml) was 
added and extracted with DCM (4 x 10 ml). The organic phases were dried over 
MgSO4, concentrated in vacuo and purified by flash chromatography with hexane: 
EtOAc 1:2. 
TLC [Hexane: EtOAc 1:2]: Rf = 0.44 
Yield: 39mg, 0.1mmol (25%) 
1H-NMR (600 MHz, CDCl3): δ =7.27-7.39 (m, 5H), 6.72-6.78 (m, 3H), 5.13-5.17 (m, 
2H), 5.09-5.13 (m, 0.5H), 4.99-5.05(m, 0.5H), 4.45-4.65(m, 1H), 3.8-3.9(m, 6H), 3.45-
3.77(m, 4H), 3.27-3.37(m, 1H), 2.85-2.95(m, 1H), 2.70-2.85 (m,2H), 2.30-2.45 (m, 
1H),2.00-2.20(m, 1H), 1.50-1.80(m, 3H), 0.86-0.94(m, 1H) 
13C-NMR (150 MHz, CDCl3): δ=  (171.81, 171.85), (155.71, 155.90), 148.90, (147.58, 
147.52), 136.40, (131.58, 131.23), (128.55, 128.52), (128.17, 128.10), (127.95,  
127.80), (120.74, 120.68), (112.05, 111.93), (111.19, 111.14), (67.52, 67.45), 56.17, 
(55.88, 55.85), 53.65, 53.20, (46.55, 46.27), (46.20, 45.73), (33.79, 33.72), (33.25, 
31.90), (28.76, 28.65), (15.33, 15.24) 
HRMS : m/z: found 468.2484 [M] +, calculated 453.2389 [M] + 
 
7.2.19 Synthesis of 3- (2- (3, 4- dimethoxyphenoxy) ethyl) -3, 9- 
diazabicyclo [3.3.1]nonan-2-one 31a  
 
To a solution of benzyl 3-(3,4-dimethoxyphenethyl)-2-oxo-3,9-
diazabicyclo[3.3.1]nonane-9-carboxylate 30a (104mg, 0.2mmol) in 1 ml anhydrous 
MeOH, catalytic amounts of palladium on carbon was added. The reaction mixture 
was degassed with H2 and stirred at room temperature under 1 atm H2 for 2 h, 
filterted through celite, concentrated in vacuo and used for the next step without 
further purification. 
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TLC [MeOH: CHCl3 1:9]: Rf = 0.4 
Yield: 73mg, 0.2mmol (100%) 
1HNMR (600 MHz, CDCl3) δ= 6.80(d, 1H, J=8.75 Hz), 6.51(s, 1H), 6.39-6.44(m, 1H), 
4.15-4.25(m, 2H), 3.9-4(m, 1H), 3.8-3.89(m, 7H), 3.54-3.64(m, 2H), 3.45-3.51(m, 1H), 
3.35-3.43(m, 1H), 2.39(s, 1H), 1.55-2(m, 6H) 
13C NMR (300 MHz, CDCl3) δ= 171.35, 153.08, 149.89, 143.71, 111.95, 104.02, 
100.53, 66.81, 56.45, 55.9, 54.4, 54.3, 46.6, 45.9, 31.8, 28.9, 18.22 
HRMS : m/z: found 321.1808[M + H] +, calculated 321.1814[M + H] + 
 
7.2.20 Synthesis of 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-3, 10-
diazabicyclo [4.3.1] decan-2-one 32a  
 
To a solution of benzyl 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-2-oxo-3, 10-diazabicyclo 
[4.3.1] decane-10-carboxylate 30a (60mg, 0.1mmol) in 1 ml anhydrous MeOH, 
catalytic amounts of palladium on carbon was added. The reaction mixture was 
degassed with H2 and stirred under 1 atm H2 at room temperature for 1 h, filtered 
through celite, concentrated in vacuo and used for the next step without further 
purification. 
TLC [10% MeOH in CHCl3]: Rf = 0.17 
Yield: 41mg, 0.1mmol (97%) 
1H-NMR (600 MHz, CDCl3): δ= 6.76 (d, 1H), 6.50 (d, 1H), 6.40 (m, 1H), 4.08-4.15 (m, 
3H), 3.85(s, 3H), 3.83 (s, 3H), 3.75-3.82(m, 3H), 3.33-3.35 (m, 1H), 3.2-3.26 (m, 1H), 
2.23-2.24 (m, 1H), 1.98-2.12(m, 2H), 1.5-1.75 (m, 6H) 
13C-NMR (150 MHz, CDCl3): δ= 172.23, 153.27, 149.85, 143.56, 111.90, 103.89, 
100.48, 67.32, 57.97, 56.43, 55.86, 51.05, 47.99, 45.91, 33.79, 30.28, 29.68, 29.85. 
MS (ESI) m/z: found 335.13 [M + H] +, calculated 335.19[M + H] + 
 
7.2.21 Synthesis of 3-(3,4-dimethoxyphenethyl)-3,10-
diazabicyclo[4.3.1]decan-2-one 32b  
 
To a solution of benzyl 3-(3,4-dimethoxyphenethyl)-2-oxo-3,10-
diazabicyclo[4.3.1]decane-10-carboxylate 30b (10mg, 0.02mmol) in 1 ml anhydrous 
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MeOH, catalytic amounts of palladium on carbon was added. The reaction mixture 
was degassed with H2 and stirred under 1 atm H2 at room temperature for 1 h, 
filtered through celite, concentrated in vacuo and used for the next step without 
further purification.  
TLC [10% MeOH in CHCl3]: Rf = 0.51 
Yield: 5mg, 0.02mmol (71%) 
MS (ESI) m/z: found 319.42 [M + H] +, calculated 319.20[M + H] + 
 
7.2.22 Synthesis of 2-oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a 
 
1-(3,4,5-Trimethoxyphenyl)ethanone (2.93g, 13.9mmol) and selenium dioxide (2.32g, 
20.9mmol) in 60 ml pyridine were heated to 100°C for 14 h. The mixture was filterted 
through celite, concentrated in vacuo and purified by flash chromatography with 
hexane: EtOAc: AcOH 1:15:1. 
TLC [Hexane: EtOAc: AcOH 1:15:1]: Rf = 0.14 
Yield: 2.19g, 9.1mmol (65%) 
1HNMR (600 MHz, CDCl3) δ= 3.91(s, 6H), 3.95(s, 3H),7.50 (s, 2H) 
13C NMR (150 MHz, CDCl3) δ= 56.31, 61.03, 108.04, 127.55, 144.19, 153.06, 
165.74, 186.94 
HRMS(EI): m/z: found 240.0624[M] +, calculated 240.0634[M] + 
 
7.2.23 Synthesis of  3,3-dimethyl-2-oxopentanoic acid   33b    
 
To a solution of NaOH (175mg, 4.4mmol) and KMnO4 (543mg, 3.4mmol) in 5 ml 
water at 0°C was added 3,3-dimethyl-2-pentanone (200mg, 1.8mmol). After stirring 
for 1 h at 0°C and 3 days at room temperature, the reaction was acidified with 
concentrated HCl and extracted with DCM (4 x 10 ml). The organic phases were 
dried over MgSO4, concentrated in vacuo and purified by flash chromatography with 
hexane: EtOAc 5:1.  
TLC [Hexane: EtOAc 5:1]: Rf = 0.45 
Yield: 97mg, 0.7mmol (39%) 
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1HNMR (300 MHz, CDCl3) δ=1.61(q, 2H,J=7.49,7.49,7.51Hz), 1.21(s, 6H), 0.91(t,3H, 
J=7.49,7.49Hz),  
13C NMR (150 MHz, CDCl3) δ= 9.18, 24.38, 33.13, 42.49, 185.25 
 
7.2.24 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)eth.yl)-2-oxo-3,9-
diazabicyclo [3.3.1]nonan-9-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-
dione 4a  
 
3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (35mg, 
0.1mmol) in 6 ml DCM was treated sequentially with 2-oxo-2-(3, 4, 5-
trimethoxyphenyl) acetic acid 33a (29mg, 0.1mmol), EDC-HCl (20mg, 0.1mmol), 
HOBt (18mg, 0.1mmol), TEA (13mg, 0.1mmol) at room temperature and stirred 
overnight. The reaction was quenched with saturated NH4Cl solution (5 ml) and 
extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO4 and 
concentrated in vacuo. The mixture was purified by flash chromatography with 
EtOAc.  
TLC [EtOAc]: Rf = 0.54 
HPLC [0-100% Solvent B, 30 min]: Rt = 21.5 min, purity (280 nm) = 99% 
Yield: 14mg, 0.03mmol (24%)  
1HNMR (600 MHz, CDCl3) δ= 7.19(d, 2H, J=22.63), 6.72-6.8(m, 1H), 6.42-6.48(m, 
1H), 6.34-6.39(m, 1H), 5.22(s, 0.5H), 5.07(s, 0.5H), 4.17-4.27(m, 1.5H), 4.08-4.16(m, 
1.5H), 4.04-4.07(m, 0.5H), 3.97-4.04(m, 1.5H), 3.94(d, 3H, J=7.39), 3.79-3.92(m, 
12H), 3.62-3.65(m, 0.5H), 3.47-3.56(m, 1.5H), 2.13-2.18(m, 0.5H), 1.93-2.02(m, 
1.5H), 1.79-1.9(m, 2H), 1.7-1.78(m, 2H) 
13C NMR (300 MHz, CDCl3) δ= (189.57, 189.30), (167.24, 166.73), (163.90, 163.38), 
153.43, 153.39, (152.77, 152.76), (149.92, 149.90), (144.48, 144.46), (143.88, 
143.85), (127.86, 127.74), (111.87, 111.85), (107.09, 107.00), (103.94, 103.85), 
(100.36, 100.35), (66.81, 66.80), (61.07, 61.04), 60.38, (56.39, 56.36), (56.29,56.14), 
(55.89, 55.86), (53.39, 52.68), 51.17, 49.36, (46.71, 46.55), 42.84, (31.35, 30.49), 
(28.95, 28.30), (18.03, 17.92) 
HRMS(EI) : m/z: found 542.2264 [M] +, calculated 542.2264 [M] + 
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7.2.25 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-
diazabicyclo[3.3.1]nonan-9-yl)-3,3-dimethylpentane-1,2-dione 4b  
 
3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (20mg, 
0.06mmol) in 3 ml DCM was treated sequentially with 3,3-dimethyl-2-oxopentanoic 
acid 33b (18mg, 0.13mmol), EDC-HCl (23mg, 0.13mmol), HOBt (17mg, 0.13mmol), 
TEA (8mg, 0.08mmol) at room temperature and stirred overnight. The reaction was 
quenched with saturated NH4Cl solution (5 ml) and extracted with DCM (4 x 10 ml). 
The organic layers were dried over MgSO4 and concentrated in vacuo. The mixture 
was purified by flash chromatography with EtOAc.  
TLC [EtOAc]: Rf = 0.6 
HPLC [0-100% Solvent B, 16 min]: Rt = 14.9 min, purity (280 nm) = 98% 
Yield: 21mg, 0.05mmol (76%)  
1HNMR (600 MHz, CDCl3) δ= 6.74 (d, 1H, J=8.76 Hz), 6.44(t, 1H, J=2.86, 2.86 Hz), 
6.35(dt, 1H, J=2.95, 2.95, 8.74Hz), 5.04 (s, 0.5H), 4.89(s, 0.5H), 4.16(ddd, 2H, 
J=6.88, 11.94, 14.20Hz), 3.85-4.03(m, 2.5H), 3.83(d, 3H, J=2.67Hz),  3.80(s, 3H), 
3.69-3.75(m, 1H), 3.56-3.63(m, 0.5H), 3.46-3.54(m, 1H),1.95-2.1(m, 1H), 1.75-1.9(m, 
3H), 1.65-1.57(m, 4H), 1.16-1.26(m, 3H), 1.11(d, 3H, J=5.56 Hz), 0.78-0.88(m, 3H) 
13C NMR (300 MHz, CDCl3) δ= (207.03, 206.85), (167.30, 166.9), (164.44, 163.63), 
(152.85, 152.84), 149.88, 143.81, (111.92, 111.87), (103.99, 103.83), (100.43, 
100.42), (67.92, 25.57), (66.82, 66.59), (56.39, 56.09), (55.86, 55.83), (53.36, 52.50), 
(50.76, 42.32),  (48.16, 46.47), (46.71, 46.64), (32.40, 32.32), (31.26, 27.96), (30.19, 
28.51), (23.63, 23.37), (23.33, 22.84), (18.00, 17.94), (8.84, 8.71) 
HRMS : m/z: found 446.2413[M + H], calculated 446.2417[M + H] +   
 
7.2.26 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-
diazabicyclo [4.3.1]decan-10-yl)-3,3-dimethylpentane-1,2-dione 5b  
 
To a solution of 3-(2-(3, 4-dimethoxyphenoxy) ethyl)-3, 10-diazabicyclo [4.3.1] decan-
2-one 32a (22mg, 0.06mmol) in 3 ml DCM was added sequentially 3,3-dimethyl-2-
oxopentanoic acid 33b (19mg, 0.1mmol), EDC-HCl (25mg, 0.1mmol), HOBt (17mg, 
0.1mmol), TEA (8mg, 0.08mmol) at room temperature and stirred overnight. The 
reaction was quenched with saturated NH4Cl solution (5 ml), extracted with DCM (4 x 
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10 ml). The organic layers were dried over MgSO4 and concentrated in vacuo. The 
reaction mixture was purified by flash chromatography with EtOAc.  
TLC [EtOAc]: Rf = 0.69 
HPLC [0-100% Solvent B, 16 min]: Rt = 10.2 min, purity (280 nm) = 98% 
Yield: 18mg, 0.04mmol (60%)  
1H-NMR (600 MHz, CDCl3): δ= 6.77(d, J=8.75) 1H, 6.47-6.5(m,1H), 6.37-6.4(m, 1H), 
5.36-5.38 (m, 0.5H), 4.88-4.94 (m, 0.5H), 4.14-4.17(m, 1H), 4.09-4.14(m, 1H), 4.01-
4.07(m, 1.5H), 3.96-4.01 (m, 0.5H), 3.92-3.955 (m, 0.5H), 3.85-3.88 (m, 0.3H), 
3.85(s, 3H), 3.832-3.84(m, 0.2H), 3.83(d, J=1.69, 3H), 3.77-3.81(m, 0.5H), 3.66-
3.77(m, 1.5H), 3.56-3.62(m, 0.5H), 3.28-3.35(m, 1H), 2.44-2.50(m, 1H), 2.36-2.42(m, 
1H), 2.27-2.34(m, 1H), 2.16-2.23(m, 1H), 1.99-2.08(m, 1H), 1.78-1.86(m, 1H), 1.52-
1.74(m, 6H), 1.24(s, 1.5H), 1.12-1.19(m, 4.5H), 0.82-0.91(m, 3H) 
13C-NMR (150 MHz, CDCl3): δ= (208.39, 207.54), (170.67, 170.39), (167.50, 166.19), 
(153.11, 153.06), 149.85, (143.68, 143.65), (111.92, 111.85), (103.95, 103.90), 
(100.53, 100.47), (67.20, 67.17), (58.59, 49.40) (56.41, 56.40), 55.85, (52.74, 43.06), 
(51.32, 51.13), (47.73, 47.39), (46.71, 46.52), (32.57, 31.90), (32.54, 32.53), (30.02, 
28.72 ), (29.25, 29.11), (24.11, 23.39), (23.05, 22.7), (15.81, 15.67), (8.74,8.73) 
HRMS(EI) : m/z: found 460.2571 [M] +, calculated 460.2573 [M] + 
 
7.2.27 Synthesis of     1-(3-(3,4-dimethoxyphenethyl)-2-oxo-3,10-
diazabicyclo [4.3.1]decan-10-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-
dione 5d 
   
To a solution of 3-(3,4-dimethoxyphenethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 32b 
(27mg, 0.09mmol) in 3 ml DCM were added sequentially 2-oxo-2-(3, 4, 5-
trimethoxyphenyl) acetic acid 33a (23mg, 0.1mmol), EDC-HCl (20mg, 0.1mmol), 
HOBt (14mg, 0.1mmol) and TEA (10mg, 0.1mmol) at room temperature followed by 
stirring overnight. The reaction was quenched with saturated NH4Cl solution (5 ml) 
and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO4 and 
concentrated in vacuo. The reaction mixture was purified by flash chromatography 
with EtOAc.  
TLC [EtOAc]: Rf = 0.42 
HPLC [0-100% Solvent B, 16 min]: Rt = 14.4 min, purity (280 nm) = 99% 
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Yield: 35mg, 0.07mmol (75%)  
1H-NMR (600 MHz, CDCl3): δ= 7.17(d, 2H ,J=2.09), 6.74-6.82 (m, 5H), 4.27-4.30(m, 
1H), 3.94(d, 3H, J=4.9), 3.90(d, 6H, J=3.27), 3.87(d, 3H, J=2.64), 3.85(d, 3H, 
J=2.45), 3.80-3.84(m, 1H), 3.66-3.78 (m, 2H), 3.54-3.66 (m, 1H), 2.96-3.03 (m, 1H), 
2.78-2.87 (m, 2H), 2.50-2.58 (m, 1H), 2.32-2.38 (m, 1H), 2.23-2.31 (m, 1H), 2.05-2.12 
(m, 1H), 1.77-1.91 (m, 2H), 1.69-1.76 (m, 1H), 1.51-1.59 (m, 1H) 
13C NMR (150 MHz, CDCl3):δ= (190.59, 190.23), 171.11, (170.02, 169.72), (166.95, 
165.85), (155.48, 153.44), (148.95, 148.91), (147.63, 147.61), (144.44, 144.38), 
(131.40, 131.30), (127.99, 127.81), (120.78, 120.77), (112.05, 111.97), (111.33, 
111.28), (106.94, 106.78), (61.06, 61.05), 58.71, (56.38, 56.35), (55.92, 55.89), 
(55.86, 55.85), (53.63, 53.35), 53.05, 49.61, (46.38, 46.26), 43.15, (33.89, 33.75), 
(33.25, 32.06), 30.15, (29.65, 29.45), (29.2, 28.95), 21.03, (15.78, 15.58), 14.18 
MS (ESI) m/z: found 541.27 [M + H] +, calculated 541,25 
HRMS(EI) : m/z: found 540.2479 [M] +, calculated 540.2472 [M] + 
  
7.2.28 Synthesis of     1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-
diazabicyclo [4.3.1]decan-10-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1,2-
dione  5a  
 
3-(2-(3,4-Dimethoxyphenoxy) ethyl)-3,10-diazabicyclo [4.3.1] decan-2-one 32a 
(20mg, 0.06mmol) in 3 ml DCM were treated sequentially with 2-oxo-2-(3, 4, 5-
trimethoxyphenyl) acetic acid 33a (16mg, 0.07mmol), EDC-HCl (14mg, 0.07mmol), 
HOBt (10mg, 0.07mmol) and TEA (7mg, 0.07mmol) at room temperature followed by 
stirring for 6 h.  The reaction was quenched with saturated NH4Cl solution (5 ml) and 
extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO4 and 
concentrated in vacuo. The reaction mixture was purification by flash 
chromatography with EtOAc.  
TLC [EtOAc]: Rf = 0.23 
HPLC [0-100% Solvent B, 30 min]: Rt = 23.2 min, purity (280 nm) = 98% 
Yield: 22mg, 0.04mmol (67%)  
1H-NMR (600 MHz, CDCl3): δ= 7.2(d, 2H, J=3.95), 6.78-6.82 (m, 1H), 6.51-6.55 (m, 
1H), 6.4-6.46 (m, 1H), 5.59(s, 0.5H), 5.12(s, 0.5H), 4.0-4.36 (m, 5H), 3.97 (d, 3H, 
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J=2.62), 3.92 (d, 6H, J=2.23), 3.88(d, 3H, J=2.67), 3.86(d, 3H, J=2.02), 3.6-3.7(m, 
1H), 3.36-3.46 (m, 1H), 2.4-2.6 (m, 2H), 1.5-1.8 (m, 6H) 
13C-NMR (150 MHz, CDCl3): δ=(190.62, 190.22), (170.56, 170.30), 167.04, 165.98, 
(153.54, 153.49), (153.14, 153.13), 149.95, (144.51, 144.48), (143.80, 143.77), 
(128.04, 127.86), (112.02, 111.99), 107.01, 106.88, (104.15, 104.09), (100.65, 
100.55), (67.33, 67.29), (61.09, 61.07), 58.68, 56.46, 56.45, 56.39, 55.91, 53.09, 
(51.27, 51.23), 49.81, (47.58, 43.38), (29.7, 29.66), 29.47, 29.03 
HRMS(EI) : m/z: found 556.2417 [M] +, calculated 556.2421 [M] + 
 
7.2.29 Synthesis of 1-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-
diazabicyclo [4.3.1]decan-10-yl)-2-((1S)-2-ethyl-1-
hydroxycyclohexyl)ethane-1,2-dione 5c  
 
2-((1S,2R)-2-Ethyl-1-hydroxycyclohexyl)-2-oxoacetic acid (25mg, 0.1mmol)196 in 3 ml 
DCM was treated sequentially with HATU (55mg, 0.1mmol), TEA (15mg, 0.1mmol), 
and 3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 32a 
(40mg, 0.1mmol) at room temperature followed by stirring overnight. The reaction 
was quenched with saturated NH4Cl solution (5 ml) and extracted with DCM (4 x 10 
ml). The organic layers were dried over MgSO4 and concentrated in vacuo. The 
mixture was purified by preparative TLC in EtOAc. 
TLC [EtOAc]: Rf = 0.63 
HPLC [0-100% Solvent B, 30 min]: Rt = 23.2 min, purity (280 nm) = 98% 
Yield: 14mg, 0.03mmol (23%)  
1HNMR (600 MHz, CDCl3) δ= 6.78-6.84(m, 1H), 6.52-6.56(m, 1H), 6.38-6.44(m, 1H), 
5-5.06(m, 1H), 4.68-6.76(m, 0.5H), 4.05-4.13(m, 0.5H),  3.93-4.03(m, 2H), 3.74-
3.84(m, 2H), 3.64-3.74(m, 6H), 3.46-3.64(m, 2H), 3.2-3.3(m, 2H), 2.05-2.3(m, 2H), 
1.75-1.95(m, 1H), 1.35-1.7(m, 9H), 1.05-1.3(m, 4H), 0.78-0.86(m, 1H), 0.65-0.85(m, 
3H) 
13C NMR (100 MHz, CDCl3) δ= (209.75, 209.20, 208.90, 208.75), (170.27, 170.25, 
169.95, 169.75), (168.00, 167.95, 167.70, 167.30), (153.30, 153.27, 153.25), 
(150.15, 150.13), (143.71,143.67), (113.33, 113.27), (104.80, 104.77, 104.65), 
(101.28, 101.26, 101.24, 101.16), (81.66, 81.26, 81.19, 81.17), (66.37, 66.30, 66.26, 
66.18), 58.13, 56.54, 55.90, (52.80, 52.66), (50.18, 50.12, 50.08, 50.02), (49.15, 
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49.25), (46.82, 46.65, 46.48, 46.35), ( 43.90, 43.50, 43.46, 43.37), (32.20, 32.05, 
31.95, 31.80), (29.45, 29.40, 29.30, 29.25), (29.23, 29.17, 29.15, 29.13), (28.85, 
28.83, 28.73, 28.67), (25.23, 25.15, 25.07, 25.03), (23.23, 23.07, 23.03, 22.52), 
(20.67, 20.57, 20.50, 20.47), (15.85, 15.75, 15.65), (12.37, 12.27, 12.25, 12.23) 
HRMS : m/z: found 517.3024 [M] +, calculated 517.2914[M + H] + 
 
7.2.30 Synthesis of 1-tert-butyl 2-(2-(3,4-dimethoxyphenoxy)ethyl) 
piperidine-1,2-dicarboxylate 38 
 
38 was prepared as described. 196 
 
7.2.31 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl piperidine-2-
carboxylate 39  
 
1-tert-Butyl 2-(2-(3,4-dimethoxyphenoxy)ethyl) piperidine-1,2-dicarboxylate 38 
(456mg, 1.1mmol) in 10 ml 20% TFA in DCM was stirred at room temperature for 2 h. 
The reaction mixture was concentrated in vacuo and used for next step without 
further purification . 
TLC [Hexane: EtOAc: TEA 7.5:2.3:0.4]: Rf = 0.19 
Yield: 344mg, 1.1mmol (100%) 
1H NMR (600 MHz, CDCl3) δ= 6.76 (d, 1H, J= 9 Hz), 6.50 (d, 1H, J= 3 Hz), 6.35 (dd, 
1H, J= 3, 9 Hz), 4.45-4.54(m, 2H), 4.11 (t, 2H, J= 4.2 Hz), 3.92 (dd, 1H, J= 3.6, 11.4 
Hz), 3.83 (s, 3H), 3.82 (s, 3H), 3.55 (d, 1H, J= 12.6 Hz), 2.99-3.04 (m, 1H), 2.24-2.28 
(m, 1H), 1.82-1.97 (m, 4H), 1.54-1.61 (m, 1H), 
13C NMR (150 MHz, CDCl3) δ= 168.48, 152.71, 149.91, 143.98, 111.74, 103.94, 
100.97, 65.85, 64.71, 56.83, 56.39, 55.81, 44.14, 25.60, 21.74, 21.50, 
HRMS(EI): m/z: found 309.1580 [M] +, calculated 309.1576 [M] + 
 
7.2.32 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(2-oxo-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate 6a  
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2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.2mmol) in 10 
ml acetonitrile under argon was treated sequentially with DIPEA (63mg, 0.5mmol), 2-
oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 33a (44mg, 0.2mmol) and HATU (58mg, 
0.2mmol). After stirring at room temperature for 3 days, it was concentrated in vacuo 
followed by addition of 5 ml H2O and extraction with DCM (3 x 10 ml). The organic 
phases were dried over MgSO4, concentrated in vacuo and purified by flash 
chromatography with hexane: EtOAc 3:1  
TLC [Hexane: EtOAc 1:1]: Rf = 0.32 
HPLC [0-100% Solvent B, 16 min]: Rt = 15.5 min, purity (280 nm) = 99% 
Yield: 36mg, 0.07mmol (42%)  
1HNMR (300 MHz, CDCl3) δ= 7.33-7.39(m,1.5H), 7.21-7.23(m, 0.5H), 6.73-6.8(m, 
1H), 6.46-6.54(m, 1H), 6.3-6.43(m, 1H), 5.41-5.46(m, 1H), 4.5-4.65(m, 2H), 4.1-
4.2(m, 2H), 3.94(d, 9H, J=1.96Hz), 3.84(d, 6H, J=2.16 Hz),3.22-3.54(m, 2H),2.2-
2.44(m, 2H), 1.73-1.88(m, 2H), 1.51-1.69(m, 2H) 
13C NMR (300 MHz, CDCl3) δ= (190.83, 190.34), (170.44, 170.19), (167.89, 166.87), 
(153.54, 153.27), (152.92, 152.78), (149.96, 149.92), (144.01, 143.99), (128.11, 
128.01), (111.78, 111.76), 107.25, 107.00, (104.05, 104.0), (101.16, 101.08), (66.34, 
66.27), (63.80, 63.78), (60.98, 60.35), 56.43, 56.41, 56.31, 55.87, 51.75, 44.26, 
26.31, 24.75, (21.16, 21.02) 
HRMS(EI) : m/z: found 531.2105 [M] +, calculated 531.2104 [M] + 
 
7.2.33 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(3,5-
dichlorophenylsulfonyl)piperidine-2-carboxylate 6e 
 
2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.16mmol)  in 1 
ml DCM was treated with DIPEA (63mg, 0.49mmol) and stirred for 30min at room 
temperature followed by addition of 3,5-dichlorobenzene sulfony chloride 34a (40mg, 
0.16mmol). After stirring overnight at room temperature, the reaction was quenched 
with saturated NH4Cl solution (5 ml), extracted with DCM (4 x 10 ml). The organic 
layers were dried over MgSO4 and concentrated in vacuo. The mixture was purified 
with preparative TLC in cyclohexane:EtOAc 3:1. 
TLC [Cyclohexane: EtOAc 3:1]: Rf = 0.57 
HPLC [0-100% Solvent B, 30 min]: Rt = 27.2 min, purity (280 nm) = 99% 
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Yield: 17mg, 0.03mmol (20%)  
1HNMR (600 MHz, CDCl3) δ= 7.64(d, 2H, J=1.85Hz), 7.49 (t, 1H, J=1.86, 1.86Hz), 
6.76(d, 1H, J=8.76Hz), 6.48(d, 1H, J=2.8Hz), 6.34(dd, 1H, J=2.83, 8.73Hz), 4.75-
4.8(m, 1H), 4.35-4.4(m, 1H), 4.25-4.3(m, 1H), 4.03-4.08(m, 1H), 3.97-4.03(m, 1H), 
3.83(d, 6H, J=7.88Hz), 3.72-3.77(m, 1H), 3.16-3.24(m, 1H), 2.16-2.21(m, 1H), 1.73-
1.85(m, 1H), 1.65-1.71(m, 1.8H), 1.47-1.63(m, 2H), 1.33-1.36(m, 0.5H) 
13C NMR (300 MHz, CDCl3) δ= 170.23, 152.82, 149.92, 143.99, 142.67, 135.64, 
132.29, 125.55, 111.76, 103.99, 101.06, 66.13, 63.48, 56.41, 55.85, 55.31, 42.88, 
27.92, 24.73, 19.88 
HRMS : m/z: found 518.1343 [M + H] +, calculated 518.0807 [M + H] + 
 
7.2.34 Synthesis of  2-(3,4-dimethoxyphenoxy)ethyl 1-(benzo[d]thiazol-6-
ylsulfonyl)piperidine-2-carboxylate 6f     
 
2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.16mmol) in 1 
ml DCM under argon was treated sequentially with DIPEA (42mg, 0.32mmol) and  
1,3-benzothiazole-6-sulfonyl chloride 34b (76mg,  0.32mmol). After stirring at room 
temperature overnight, the reaction was quenched with saturated NH4Cl solution (5 
ml) and extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO4 
and concentrated in vacuo. The mixture was purified by flash chromatography with 
cyclohexane: EtOAc 1:1.  
TLC [Cyclohexane: EtOAc 1:1]: Rf = 0.3 
HPLC [0-100% Solvent B, 30min]: Rt = 23.7 min, purity (280 nm) = 98% 
Yield: 39mg, 0.077mmol (48%)  
1HNMR (300 MHz, CDCl3) δ= 9.18-9.22(m, 1H), 8.47-8.51(m, 1H), 8.19-8.24(m, 
1H),7.90-7.96 (m, 1H),  6.75-6.81(m, 1H), 6.47-6.51(m, 1H), 6.31-6.37(m, 1H), 4.85-
4.91 (m, 1H), 4.09-4.38 (m, 2H), 3.89-4.05(m, 2H), 3.83-3.89 (d, 6H, J=2.01Hz), 
3.74-3.83(m, 1H),3.21-3.34(m, 1H),2.15-2.25(m, 1H), 1.74-1.88(m, 1H), 1.62-1.74(m, 
2H), 1.3-1.62(m, 2H) 
13C NMR (75 MHz, CDCl3) δ= 170.56, 157.63, 155.2, 152.84, 149.94, 144.01, 
137.34, 133.95, 124.98, 123.98, 122.00, 111.80, 104.07, 101.09, 66.16, 63.37, 
56.44, 55.89, 55.21, 42.80, 27.94, 24.75, 19.98 
HRMS : m/z: found 507.1779 [M + H] +, calculated 507.1260 [M + H] + 
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7.2.35 Synthesis of 2-(3,4-dimethoxyphenoxy)ethyl 1-(2-oxo-2,3-
dihydrobenzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate 6g 
 
2-(3,4-Dimethoxyphenoxy)ethyl piperidine-2-carboxylate 39 (50mg, 0.16mmol) in 1 
ml DCM under argon was treated sequentially with DIPEA (42mg, 0.32mmol) and  2-
oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c (81mg, 0.32mmol). After 
strring at room temperature overnight, the reaction was quenched with saturated 
NH4Cl solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were 
dried over MgSO4 and concentrated in vacuo. The mixture was purified with 
preparative HPLC using a gradient of  40-50% buffer B in 16 minutes. 
TLC [Cyclohexane: EtOAc 1:1]: Rf = 0.74 
HPLC [0-100% Solvent B, 30 min]: Rt = 22.0 min, purity (280 nm) = 99% 
Yield: 28mg, 0.05mmol (33%)  
1HNMR (400 MHz, DMSO-D6) δ= 12.30(s, 1H), 8.05(d, 1H, J=1.86Hz), 7.62(dd,1H, 
J=1.96, 8.44Hz), 7.19(d, 1H, J=8.45Hz), 6.79(d, 1H, J=8.81Hz), 6.49(d, 1H, 
J=2.83Hz), 6.35(dd, 1H, J=2.85, 8.75Hz), 4.57-4.68(m,1H), 4.10-4.28(m, 2H), 3.91-
4.07(m,2H), 3.68(s, 3H), 3.64(s, 3H), 3.54-3.62(m,1H), 3.01-3.14(m, 1H), 1.87-
1.98(m,1H), 1.44-1.62(m, 3H), 1.04-1.29(m, 2H)   
13C NMR (100 MHz, DMSO-D6) δ= 170.75, 170.61, 152.97, 150.09, 143.80, 140.23, 
133.95, 126.03, 124.64, 122.46, 113.10, 111.91, 104.79, 101.36, 66.31, 63.65, 
56.48, 55.89, 55.13, 42.72, 27.64, 24.39, 19.82 
HRMS : m/z: found 523.1185 [M + H] +, calculated 523.1209 [M + H] + 
 
7.2.36 Synthesis of  9-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-3,9-diazabicyclo [3.3.1]nonan-2-one 4e  
 
3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (24mg, 
0.08mmol) in 3 ml DCM was treated with DIPEA (12mg, 0.09mmol) and stirred for 
30min at room temperature followed by addition of 3,5-dichlorobenzene sulfonyl 
chloride 34a (22mg, 0.09mmol). After stirring for 6 h at room temperature, the 
reaction was quenched with saturated NH4Cl solution (5 ml) and extracted with DCM 
(4 x 10 ml). The organic layers were dried over MgSO4 and concentrated in vacuo. 
The mixture was purified by flash chromatography with hexane: EtOAc 1:1. 
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TLC [EtOAc]: Rf = 0.48 
HPLC [0-100% Solvent B, 30 min]: Rt = 23.8 min, purity (280 nm) = 99% 
Yield: 21mg, 0.04mmol (53%)  
1HNMR (600 MHz, CDCl3) δ= 7.66-7.73(m, 2H), 7.33-7.39(m, 1H), 6.74-6.79(m, 1H), 
6.36-6.41(m, 1H), 6.28-6.33(m, 1H), 4.43(s, 1H), 4.28-4.33(m, 1H), 4.04-4.10(m, 1H), 
3.88-3.94(m, 1H), 3.73(d, 6H, J= 6.56 Hz ), 3.65-3.72(m, 1.5H), 3.55-3.62(m, 1H), 
3.3-3.37(m, 1.5H), 1.88-2.02(m, 2H), 1.72-1.84(m, 2H), 1.54-1.72(m, 2H)    
13C NMR (300 MHz, CDCl3) δ= 166.85, 152.74, 149.83, 143.85, 142.76, 136.14, 
132.87, 125.29, 111.92, 103.94, 100.36, 66.89, 56.45, 55.85, 55.12, 52.12, 47.40, 
46.57, 31.46, 28.13, 17.27 
HRMS(EI) : m/z: found 528.0893 [M] +, calculated 528.0889[M] + 
 
7.2.37 Synthesis of  9-(benzo[d]thiazol-6-ylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 4f  
 
3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (32mg, 
0.1mmol) in 3 ml DCM was treated with DIPEA (15mg, 0.12mmol) and stirred for 
30min at room temperature followed by addition of 1,3-benzothiazole-6-sulfonyl 
chloride 34b (28mg, 0.12mmol). The reaction was stirred overnight at room 
temperature. The reaction was quenched with saturated NH4Cl solution (5 ml) and 
extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO4 and 
concentrated in vacuo. The mixture was purified with preparative TLC in 10% MeOH 
in CHCl3. 
TLC [EtOAc]: Rf = 0.47 
HPLC [0-100% Solvent B, 16 min]: Rt = 19.5 min, purity (280 nm) = 99% 
Yield: 8mg, 0.02mmol (15%)  
1HNMR (600 MHz, CDCl3) δ= 9.13(s, 1H), 8.51(d, 1H, J= 1.33Hz), 8.18(d, 1H, J= 
8.62Hz), 7.93 (dd, 1H, J= 1.87, 8.63Hz), 6.72(d, 1H, J=8.79Hz), 6.31(d, 1H, J= 
2.82Hz), 6.18-6.23(m, 1H), 4.43-4.46(m, 1H),4.35-4.39(m, 1H), 3.92-3.98(m, 1H), 
3.78-3.83(m, 6H), 3.7-3.74(m, 1H), 3.5-3.59(m, 2H), 3.29-3.33(m, 1H), 2.97-3.05(m, 
1H), 1.96-2.01(m, 1H), 1.9-1.96(m, 1H), 1.76-1.84(m, 1H), 1.7-1.75(m, 1H), 1.6-
1.68(m, 2H) 
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13C NMR (300 MHz, CDCl3) δ= 167.25, 158.13, 155.6, 152.66, 149.80, 143.76, 
136.86, 134.3, 124.55, 124.38, 122.18, 111.83, 103.86, 100.29, 66.60, 56.39, 55.84, 
55.03, 51.90, 47.21, 46.23, 31.53, 28.04, 17.30 
HRMS(EI) : m/z: found 517.1340 [M] +, calculated 517.1341 [M] + 
 
7.2.38 Synthesis of  10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-3,10-diazabicyclo [4.3.1]decan-2-one 5e  
 
3-(2-(3,4-Dimethoxyphenoxy) ethyl)-3,10-diazabicyclo [4.3.1] decan-2-one 32a 
(22mg, 0.07mmol) in 3 ml DCM was treated with DIPEA (10mg, 0.08mmol) and 
stirred for 30min at room temperature followed by addition of 3,5-dichlorobenzen 
sulfony chloride 34a (19mg, 0.08mmol). After stirring overnight at room temperature, 
the reaction was quenched with saturated NH4Cl solution (5 ml) and extracted with 
DCM (4 x 10 ml). The organic layers were dried over MgSO4 and concentrated in 
vacuo. The mixture was purified by flash chromatography with cyclohexane: EtOAc 
2:1. 
TLC [Cyclohexane/EtOAc 1:1]: Rf = 0.40 
HPLC [0-100% Solvent B, 30 min]: Rt = 25.5 min, purity (280 nm) = 99% 
Yield: 16mg, 0.03mmol (45%)  
1HNMR (600 MHz, CDCl3) δ= 7.69(s, 1H), 7.68(s, 1H), 7.48-7.53(m, 1H), 6.74-6.8(m, 
1H),6.47-6.5(m, 1H),6.36-6.41(m, 1H), 4.68-4.72(m, 1H), 4.34-4.42(m, 1H), 4.07-
4.17(m, 2H), 3.98-4.07(m, 1H), 3.93-3.98(m, 1H), 3.86(s, 3H), 3.82(s, 3H), 3.64-
3.68(m, 2H), 3.43-3.48(m, 0.5H), 3.31-3.4(m, 1.5H), 2.2-2.3(m, 2H), 1.95-2.05(m, 
2H), 1.55-1.75(m, 2H) 
13C NMR (300 MHz, CDCl3) δ= 170.50, 153.15, 149.9, 144.15, 143.75, 136.30, 
132.63, 124.92, 111.98, 104.06, 100.56,  67.25, 57.05,56.45, 55.90, 51.42, 51.36, 
49.1, 48.2, 32.7, (28.35,27.9), (14.8, 14.1) 
HRMS(EI) : m/z: found 542.1045 [M] +, calculated 542.1045 [M] + 
 
7.2.39 Synthesis of  10-(benzo[d]thiazol-6-ylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-3,10-diazabicyclo [4.3.1]decan-2-one 5f  
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3-(2-(3, 4-Dimethoxyphenoxy) ethyl)-3, 10-diazabicyclo [4.3.1] decan-2-one 32a 
(24mg, 0.07mmol) in 3 ml DCM was treated with DIPEA (11mg, 0.09mmol) and 
stirred for 30min at room temperature followed by addition of 1,3-benzothiazole-6-
sulfonyl chloride 34b (20mg, 0.09mmol). After stirring overnight at room temperature, 
the reaction was quenched with saturated NH4Cl solution (5 ml), extracted with DCM 
(4 x 10 ml). The organic layers were dried over MgSO4 and concentrated in vacuo. 
The mixture was purified with preparative TLC in 10% MeOH in CHCl3. 
TLC [EtOAc]: Rf = 0.54 
HPLC [0-100% Solvent B, 30 min]: Rt = 20.7 min, purity (280 nm) = 99% 
Yield: 5mg, 0.01mmol (13%)  
1HNMR (600 MHz, CDCl3) δ= 9.18(s, 1H), 8.48-8.52(m, 1H), 8.23 (d, 1H, J= 8.63Hz), 
7.93(dd, 1H, J=1.86, 8.64Hz), 6.77(d, 1H, J= 8.78Hz), 6.47(d, 1H, J= 2.84Hz), 6.36-
6.39(m, 1H), 4.74-4.78(m, 1H), 4.42-4.48(m, 1H), 4.09-4.15(m, 2H), 4.02-4.08(m, 
1H), 3.95-3.99(m, 1H), 3.84(s, 3H), .815-3.825(m, 3H), 3.6-3.65(m, 2H), 3.3-3.35(m, 
1H), 3.05-3.1(m, 1H), 2.25-2,33(m, 1H), 2.15-2.2(m, 1H), 1.97-2.03(m, 1H), 1.7-
1.85(m, 1H),1.55-1.63(m, 1H), 1.1-1.2(m, 1H) 
13C NMR (300 MHz, CDCl3) δ= 166.1, 153.15, 150.70, 148.4, 145.1, 138.93, 133.75, 
129.62, 119.86, 119.35, 116.84, 107.10, 99.21, 95.75, 62.45, 52.15, 51.65, 51.12, 
44.03, 43.52, 37.15, 24.93, 27.95, 23.02, 17.85 
HRMS : m/z: found 532.1560 [M] +, calculated 532.1576[M + H] +, 
 
7.2.40 Synthesis of  6-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,9-
diazabicyclo [3.3.1]nonan-9-ylsulfonyl)benzo[d]thiazol-2(3H)-one 4g 
 
3-(2-(3,4-Dimethoxyphenoxy)ethyl)-3,9-diazabicyclo[3.3.1]nonan-2-one 31a (40mg, 
0.13mmol) in 3 ml DCM was treated with DIPEA (32mg, 0.25mmol) and stirred for 
30min at room temperature followed by addition of 2-oxo-2,3-
dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c (62mg, 0.25mmol). After stirring 
overnight at room temperature, the reaction was quenched with saturated NH4Cl 
solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried 
over MgSO4 and concentrated in vacuo. The mixture was purified by preparative 
HPLC using a gradient of 50-57% buffer B in 16 minutes. 
TLC [EtOAc]: Rf = 0.38 
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HPLC [0-100% Solvent B, 16 min]: Rt = 13.0 min, purity (280 nm) = 99% 
Yield: 35mg, 0.07mmol (53%)  
1HNMR (300 MHz, DMSO) δ= 12.33-12.40(m, 1H), 8.11-8.15(m, 1H), 7.64-7.71(m, 
1H), 7.20-7.26(m, 1H), 6.75-6.85(m, 1H), 6.44-6.48(m, 1H), 6.23-6.32(m, 1H), 4.19-
4.28(m, 1H), 4.12-4.18(m, 1H), 3.71-3.83(m, 2H), 3.69(s, 3H), 3.66(s, 3H), 3.36-
3.50(m, 2H), 3.20-3.29(m, 1H), 2.97-3.10(m, 1H), 1.35-1.82(m, 6H) 
13C NMR (75 MHz, DMSO) δ= 170.69, 166.56, 152.95, 150.12, 143.74, 140.65, 
133.40, 126.15, 124.90, 122.45, 113.20, 112.11, 104.48, 101.25, 65.55, 56.51, 
55.92, 54.85, 50.70, 47.20, 45.41, 31.27, 28.09, 17.25 
HRMS (EI) m/z: found 533.1299[M] +, calculated 533.1290[M] + 
 
7.2.41 Synthesis of  6-(3-(2-(3,4-dimethoxyphenoxy)ethyl)-2-oxo-3,10-
diazabicyclo [4.3.1]decan-10-ylsulfonyl)benzo[d]thiazol-2(3H)-one 5g  
 
3-(2-(3,4-Dimethoxyphenoxy) ethyl)-3,10-diazabicyclo [4.3.1] decan-2-one 32a 
(15mg, 0.05mmol) in 3 ml DCM was treated with DIPEA (12mg, 0.09mmol) and 
stirred for 30min at room temperature followed by addition of 2-oxo-2,3-
dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c (22mg, 0.09mmol). After stirring 
overnight at room temperature, the reaction was quenched with saturated NH4Cl 
solution (5 ml) and extracted with DCM (4 x 10 ml). The organic layers were dried 
over MgSO4 and concentrated in vacuo. The mixture was purified by preparative 
HPLC using a gradient of 55-65% buffer B in 16mins. 
TLC [EtOAc]: Rf = 0.54 
HPLC [0-100% Solvent B, 16 min]: Rt = 13.6 min, purity (280 nm) = 99% 
Yield: 5mg, 0.01mmol (20%)  
1HNMR (300 MHz, DMSO) δ= 12.07-12.13(s, 1H), 7.85-7.88(m, 1H), 7.56-7.61(m, 
1H), 7.12-7.18(m, 1H), 6.68-6.73(m, 1H), 6.67-6.73(m, 1H), 6.41-6.46(m, 1H), 6.29-
6.34(m, 1H),4.54-4.60(m, 1H), 4.20-4.29(m, 1H),3.93-4.02(m, 2H), 3.75-3.93(m, 2H), 
3.65-3.75(m, 8H), 3.20-3.27(m, 1H),2.15-2.25(m, 1H),1.95-2.05(m, 1H),1.87-1.93(m, 
1H),1.05-1.45(m, 3H) 
13C NMR (75 MHz, DMSO) δ= 175.49, 175.30, 157.94, 154.62, 148.30, 144.97, 
139.84, 129.90, 126.01, 125.95, 117.40, 113.70, 109.12, 105.60, 71.41, 61.47, 
61.20, 60.57, 55.53, 53.13, 52.60, 37.32, 32.66, 32.36, 19.54  
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HRMS (EI) m/z: found 547.1446[M] +, calculated 547.1447[M] + 
 
7.2.42 Synthesis of 3,9-diazabicyclo[3.3.1]nonan-2-one 35  
 
To a solution of benzyl 2-oxo-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate 17 (84mg, 
0.3mmol) in 1 ml anhydrous MeOH were added catalytic amounts of palladium on 
carbon followed by degassing with H2. After stirring under 1 atm H2 at room 
temperature for 2 h, the reaction mixture was filtered through celite, concentrated in 
vacuo and used for the next step without further purification. 
TLC [20% MeOH in CHCl3]: Rf = 0.17 
Yield: 35mg, 0.25mmol (82%) 
 
7.2.43 Synthesis of 3,10-diazabicyclo[4.3.1]decan-2-one 36  
 
To a solution of benzyl 2-oxo-3, 10-diazabicyclo [4.3.1] decane-10-carboxylate 27 
(33mg, 0.1mmol) in 1 ml anhydrous MeOH were added catalytic amounts of 
palladium on carbon followed by degassing with H2. After stirring under 1 atm H2 at 
room temperature for 3 h, the reaction mixture was filtered through celite, 
concentrated in vacuo and used for the next step without further purification. 
TLC [20% MeOH in CHCl3]: Rf = 0.26 
Yield: 17mg, 0.1mmol (100%)  
 
7.2.44 Synthesis of 6-(2-oxo-3,9-diazabicyclo [3.3.1]nonan-9-
ylsulfonyl)benzo[d]thiazol-2(3H)-one 4h  
 
3,9-Diazabicyclo[3.3.1]nonan-2-one 35 (25mg, 0.2mmol) in 1 ml DCM under argon 
was treated with DIPEA (69mg, 0.5mmol) and stirred for 30min at room temperature 
followed by addition of 2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c 
(53mg, 0.2mmol). After stirring overnight at room temperature, the reaction was 
quenched with saturated NH4Cl solution (5 ml) and extracted with DCM (4 x 10 ml). 
The organic layers were dried over MgSO4 and concentrated in vacuo.  The mixture 
was purified by preparative HPLC using a gradient of 45% buffer B in 16mins. 
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TLC [10% MeOH in DCM]: Rf = 0.71 
HPLC [0-100% Solvent B, 16 min]: Rt = 10.2 min, purity (280 nm) = 99% 
Yield: 27mg, 0.08mmol (43%)  
1HNMR (600 MHz, DMSO-D6) δ= 8.13(d, 1H, J=1.88Hz), 7.68 (dd, 1H, J=1.98, 
8.44Hz), 7.60(s, 1H), 7.21(d, 1H, J=8.39Hz), 4.12-4.15(m, 1H), 4.01-4.04(m, 1H), 
3.17-3.25(m, 1H), 2.93-2.97(m, 1H), 1.57-1.73(m, 5H), 1.40-1.50(m, 1H ) 
13C NMR (300 MHz, DMSO) δ= 170.80, 167.59, 140.59, 133.66, 126.07, 124.82, 
122.52, 112.14, 54.62, 46.17, 44.07, 31.11, 27.63, 17.59 
HRMS(EI+) : m/z: found 353.0458 [M] +, calculated 353.0504 [M] + 
 
7.2.45 Synthesis of 6-(2-oxo-3,10-diazabicyclo[4.3.1]decan-10-
ylsulfonyl)benzo[d]thiazol-2(3H)-one 5h  
 
3,10-Diazabicyclo[4.3.1]decan-2-one 36 (17mg, 0.1mmol) in 1 ml DCM under argon 
was treated with DIPEA (43mg, 0.3mmol) and stirred for 30min at room temperature 
followed by addition of 2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonyl chloride 34c 
(33mg, 0.1mmol). After stirring overnight at room temperature, the reaction was 
quenched with saturated NH4Cl solution (5 ml) and extracted with DCM (4 x 10 ml). 
The organic layers were dried over MgSO4 and concentrated in vacuo.  The mixture 
was purified by preparative HPLC using a gradient of 45% buffer B in 16mins. 
TLC [10% MeOH in DCM]: Rf = 0.72 
HPLC [0-100% Solvent B, 16 min]: Rt = 10.6 min, purity (280 nm) = 98% 
Yield: 5mg, 0.01mmol (12%)  
1HNMR (600 MHz, DMSO) δ= 8.19(d, 1H, J=1.93Hz), 7.90-7.95 (m, 1H), 7.73(dd, 
1H, J=1.98Hz, 8.43Hz), 7.25(d, 1H, J=8.44Hz), 4.39-4.43(m, 1H), 4.25-4.31(m, 1H), 
3.25-3.30(m, 1H), 2.84-2.9(m, 1H), 2.03-2.17(m, 1H), 1.85-1.93(m, 1H), 1.67-1.77(m, 
1H ), 1.42-1.50(m, 1H), 1.17-1.33(m, 2H), 1.05-1.15(m, 2H) 
13C NMR (300 MHz, DMSO) δ= 172.4, 170.8, 140.4, 135.3, 125.5, 124.9, 122.1, 
112.3, 56.3, 49.1, 38.9, 33.25, 28.0, 26.9, 14.8 
HRMS : m/z: found 368.0736 [M + H] +, calculated 368.0739 [M + H] + 
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7.2.46 Synthesis of  10-(3,5-dichloro-4-hydroxyphenylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 5i 
 
3-(2-(3, 4-dimethoxyphenoxy) ethyl)-3, 10-diazabicyclo [4.3.1] decan-2-one 32a 
(24mg, 0.07mmol) in 3 ml DCM was treated with DIPEA (23mg, 0.09mmol) and 
stirred for 30min at room temperature followed by addition of 3,5-dichloro-4-hydroxy 
benzenesulfonylchloride 34d (23mg, 0.09mmol). After stirring overnight at room 
temperature, the reaction was quenched with saturated NH4Cl solution (5 ml) and 
extracted with DCM (4 x 10 ml). The organic layers were dried over MgSO4 and 
concentrated in vacuo. The mixture was purified by flash chromatography with EtOAc 
followed by 10% MeOH in CHCl3. 
TLC [EtOAc]: Rf = 0.6 
HPLC [0-100% Solvent B, 30 min]: Rt = 21.5 min, purity (280 nm) = 98% 
Yield: 10mg, 0.02mmol (25 %)  
1HNMR (300 MHz, CDCl3) δ= 7.78(s, 2H), 6.76-6.82(m, 1H), 6.5-6.54(m, 1H), 6.38-
6.44(m, 1H), 4.68-4.74(m, 1H), 4.3-4.45(m, 1H), 3.93-4.24(m, 3H), 3.85-3.9(m, 7H), 
3.6-3.73(m, 3H), 3.3-3-45(m, 1H), 2.2-2.4(m, 2H), 1.95-2.1(m, 2H), 1.6-1.7(m, 1H), 
1.35-1.45(m, 1H) 
13C NMR (75 MHz, CDCl3) δ=170.4, 153.14, 151.5, 149.9, 143.7, 134.4, 126.83, 
122.09, 111.99, 104.07, 100.59, 67.25, 56.93, 56.46, 55.91, 51.43, 51.35, 48.91,  
48.27, 31.92, 22.69, 14.11 
HRMS(EI) : m/z: found 558.0993 [M] +, calculated 558.0994 [M] + 
 
7.2.47 Synthesis of tert-butyl allyl(2-(3,4-
dimethoxyphenoxy)ethyl)carbamate 48  
 
To a solution of tert-butyl N-allylcarbamate (144mg, 0.92mmol) in 1ml DMF was 
added NaH (22mg, 0.92mmol) under argon and the reaction mixture was stirred for 
30min at 0°C followed by addition of 4-(2-bromoethoxy)-1,2-dimethoxybenzene 28a 
(200mg, 0.77mmol) and stirring at 0°C for 2 h. To the mixture a saturated NH4Cl 
solution (10ml) was added and extracted with DCM (5 x 10 ml). The organic layers 
were dried over MgSO4, filtered and concentrated in vacuo. The pure product was 
obtained by flash chromatography with cyclohexane: EtOAc 5:1. 
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TLC [cyclohexane: EtOAc 5:1]: Rf = 0.26 
Yield: 178mg, 0.53mmol (69%) 
1HNMR (400 MHz, CDCl3) δ= 6.76(d,1H, J=8.75Hz), 6.49(s,1H), 6.31-6.43(m,1H), 
5.70-5.90(m,1H), 5.02-5.23(m,2H), 3.98-4.08(m,2H), 3.88-3.98(m,2H), 3.84(s,3H), 
3.81(s,3H), 3.55 (s,2H), 1.45(s,9H) 
MS(ESI) : m/z: found 337.93 [M+Na] +, calculated 338.19 [M+H] + 
 
7.2.48 Synthesis of tert-butyl 2-(3,4-dimethoxyphenoxy)ethyl(4-
(trimethylsilyl)but-2-enyl)carbamate 50 
 
To a solution of tert-butyl allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamate 48 (100mg, 
0.30mmol) and allyltrimethylsilane (135mg, 1.18mmol) in 3ml DCM was added 
Grubbs catalyst generation I (24mg, 0.03mmol, Sigma-Aldrich) and heated under 
reflux overnight. The mixture was filtered through celite and concentrated in vacuo. 
The pure product was obtained by flash chromatography with cyclohexane: EtOAc 
6:1. 
TLC [cyclohexane: EtOAc 6:1]: Rf = 0.38 
Yield: 85mg, 0.20mmol (67%) 
1HNMR (400 MHz, CDCl3) δ= 6.73-6.82(m,1H), 6.46-6.56(m,1H), 6.35-6.45(m,1H), 
5.45-5.67(m,1H), 5.18-5.45(m,1H), 3.87-4.15(m,4H), 3.86(s,3H), 3.84(s,3H), 3.43-
3.63(m,2H), 1.50-1.75(m,2H), 1.47(s,9H), -0.09-0.03(m,9H) 
13C NMR (100 MHz, CDCl3) δ=155.50, 153.33, 149.89, 143.55, 129.55, 123.57, 
111.91, 103.80, 100.82, 79.54, 67.02, 56.45, 55.82, 50.01, 45.50, 28.45, 22.69, -1.81 
MS(ESI) : m/z: found 446.93 [M+Na] +, calculated 446.60 [M+Na] + 
 
7.2.49 Synthesis of N-(2-(3,4-dimethoxyphenoxy)ethyl)-4-
(trimethylsilyl)but-2-en-1-amine 51  
 
Excess amount of SiO2 was added to tert-butyl 2-(3,4-dimethoxyphenoxy)ethyl(4-
(trimethylsilyl)but-2-enyl)carbamate 50 (220mg, 0.52mmol) and stirred at 150°C in 
vacuo for 2 h. The SiO2 was washed with EtOAc for 3 times and the organic layers 
were collected and concentrated in vacuo. The compound was used for the next step 
without further purification. 
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TLC [5% TEA in EtOAc ]: Rf = 0.6 
Yield: 143mg, 0.44mmol (85%) 
MS(ESI): m/z: found  323.93 [M+H] +, calculated 324.20 [M+H] + 
 
7.2.50 Synthesis of (S)-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxo-N-(4-
(trimethylsilyl)but-2-enyl)piperidine-2-carboxamide 53 
 
To a solution of (S)-6-oxo-2-piperidinecarboxylic acid 52 (109mg, 0.76mmol) in 5ml 
DCM was added sequentially DIPEA (205mg, 1.58mmol), HOAt(104mg, 0.76mmol) 
and EDC-HCl(118mg, 0.76mmol) followed by stirring for 30 min at room temperature 
and addition of  N-(2-(3,4-dimethoxyphenoxy)ethyl)-4-(trimethylsilyl)but-2-en-1-amine 
51 (205mg, 0.63mmol). After 24 h, brine (10ml) was added and extracted with DCM 
(5 x 10 ml). The organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. The pure product was obtained by flash chromatography with 5% TEA in 
EtOAc. 
TLC [5% TEA in EtOAc]: Rf = 0.27 
Yield: 260mg, 0.58mmol (90%) 
MS(ESI) : m/z: found  449.57 [M+H] +, calculated 449.24[M+H] + 
 
7.2.51 Synthesis of (S)-tert-butyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-
(trimethylsilyl)but-2-enyl)carbamoyl)-6-oxopiperidine-1-carboxylate 54  
 
To a solution of (S)-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxo-N-(4-(trimethylsilyl)but-
2-enyl)piperidine-2-carboxamide 53 (1070mg, 2.39mmol) in 15ml THF was added 1M 
BuLi solution in hexanes (184mg, 2.87mmol) dropwise under argon at -78°C and 
stirred for 1 h followed by addition of di-tert-butyl dicarbonate (1040mg, 4.78mmol). 
After stirring at -78°C overnight, a saturated NH4Cl solution (20ml) was added at 
room temperature and extracted with DCM (6 x 20ml). The organic layers were dried 
over MgSO4, filtered and concentrated in vacuo. The pure product was obtained by 
flash chromatography with cyclohexane: EtOAc 1:1. 
TLC [cyclohexane: EtOAc 1:1]: Rf = 0.4 
Yield: 947mg, 1.73mmol (72%) 
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1HNMR (400 MHz, CDCl3) δ= 6.72-6.79(m,1H), 6.44-6.53(m,1H), 6.31-6.42(m,1H), 
5.55-5.75(m,1H), 5.15-5.45(m,1H), 4.95-5.05(m,1H), 3.95-4.25(m,4H), 3.77-
3.90(m,6H), 3.55-3.77(m,2H), 2.54-2.65(m,1H), 2.35-2.50(m,1H), 1.50-1.65(m,4H), 
1.38-1.49(m,9H), 0(t,9H,J=12.30,12.30Hz) 
13C NMR (100 MHz, CDCl3) δ= 171.37, 171.13, 153.13, 153.09, 149.76, 143.51, 
131.93, 122.53, 111.80, 103.95, 100.51, 83.04, 66.64, 55.82, 55.57, 51.36, 45.29, 
34.40, 27.96, 25.84, 22.91,19.13, -1.92 
MS(ESI) : m/z: found  571.34 [M+H] +, calculated 571.28[M+H] + 
 
7.2.52 Synthesis of (1S,5S,6R)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-
3,10-diazabicyclo[4.3.1]decan-2-one 57  
 
To a solution of (S)-tert-butyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-(trimethylsilyl)but-
2-enyl)carbamoyl)-6-oxopiperidine-1-carboxylate 54 (100mg, 0.18mmol) in 1ml THF 
under argon was added dropwise DIBAL-H (78mg, 0.55mmol) and stirred at -78°C 
for 1 h followed by removal of the solvent in vacuo. The oily residue in 1ml DCM was 
treated dropwise with 1ml 10% TFA in DCM at -78°C followed by stirring at 0°C for 2 
h, addition of 1mL TFA and stirring for another 2 h. A saturated NaHCO3 solution 
(10ml) was added and extracted with DCM (6 x 10ml). The organic layers were dried 
over MgSO4, filtered and concentrated in vacuo. The pure product was obtained by 
preparative TLC with 5% MeOH and 5% TEA in EtOAc. 
TLC [5% MeOH, 5% TEA in EtOAc]: Rf = 0.38 
Yield: 50mg, 0.14mmol (76%) 
1HNMR (400 MHz, CDCl3) δ= 6.77(d, 1H, J=8.76Hz), 6.49(d, 1H, J=2.81Hz), 6.38(dd, 
1H, J=2.84,8.73Hz), 5.65-5.76(m, 1H), 5.07(s, 1H), 5.01-5.05(m, 1H), 4.22-4.30(m, 
1H), 4.13-4.20(m,1H), 3.99-4.10(m,2H), 3.84-3.90(m,1H), 3.83(s,3H), 3.82(s,3H), 
3.55-3.78(m,1H), 3.26-3.35(m,1H), 2.97-3.04(m,1H), 2.73-2.83(m,1H), 2.23-
2.32(m,1H), 1.69-1.82(m,2H), 1.48-1.68(m,4H) 
13C NMR (100 MHz, CDCl3) δ= 172.90, 153.11, 149.81, 143.56, 138.58, 115.55, 
111.77, 103.46, 100.48, 67.33, 57.00, 56.40, 55.79, 52.73, 52.51, 51.34, 48.88, 
28.70, 27.28, 16.24 
MS(ESI) : m/z: found  361.09 [M+H] +, calculated 361.21[M+H] + 
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7.2.53 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 71  
 
 A solution (1S,5S,6R)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo 
[4.3.1]decan-2-one 57 (80mg, 0.22mmol) in 1mL DCM under argon was treated with 
DIPEA (34.4mg, 0.266mmol) and stirred for 30 min at room temperature followed by 
addition of 3,5-dichlorobenzene sulfonyl chloride 34a (65mg, 0.27mmol). After stirring 
overnight at room temperature, the pure product was obtained by preparative TLC 
with cyclohexane: EtOAc 1:1. 
TLC [cyclohexane: EtOAc 1:1]: Rf = 0.68 
Yield: 60mg, 0.11mmol (48%) 
1HNMR (600 MHz, CDCl3) δ= 7.68(d, 2H, J=1.85Hz), 7.53(t, 1H, J=1.85, 1.85Hz), 
6.76(d, 1H, J=8.77Hz), 6.46(d, 1H, J=2.79Hz), 6.36(dd, 1H, J=2.81, 8.75Hz), 5.77-
5.86(m, 1H), 5.05-5.16(m, 2H), 4.65-4.71(m,1H), 4.07-4.21(m,3H), 3.99-4.05(m,1H), 
3.94-3.98(m,1H), 3.83(s,3H), 3.82(s,3H), 3.45-3.53(m,1H), 3.22-3.3(m,1H), 2.67-
2.76(m,1H), 2.24(d,1H, J=13.52Hz), 1.42-1.53(m,3H), 1.14-1.22(m,2H) 
13C NMR (150 MHz, CDCl3) δ= 170.18, 153.04, 149.83, 144.05, 143.66, 137.52, 
136.31, 132.67,  124.84, 116.54, 111.81, 103.52, 100.52, 67.29, 56.80, 56.40, 55.79, 
54.92, 53.39, 51.60, 49.25, 27.60, 26.27, 15.41 
MS(ESI)  : m/z: found 570.62 [M+H] +, calculated 570.51[M+H] + 
 
7.2.54 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-
dihydroxyethyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo 
[4.3.1] decan-2-one 72 diastereomeric mixture 
 
To a solution of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 71 (20mg, 
0.04mmol) in 2ml t-BuOH and water (1:1) was added AD-mix-alpha (308 mg) at room 
temperature and stirred two days. The pure product was obtained by preparative TLC 
with 1% AcOH in cyclohexane: EtOAc 1:4. 
TLC [1% AcOH in cyclohexane: EtOAc 1:4]: Rf = 0.35 
HPLC [40-42% Solvent B, 30 min]: Rt = 17.5 min, purity (280 nm) = 99% 
Yield: 12mg, 0.03mmol (57%) 
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1HNMR (300 MHz, CDCl3) δ= 7.68-7.72(m,2H), 7.52-7.56(m,1H), 6.74-6.81(m,1H), 
6.54-6.58(m,1H), 6.38-6.44(m,1H), 4.67-4.74(m,1H), 3.90-4.35(m,6H), 3.85(s,3H), 
3.82(s,3H), 3.30-3.80(m,6H), 2.08-2.30(m,3H), 1.35-1.55(m,3H), 0.82-0.85(m,1H) 
13C NMR (75 MHz, CDCl3) δ=169.95, 153.09, 149.90, 143.85, 143.82, 136.36, 
132.75, 124.86, 111.95, 104.05, 100.76, 72.70, 65.35, 63.90, 56.95, 56.41, 55.89, 
52.35, 51.75, 50.55, 49.78, 46.76, 28.25, 22.66, 14.15  
MS(ESI) : m/z: found 604.05[M+H]+, calculated 604.51[M+ H]+ 
 
7.2.55 Synthesis of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-
dihydroxyethyl)-3-(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo 
[4.3.1] decan-2-one 73  diastereomeric mixture 
 
To a solution of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one 71 (20mg, 
0.04mmol) in 2ml t-BuOH and water (1:1) was added AD-mix-beta (88mg) at room 
temperature and stirred overnight. The pure product was obtained by preparative 
TLC with 1% AcOH in cyclohexane: EtOAc 1:4. 
TLC [1% AcOH in cyclohexane: EtOAc 1:4]: Rf = 0.35 
HPLC [0-100% Solvent B, 30 min]: Rt = 21.6 min, purity (280 nm) = 99% 
Yield: 20mg, 0.03mmol (94%) 
1HNMR (300 MHz, CDCl3) δ= 7.68-7.72(m,2H), 7.52-7.56(m,1H), 6.74-6.81(m,1H), 
6.54-6.58(m,1H), 6.38-6.44(m,1H), 4.67-4.74(m,1H), 3.90-4.35(m,6H), 3.85(s,3H), 
3.82(s,3H), 3.30-3.80(m,6H), 2.08-2.30(m,3H), 1.35-1.55(m,3H), 0.82-0.85(m,1H) 
13C NMR (75 MHz, CDCl3) δ=169.95, 153.09, 149.90, 143.85, 143.82, 136.36, 
132.75, 124.86, 111.95, 104.05, 100.76, 72.70, 65.35, 63.90, 56.95, 56.41, 55.89, 
52.35, 51.75, 50.55, 49.78, 46.76, 28.25, 22.66, 14.15  
MS(ESI) : m/z: found 604.05[M+H]+, calculated 604.51[M+ H]+ 
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7.2.56 Synthesis of (1R,5S,6S)-10-(3,5-dichlorophenylsulfonyl)-3-(2-(3,4-
dimethoxyphenoxy)ethyl)-5-(2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-
disiladecan-5-yl)-3,10-diazabicyclo[4.3.1]decan-2-one 74 diastereomeric 
mixture 
 
To a solution of (1S,5S,6R)-10-(3,5-dichlorophenylsulfonyl)-5-(1,2-dihydroxyethyl)-3-
(2-(3,4-dimethoxyphenoxy)ethyl)-3,10-diazabicyclo[4.3.1]decan-2-one 73 (20mg, 
0.03mmol) in 1ml DCM at 0°C was added 2,6-lutidine (18mg, 0.17mmol) and tert-
Butyldimethylsilyl trifluoromethanesulfonate (88mg, 0.33mmol). After stirring for 29 h, 
no 73 was still existed. The organic layers were concentrated in vacuo. The attempt 
to purify with preparative HPLC using a gradient of 80-90% buffer B in 16 minutes 
was failed. As a test reaction, further efforts for purification were not put forth.  
MS(ESI) : m/z: found 831.98[M+H]+, calculated 832.31[M+ H]+ 
 
7.2.57 Synthesis of (2S)-1-benzyl 2-methyl 6-hydroxypiperidine-1,2-
dicarboxylate 66 and (S)-methyl 2-(benzyloxycarbonylamino)-6-
hydroxyhexanoate 67 
 
To a solution of (S)-1-benzyl 2-methyl 6-oxopiperidine-1,2-dicarboxylate 65 (100 mg, 
0.34 mmol) in 2ml MeOH at 0°C was added NaBH4 (29 mg, 0.76 mmol) and stirred 
for 6 h. The pure products were obtained by flash chromatography with cyclohexane: 
EtOAc 4:1 
TLC [cyclohexane: EtOAc 1:1]: Rf = 0.64 for 66 and Rf = 0.25 for 67 
Yield: 26mg, 0.09mmol (26%) for 66 and 22mg, 0.07mmol (21%) for 67 
1HNMR (300 MHz, CDCl3) of 66 δ= 7.3-7.45(m,5H), 5.75-5.85(m,0.5H), 5.1-
5.3(m,2H), 4.8-4.9(m,0.5H), 4.70-4.80(m,0.5H), 4.25-4.35(m,0.5H), 3.6-3.9(m,3H), 
2.2-2.3(m,0.5H), 1.5-1.8(m,2.5H), 1.2-1.4(m,3H), 
1HNMR (300 MHz, CDCl3) of 67 δ= 7.3-7.4(m,5H), 5.3-5.4(m,1H), 5.05-5.15(m,2H), 
4.35-4.45(m,1H), 3.7-3.8(s,3H), 3.56-3.7(m,2H), 1.8-1.95(m,1H), 1.65-1.8(m,1H), 1.5-
1.65(m,2H), 1.35-1.5(m,2H) 
MS(ESI) : m/z: found 316.87[M+Na]+, calculated 316.32[M+ Na]+ for 66  
m/z: found 318.87[M+Na]+, calculated 318.33[M+ Na]+ for 67 
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7.2.58 Synthesis of N-(2-(3,4-dimethoxyphenoxy)ethyl)prop-2-en-1-amine 
58 
 
To a solution of tert-butyl allyl(2-(3,4-dimethoxyphenoxy)ethyl)carbamate 48 (285mg, 
0.85mmol) in 5ml DCM at room temperature were added 2.5 ml TFA. The reaction 
mixture was stirred for 1 h, concentrated in vacuo, dissolved in H2O (5 ml) and 
extracted with EtOAc (3 x 5 ml). The aqueous layers were basified with saturated 
Na2CO3 solution and extracted with EtOAc (6 x 6 ml). The collected organic layers 
were dried over MgSO4 and concentrated in vacuo. This crude product was used for 
next reaction without further purification. 
TLC [ 10% MeOH in CHCl3 ]: Rf = 0.46 
Yield: 200mg, 0.85mmol (100%) 
1HNMR (300 MHz, CDCl3) δ= 6.78 (d, 1H, J=8.75 Hz), 6.54 (d, 1H, J=2.8 Hz), 6.41 
(d, 1H, J=8.73 Hz), 5.85-6.0 (m, 1H), 5.1-5.3(m,2H), 4.0-4.1(m,2H), 3.86 (s, 3H), 3.84 
(s, 3H), 3.3-3.4(m,2H), 3.0-3.05(m,2H), 2.6-2.8(m,1H) 
13C NMR (75 MHz, CDCl3) δ= 153.37, 149.87, 143.66, 135.93, 116.70, 111.82, 
103.85, 100.97, 67.58, 56.43, 55.82, 52.06, 48.06 
 
7.2.59 Synthesis of (S)-N-allyl-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-
oxopiperidine-2-carboxamide 59 
 
To a solution of (S)-6-oxo-2-piperidinecarboxylic acid 52 (50mg, 0.35mmol) in 5ml 
DCM was added sequentially with TEA (42mg, 0.42mmol), HATU(160mg, 0.42mmol) 
and stirred for 30 min at room temperature followed by addition of  N-(2-(3,4-
dimethoxyphenoxy)ethyl)prop-2-en-1-amine 58 (83mg, 0.35mmol). After 6 h, brine 
(10ml) was added and extracted with DCM (5 x 10 ml), dried over MgSO4, filtered 
and concentrated in vacuo. The pure product was obtained by flash chromatography 
with 1% TEA in EtOAc. 
TLC [1% TEA in EtOAc]: Rf = 0.1 
Yield: 116mg, 0.32mmol (91%) 
1HNMR (300 MHz, CDCl3) δ= 6.75-6.8 (m, 1H), 6.5-6.55 (m, 1H), 6.35-6.4 (m, 1H), 
5.7-5.85 (m, 1H), 5.1-5.3(m,2H), 4.55-4.65(m, 0.4H), 4.35-4.4 (m, 0.6H), 4.25-4.3 (m, 
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0.4H), 4.0-4.1(m,3H), 3.8-3.9(m,6.6H), 3.73-3.8(m,1H), 3.55-3.65 (m,1H), 2.3- 2.35 
(m, 2H), 1.8- 2.1 (m, 2H), 1.6- 1.8 (m, 2H) 
13C NMR (75 MHz, CDCl3) δ= 173.55, 171.82, 153.02, 149.84, 143.61, 132.65, 
117.65, 111.93, 103.97, 100.68, 66.26, 56.42, 55.88, 52.70, 51.30, 47.09, 30.57, 
25.53, 18.62 
MS(ESI) : m/z: found  363.47[M+H]+, calculated 363.42[M+H]+ 
 
7.2.60 Synthesis of (S)-benzyl 2-(allyl(2-(3,4-dimethoxyphenoxy)ethyl) 
carbamoyl)-6- oxopiperidine-1-carboxylate 60 
 
To a solution of (S)-N-allyl-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxopiperidine-2-
carboxamide 59 (2.33g, 6.43mmol) in 70ml THF was added BuLi (0.5g, 7.71mmol) 
dropwise and catalyttical amount of 4-Dimethylaminopyridine under argon at -78°C 
and stirred for 1 h followed by addition of Cbz-Cl (2.2g, 12.86mmol). After 2 h at -
78°C, a saturated NH4Cl solution (50ml) was added at room temperature and 
extracted with DCM (6 x 70ml), dried over MgSO4, filtered and concentrated in vacuo. 
The pure product was obtained by flash chromatography with cyclohexane: EtOAc 
1:2. 
TLC [hexane: EtOAc 1:2]: Rf = 0.3 
Yield: 1.92g, 3.87mmol (60%), purity >98%  
1HNMR (600 MHz, CDCl3) δ= 7.26-7.44 (m, 5H), 6.73-6.78 (m, 1H), 6.47-6.53 (m, 
1H), 6.33-6.40 (m, 1H), 6.05-6.2 (m, 1H), 5.7-5.9 (m, 2H), 5.2-5.3 (m, 2H), 5.1-5.2 (m, 
1H), 4.0-4.3 (m, 4H), 3.8-3.88 (m, 6H), 3.52-3.78 (m, 2H), 2.45-2.55 (m, 1H), 2.25-
2.45 (m, 1H), 1.8-2.1 (m, 2H), 1.5-1.8 (m, 2H). 
13C NMR (150 MHz, CDCl3) δ= 173.20, 171.18, 153.10, 154.50, 149.84, 143.66, 
153.23, 132.85, 128.49, 128.45, 128.21, 127.97, 127.88, 118.08, 111.87, 104.00, 
100.81, 68.72, 66.75, 56.42, 56.11, 55.87, 51.84, 46.26, 34.42, 25.76, 18.10 
MS (ESI): m/z=  519.47  [M + Na] +, calculated: 519.21[M + Na] +. 
 
7.2.61 Synthesis of (S)-benzyl 2-((2-(3,4-dimethoxyphenoxy)ethyl)(4-
(trimethylsilyl) but-2-enyl)carbamoyl)-6-oxopiperidine-1-carboxylate 62 
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To a solution of (S)-N-(2-(3,4-dimethoxyphenoxy)ethyl)-6-oxo-N-(4-(trimethylsilyl)but-
2-enyl)piperidine-2-carboxamide 53 (923mg, 2.06mmol) in 10ml THF was added 1M 
BuLi solution in hexanes (158mg, 2.47mmol) dropwise under argon at -78°C and 
stirred for 1 h followed by addition of Cbz-Cl (421mg, 2.47mmol). After 7 h at -78°C, a 
saturated NH4Cl solution (20ml) was added at room temperature and extracted with 
DCM (6 x 20ml), dried over MgSO4, filtered and concentrated in vacuo. The pure 
product was obtained by flash chromatography with cyclohexane: EtOAc 1:1. 
TLC [ cyclohexane: EtOAc 1:1]: Rf = 0.4 
Yield: 871mg, 1.49mmol (73%) 
1HNMR (400 MHz, CDCl3) δ= 7.26-7.42(m,5H), 6.74-6.78(m,1H), 6.47-6.52(m,1H), 
6.34-6.39(m,1H), 5.55-5.7(m,1H), 5.25-5.33(m,2H), 5.2-5.25(m,2H), 5.05-5.15(m,1H), 
4.05-4.2(m,2H), 3.9-4.05(m,2H), 3.8-3.87(m,6H), 3.70-3.75(m,1H), 3.5-3.6(m,1H), 
2.6-2.7(m,1H), 2.4-2.5(m,1H), 2.2-2.4(m,1H), 2-2.1 (m,1H), 1.7-2.0(m,2H), 1.4-1.5 
(m,2H), 0.01(t,9H,J=13.53,13.53Hz) 
13C NMR (100 MHz, CDCl3) δ= 171.24, 170.84, 154.66, 153.14, 149.83, 143.60, 
135.33, 132.13, 128.48, 128.16, 128.03, 127.92, 127.84, 122.38, 111.87, 104.03, 
100.83, 68.68, 66.64, 56.42, 56.13, 55.85, 51.38, 45.26, 34.43, 25.73, 22.92, 18.14,  
-1.77 
MS(ESI) : m/z: found  607.37 [M+H]+, calculated 607.76[M+H]+ 
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8. Abbrevations   
 
 
ACTH  Adrenocorticotropic Hormone 
AR  Androgen Receptor 
Brine  Saturated NaCl solution 
BuLi  n-butyllithium 
CN  Calcineurin 
CRH  Corticotropin Releasing Hormone 
DCM  Dichlormethane 
DCC  N,N′-Dicyclohexylcarbodiimide 
DIPEA N,N-Diisopropylethylamine  
EDC   1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid 
EE  Ethylacetate 
ER  Estrogen Receptor 
F  Phenylalanine 
FKBP  FK506 binding protein 
FP  Fluorescence Polarisation 
GR  Glucocorticoid receptor 
HOAt 1-Hydroxy-7-azabenzotriazole 
HATU 2-(1H-7-Azabenzotriazol-1-yl)--1,1,3,3-tetramethyl uronium 
hexafluorophosphate Methanaminium 
HPA Hypothalamus pituitary adrenal 
HPLC High Pressure Liquid Chromatography 
Hsp90 Heat shock protein 90 
LDC Lead Discovery Center 
LiHMDS Lithium hexamethyl disilazid 
LiOH  Lithiumhydroxid 
LMU  Ludwigs-Maximilians-University 
MeOH Methanol 
MD  Major depression 
MPI  Max-Planck-Institute 
MR  Mineralcorticoid Receptor 
NaHMDS Natrium hexamethyl disilazid 
n-Hex  n-Hexane 
NMR  Nuclear magnetic resonance 
PPIase Peptidyl-prolyl-cis/trans-Isomerase  
PR  Progesterone Receptor 
PTSD  Post-traumatic stress disorder 
Rap  Rapamycin 
RT  Room Temperature 
SAR  Structure Activity Relationship 
SHR  Steroid Hormone Receptor 
TFA  Trifluoroacetic acid 
TEA  Triethylamine 
TLC  Thin layer chromatography 
THF  Tetrahydrofuran 
V  Valine 
WT  Wildtype
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